Utah State University

DigitalCommons@USU
All Graduate Theses and Dissertations

Graduate Studies

5-2013

Bioactivities of Milk Polar Lipids in Influencing Intestinal Barrier
Integrity, Systemic Inflammation, and Lipid Metabolism
Albert Lihong Zhou
Utah State University

Follow this and additional works at: https://digitalcommons.usu.edu/etd
Part of the Food Chemistry Commons, and the Nutrition Commons

Recommended Citation
Zhou, Albert Lihong, "Bioactivities of Milk Polar Lipids in Influencing Intestinal Barrier Integrity, Systemic
Inflammation, and Lipid Metabolism" (2013). All Graduate Theses and Dissertations. 1517.
https://digitalcommons.usu.edu/etd/1517

This Dissertation is brought to you for free and open
access by the Graduate Studies at
DigitalCommons@USU. It has been accepted for
inclusion in All Graduate Theses and Dissertations by an
authorized administrator of DigitalCommons@USU. For
more information, please contact
digitalcommons@usu.edu.

BIOACTIVITIES OF MILK POLAR LIPIDS IN INFLUENCING INTESTINAL
BARRIER INTEGRITY, SYSTEMIC INFLAMMATION, AND LIPID METABOLISM
by
Albert Lihong Zhou
A dissertation submitted in partial fulfillment
of the requirements for the degree

of

DOCTOR OF PHILOSOPHY

in

Nutrition and Food Sciences
Approved:

____________________

____________________

Dr. Robert E. Ward
Major Professor

Dr. Korry J. Hintze
Committee Member

____________________

____________________

Dr. Ilka Nemere
Committee Member

Dr. Michael Lefevre
Committee Member

____________________

____________________

Dr. David A. York
Committee Member

Dr. Mark R. McLellan
Vice President for Research and
Dean of the School of Graduate Studies

UTAH STATE UNIVERSITY
Logan, Utah

2013

ii

Copyright © Albert Lihong Zhou 2013
All Rights Reserved

iii
ABSTRACT

Bioactivities of Milk Polar Lipids in Influencing Intestinal Barrier Integrity, Systemic
Inflammation, and Lipid Metabolism

by

Albert Lihong Zhou, Doctor of Philosophy
Utah State University, 2013

Major Professor: Dr. Robert E. Ward
Department: Nutrition, Dietetics and Food Sciences

Milk polar lipids reduce cholesterol, protect against bacterial infection, reduce
inflammation, and help maintain gut integrity. Four rodent models were used to test the
hypotheses that dietary milk polar lipids may increase intestinal barrier integrity, reduce
systemic inflammation, and affect lipid metabolism during obesity and inflammatory
stresses.

The dietary lipids and the polar lipids supplementation affected lipid partitioning,
gene expression, and the liver pathology in a rat model (Chapter 2). In an obese mouse
model (Chapter 3), the phospholipids increased gut permeability and systemic
inflammation, decreased the liver mass and the liver lipids, and increased the plasma
lipids; the gangliosides did not affect gut permeability, systemic inflammation, and lipid
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metabolism. In a lipopolysaccharide (LPS) stressed mouse model (Chapter 4), the
phospholipids decreased the liver mass and the polar lipids in the intestinal mucosa, and
increased gut permeability and the plasma LPS level; the gangliosides did not affect gut
permeability and systemic inflammation, and had little effect on lipid metabolism. In a
diet-induced obesity (DIO) mouse model (Chapter 5), the phospholipids increased the
body fat, the plasma LPS level and the gut permeability, increased the polar lipids level
in the liver, and deceased the polar lipids level in the intestinal mucosa; the phospholipids
did not affect the systemic inflammatory cytokines; the gangliosides increased the
expression of the tight junction protein zonula occludens-1 in the colon mucosa, did not
affect the plasma inflammatory cytokines, and had little effect on lipid metabolism. There
were dynamic changes in plasma cytokines, gut permeability, and lipid metabolism in the
LPS-stressed and the DIO models.

In summary, the milk polar lipids affected lipid partitioning and relevant gene
expression in rats. The milk phospholipids increased gut permeability in all three mouse
models. The phospholipids increased the plasma LPS level and reduced liver mass and
liver lipids in genetic obesity and during the LPS stress. The phospholipids increased the
body fat in the diet-induced obesity model. The milk gangliosides did not significantly
affect gut permeability, systemic inflammation, and lipid metabolism in all three mouse
models. Milk phospholipids as dietary supplements may have undesirable effects on gut
permeability, systemic inflammation, and lipid metabolism during obesity and
inflammatory responses.
(284 pages)
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PUBLIC ABSTRACT

Bioactivities of Milk Polar Lipids in Influencing Intestinal Barrier Integrity, Systemic
inflammation, and lipid Metabolism

by

Albert Lihong Zhou, Doctor of Philosophy
Utah State University, 2013

The purpose of lactation is for nutrient provision and also importantly for protection
from various environmental stressors. Milk polar lipids reduce cholesterol, protect against
bacterial infection, reduce inflammation and help maintain gut integrity. Dynamic
interactions within dietary fat, lipid metabolism, gut permeability and inflammatory
cytokines remain unclear in the context of obesity and systemic inflammation. A rat
model and three mouse models were developed to test the hypotheses that dietary milk
polar lipids may affect lipid metabolism and intestinal integrity and may protect against
systemic inflammation in the context of stressful diet, systemic inflammation, and obesity.

The milk polar lipids isolates had complex effects on lipid metabolism and associated
gene expression in the rat model. There were complex dynamics in lipid metabolism, gut
permeability and systemic inflammation at different time points in all mouse models. The
milk phospholipids increased gut permeability in genetic and diet-induced obesity and
during the lipopolysaccharide (LPS) -induced inflammation. The phospholipids increased
the plasma LPS level in genetic obesity and during the LPS stress. The phospholipids
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reduced liver mass and liver lipids in genetic obesity and during the LPS-induced
inflammation. The phospholipids increased the body fat in the diet-induced obesity model.
The milk gangliosides did not significantly affect gut permeability, systemic
inflammation, and lipid metabolism in all three mouse models.

Current estimate by the Centers for Disease Control is that about 1/3 Americans are
obese (body mass index, BMI ≥ 30) and 1/3 Americans are overweight (25 ≤ BMI < 30).
More than 25% of Americans today have a fatty liver which could lead to further health
problems. The data from this dissertation shed light on the complicated interrelationships
between gut permeability, systemic inflammation, and lipid metabolism in obesity. The
results contribute to our understanding of the bioactivities of milk polar lipids and
provide scientific evidence for the role of milk polar lipids rich materials in affecting
biological functions. The study of the influence of milk polar lipids on gut barrier
integrity adds new information on understanding the mechanisms of gut leakiness and
recovery. The investigation of the impact of milk polar lipids on lipid metabolism reveals
new perspectives for the development of diet-induced obesity.
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CHAPTER 1
INTRODUCTION

Milk provides the primary source of nutrition for young mammals. Interestingly,
comparative evolutionary biology suggests that the origins of lactation are not
exclusively for nutrient provision, but rather protection from various environmental
stressors (1). In modern society, especially the western world, milk and other dairy
products are common food items among all age groups. Despite their wide applications,
milk and other dairy products have not been assessed extensively for their potential
protective effects against environmental stresses. The early lactation milk, colostrum,
carries the mother's antibodies to the baby thereby reducing the risk of many diseases in
the infant. Rich in nutrients, milk provides protection for the gut and enhances the
immune system of the newborn (2, 3). The composition of milk results from selective
pressure to promote the health of infants through nutrient provision and protection against
environmental insults. Among the nutrients in milk, lipids are important in delivering
energy and providing substrates for metabolism. One fraction of the lipids, milk fat
globule membrane (MFGM) polar lipids including phospholipids (PL) and gangliosides
(GG), may have important roles in biological functions such as maintaining
gastrointestinal barrier integrity and affecting systemic inflammation, and lipid
metabolism.

Milk Fat Globule Membrane
MFGM is a biological membrane synthesized and secreted by the mammary
epithelial cells. Surrounding a triglyceride (TG) core, MFGM forms a 4- to
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10-nm multilayer membrane composed primarily of cholesterol, proteins, and polar lipids
(4). MFGM contains approximately 60% proteins and 40% lipids (Table 1.1) (5-7).
Recent proteomic and lipidomic characterizations (8-11) have shown that MFGM is the
most diverse fraction of milk. Although there are a lot of minor components in MFGM,
xanthine oxidase, periodic acid/schiff 6/7, adipophilin, and butyrophilin are the most
abundant MFGM-associated proteins (12), and polar lipids are the major lipids secondary
to TG in MFGM. Polar lipids include phospholipids and sphingolipids. The major
phospholipids include phosphatidylethanolamine (PE), phosphatidylcholine (PC),
phosphatidylserine (PS), and phosphatidylinositol (PI). The major sphingolipids are
glucosylceramide, lactosylceramide, and sphingomyelin (6, 13).

Isolation of MFGM Polar Lipids
Milk polar lipids are mainly situated in the MFGM. Mechanical treatments, such
as heating (14), homogenization (15), aeration, and agitation (16), have been used to
release MFGM from the fat globules into the corresponding serum phase. Phase inversion,
such as churning, releases MFGM from the fat globules into the serum fraction (i.e.,
buttermilk and butter serum). Once MFGM is disrupted and released into the serum, it
needs to be separated from the other components of milk. Larger amounts of MFGM can
be produced as a byproduct from buttermilk or cheese whey during butter or cheese
making processes. Tangential ﬁltration is one of the most common techniques for the
isolation of MFGM from whey, the byproduct of cheese and casein manufacturing (17).
The isolating procedures can be easily carried out in industrial settings. MFGM polar
lipids can be harvested from dried milk cream through ethanol extraction. The resulting
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lipid extract can be further processed to obtain GG enriched concentrates and PL
enriched concentrates.
Biological Properties of MFGM Polar Lipids
Forming a lipid tri-layer, MFGM stabilizes milk fat globules in the milk serum and
protects them from enzymatic attack by lipases (16, 18) so that milk fats can be passed
from mothers to babies for utilization. Both lipid and protein fractions of MFGM have
been found to have health-promoting effects (19). Due to its unique lipid profile, relative
polar lipids enrichment and widespread availability, MFGM has been suggested as a
nutraceutical (20). One type of polar lipids isolated from MFGM, sphingolipids, have
very specific nutritional benefits. Sphingolipids are hydrolyzed in the gastrointestinal
tract into ceramide, sphingosine, sphingosine 1-phosphate, and other metabolites, all of
which can modulate cell growth, differentiation, and apoptosis (21). Studies have been
conducted to investigate the physiological properties of MFGM sphingolipids, which
have been shown to reduce the uptake of cholesterol (22, 23), protect against bacterial
infections in the gut (24-26), reduce inflammatory response (27-30), and inhibit the
development of preneoplastic lesions in rodent models of colon cancer (31-33).

Sphingomyelin, one subfraction of sphingolipids, plays an important role in gut
maturation during the suckling period in rats (34). Recent work shows that
sphingomyelin content in intestinal cell membranes may regulate cholesterol absorption
(35). Another subfraction of sphingolipids, dairy GG inhibits degradation of gut occludin
tight junction (TJ) protein during lipopolysaccharide (LPS)-induced acute inflammation
(36). Dietary GG affect intestinal immune system maturation in mice during weaning
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(37). Dietary GG can be absorbed in the small intestine and distributed to different tissues.
Dietary GG alters GG levels in the intestinal mucosa, plasma and brain (38).

Dietary supplemented PL may enrich PL in circulating lipoproteins and enhance their
endotoxin-neutralizing capabilities (39). High-density lipoprotein (HDL) has the highest
percentage of PL among the lipoproteins. MFGM PL may increase plasma HDL level,
which neutralizes endotoxins in the blood (40, 41). Oral time-release capsules of PC
ameliorate gastrointestinal symptoms and facilitate recovery in patients with chronic
ulcerative colitis (42, 43). Some of this protection by PC may be partially due to its
anti-inflammatory property on human intestinal cells (44). As a constitutively developing
tissue, the gut epithelium is the most vigorously self-renewing tissue of adult mammals
(45) and is constantly differentiating from stem cells in a progenitor pool throughout the
life of the organism (46). As an essential component of cell membrane, polar lipids may
be actively involved in the process of gut epithelium regeneration and barrier
maintenance.

Being digested and incorporated into tissues, MFGM polar lipids and their
metabolites may be actively involved in lipid metabolism. The effects of dietary PL on
hepatic lipid metabolism have been studied in rats and dietary PL reduced liver TG and
cholesterol (47). A MFGM isolate increases PL and TG levels in plasma in rat (Chapter2,
48). The isolate lowers TG and total lipids levels in adipose tissue. It also reduces free
fatty acids (FFA), cholesterol esters (CE) and total lipids in the liver. PL-rich MFGM
extract reduces hepatomegaly, hepatic steatosis and hyperlipidemia in mice fed a high-fat
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diet (49). The extract also positively regulates genes associated with fatty acid synthesis
and cholesterol metabolism. A methionine and choline-deficient diet reduces PC
biosynthesis, which results in reduced very-low-density lipoprotein (VLDL) secretion
(50). The decrease of VLDL secretion is one of the many factors contributing to the
pathogenesis of hepatic steatosis and non-alcoholic steatohepatitis (NASH). High dietary
sucrose results in hepatic steatosis (51) and dietary PC may relieve the condition. The
beneficial effects of MFGM could be partially due to the choline contributed by PC when
the diets were high in sucrose in most of the aforementioned studies.

Physiology and Pathophysiology of Intestinal Barrier Integrity
The mammalian intestinal epithelium, composed of a single layer of epithelial cells,
carries out the primary functions of digestion and absorption of nutrients and forms a
barrier against luminal pathogens (52). The intestinal barrier has several components
which can be divided into extrinsic barriers and intrinsic barriers (53). The extrinsic
barrier, also known as "unstirred layer," stabilizes the microenvironment adjacent to
epithelial cell apical membranes. The intrinsic barrier has two components: the epithelial
cells (transcellular pathway) and the spaces around these cells (paracellular pathway) (54).
The major permeability route across the epithelium is located within the paracellular
pathway (55), which has two components: the TJ and the subjunctional paracellular space
(54). The TJ is the main determinant of intestinal barrier integrity. TJ are formed by
specific interactions of a wide spectrum of proteins (56). Occludin (57), claudins (58),
and junctional adhesion molecule (JAM) (59) are the important ones. The cytoplasmic
domains of these proteins interact extensively with scaffolding and regulatory proteins
such as zonula occludens (ZO)-1, ZO-2, ZO-3 (56). TJ are dynamically regulated in both
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health and disease by many mechanisms (60). Compromised function of intestinal TJ has
been implicated in the pathogenesis of several intestinal disorders such as inflammatory
bowel disease (IBD) and celiac disease (61).

Several studies have shown that gastrointestinal surface hydrophobic properties
decrease under pathological conditions. Maintenance of the PC in the hydrophobic
surface may play an important role in health and prevention of disease (62). In the ileal
and colonic mucus from patients suffering from ulcerative colitis, the concentration of PC
was signiﬁcantly lower compared with that of healthy controls (63). The PL
concentration and species composition of the intestinal mucus barrier are signiﬁcantly
altered in patients with ulcerative colitis. The alterations in PL may be important for the
pathogenesis of diseases associated with disruption of intestinal barrier integrity. The
enzymatic breakdown of intestinal PL has been linked to a higher rate of intestinal
permeability in Caco-2 cells (64).

Adipose Tissue, Obesity and Inflammation
Excess energy can be reversibly stored as lipids in adipocytes (65). Excess TG
accumulation in adipose tissue results in hypertrophy and hyperplasia (66). Adipogenesis,
proliferation and differentiation of preadipocytes into new adipocytes, results in
hyperplasia (67). Hypertrophy and hyperplasia of adipocytes contribute to excessive
adipose tissue growth, which eventually leads to obesity (68). Adipocyte function can be
impaired by excessive fat accumulation in the cell. Cellular lipid loading may initiate
inflammation and lipid mediators could play important roles in this process since they
are precursors to inflammatory signaling molecules (69). In obesity, the hypoxic adipose

7

tissue may release proinflammatory cytokines that may initiate systemic inflammation
(70-72).

Adipose tissue contains many different types of cells, including adipocytes,
ﬁbroblasts, leukocytes, and macrophages. These cells may jointly produce
proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α), and interleukin-6
(IL-6) (69). The close location of adipocytes with immune cells facilitates continuous
dynamic interactions between immune and metabolic responses (73). Macrophages and T
lymphocytes are the main components of the innate immune system in adipose tissue (7477). Monocytes are recruited to adipose tissue and become macrophages through
interaction with dysfunctional adipocytes during obesity in animal models (78).
Preadipocytes can be converted into macrophages in a macrophage environment (79).
Macrophages contribute to local proinflammatory environment in adipose tissue and also
influence systemic inflammation especially in chronic inflammatory states (80).

Adipocytes might be both the source and target of proinflammatory signals since
adipocytes express receptors for several proinflammatory molecules such as TNF-α and
IL-6 (75). Local inflammatory effectors in adipose tissue can act on adipocytes in a
paracrine manner and exacerbate inflammation and adipocyte dsyfunction (74, 75, 81).
Systemic inflammatory effectors may affect adipose tissue in a similar manner. Adipose
tissue in a lean body has the potential to develop inflammation upon systemic
inflammatory stimulation. It is not clear yet which original factor(s) triggers
inflammation in adipose tissue. Endotoxemia caused by periodontal gram-negative
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pathogens in patients with severe periodontitis might lead these people to obesity (82). It
is possible that proinflammatory signals resulting from systemic metabolic inflammation
may trigger an inflammatory response in adipose tissue and therefore cause adipocyte
dysfunction and subsequent obesity development. Proinflammatory signals resulting from
metabolic endotoxemia caused by dietary fat and associated bile release might be one of
the initiating factors for inflammation in adipose tissue during the development of
diet-induced obesity (DIO). Then in the context of DIO, systemic metabolic
inflammation and subsequent inflammation in adipose tissue may precede obesity
development, which is still lack of supporting evidence.

High Fat Diet, Intestinal Barrier Integrity, Endotoxemia, Systemic Inflammation
and Obesity
A link between high fat diets and endotoxemia has been suggested. A chronic high fat
diet could increase endotoxin absorption during the digestion of dispersed dietary lipids.
The resultant metabolic endotoxemia leads to low-grade metabolic inflammation (83).
One study found that high fat diet increases intestinal permeability in rats primarily
through excessive dietary fat and increased luminal bile juice levels instead of obesity
and metabolic disorders (84). A recent study revealed that chylomicrons could be
postprandial carriers for LPS and the digestion of emulsified dietary lipids can enhance
intestinal endotoxin absorption in healthy young men (85). The increased endotoxemia
upon high-fat diet might be contributed by enhanced endotoxin absorption through the
small intestine instead of the large intestine (84, 86).
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Current evidence suggests that high fat diets may decrease gut barrier integrity and/or
increase endotoxin absorption, which may lead to systemic inflammation independent of
obesity. Obesity may also decrease intestinal barrier integrity. Increased intestinal
permeability has been observed in obese animals (86, 87). As animals become more
obese, their intestines become larger with an increased surface area due to a larger
amount of intestinal mucosa needed to absorb the surplus of ingested nutrients (88). This
increased surface area has been shown to be caused by intestinal hyperplasia (89). The TJ
proteins may not be increased accordingly and distributed properly, which could lead to
the decrease of barrier integrity (88). Leptin-deﬁcient C57BL/6J ob/ob (ob/ob) mice were
shown to have an abnormal distribution of TJ proteins within the intestinal mucosa that
causes compromised intestinal barrier integrity leading to portal endotoxemia (90). The
genetic obesity model of ob/ob mice have been reported to have increased intestinal
permeability when fed a standard chow diet (90). Plasma levels of
lipopolysaccharide-binding protein (LBP), a marker of endotoxemia, were increased in
ob/ob mice and mice with DIO compared with lean mice (91). The systemic
inflammatory state in obesity is associated with endotoxemia resulting from increased gut
barrier permeability (92).

Obesity may potentiate systemic inflammation and the proinflammatory cytokines
can reach the gut through the circulation and result in local inflammation. Intestinal
inflammation leads to an increase of mucosal permeability and bacterial translocation. In
obese subjects, inﬂammatory cytokine levels stay high. These cytokines may alter
structure and localization of TJ and thereby cause malfunction of the intestinal barrier (93,
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94). For example, TNF-α, interferon (IFN)-γ, IL-4 and IL-13 have been shown to
increase barrier permeability in vitro (95) by altering TJ morphology and distribution (96).
Therefore, obesity, systemic inflammation and increased intestinal permeability may
generate a self-perpetuating vicious cycle (Figure 1.1) (97).

In summary, current evidence suggests that during the development of high-fat DIO,
increased gut barrier permeability, endotoxemia, systemic inflammation and obesity may
occur in sequential steps. It is also possible that in the context of high-fat DIO, obesity
develops before any other aforementioned conditions. Once obesity is developed, the
adipose tissue may release proinflammatory cytokines that may initiate systemic
inflammation. The inflammatory state may increase gut barrier permeability, which could
lead to endotoxemia and worsen the condition of inflammation (Figure 1.1). Therefore,
increased gut barrier permeability, endotoxemia, systemic inflammation and DIO are
complexly interrelated events. Lipid metabolism could be an important linkage among
these events. Diet supplemented with the buttermilk MFGM isolate was effective in
promoting mucosal integrity against LPS stress in mice (98). The effects of MFGM polar
lipids on intestinal barrier integrity could have an influence on endotoxemia and systemic
inflammation. MFGM polar lipids could also influence systemic lipid metabolism and
may interfere with the development of DIO. Dietary supplementation of MFGM polar
lipids in the context of preexisting obesity and during the development of DIO may
facilitate the understanding of the interrelationships among intestinal barrier integrity,
endotoxemia, systemic inflammation and obesity.
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Rationale for Animal Models and Diets Selections
The main endpoints of the project are gut permeability, systemic inflammation, and
lipid metabolism in the context of obesity. The C57BL/6J ob/ob (ob/ob) and wild type
mice were used. The reason to use ob/ob mice was that these mice have preexisting
obesity and its complications such as increased gut permeability and systemic
inflammation. Since these mice are leptin deficient, caution should be taken in
interpreting the data. By using these mice, MFGM polar lipids can be tested to see if they
have any beneficial effects on gut permeability and systemic inflammation, which may
result from obesity and may be sustained and/or exacerbated by fat intake. For wild type
mice, it took time for them to develop obesity even when they were fed a high fat diet.
High fat diet feeding has been shown to increase gut permeability and induce subsequent
metabolic inflammation. Wild type mice were used to determine if MFGM polar lipids
can prevent the increase of gut permeability and systemic inflammation during the
development of obesity. Data from this study may shed some light on how the
supplements may affect the complicated causal relationships among gut permeability,
systemic inflammation and DIO.

Diets based on AIN-93G rodent diet were used. Part of the fat source in experimental
diets was provided by MFGM polar lipids. The fat provided 34% energy (16.8% by
weight). This amount of fat is considered high compared with 16% (energy) fat in regular
mice chow diet. High fat diets with 30% or more fat as energy have successfully induced
obesity in C57BL/6J mice (99). Data from National Health and Nutrition Examination
Survey (NHANES 2007-2008) indicates that the mean amount of fat consumed per
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individual American is 34% by energy. Using diets with 34% (energy) fat emulated real
dietary practices in America. Current estimates by Centers for Disease Control is that
about 1/3 Americans are obese (BMI ≥ 30) and 1/3 Americans are overweight (25 ≤ BMI
< 30). So it could be common practice to have diets with 34% (energy) fat in the
background of obesity or overweight.

When the same diets were used in both animal models, these two experiments could
be compared to generate hypotheses. The DIO model had at least two stressors, high
dietary fat and DIO. Dietary fat was a constant stressor while DIO was added on later.
The effects of the milk polar lipids on the stresses caused by dietary fat (and maybe also
bile) were tested during the early part of the experiment. Once the animals developed
obesity, the effects of the milk polar lipids on complications of DIO were also tested. The
results from the ob/ob model were negative and the results from the DIO model were
positive for the early part but negative for the latter part, meaning that the milk polar
lipids prevented the detrimental effects of dietary fat but could not ameliorate the
complications of obesity. The milk polar lipids did not ameliorate complications in ob/ob
mice and did not improve complications of DIO, meaning that the lack of beneficial
effects of milk polar lipids on obesity complications may not be leptin-dependent.

The LPS injection is widely used in mice for modeling the acute and chronic systemic
inflammation. The subcutaneous injection of LPS induces endotoxemia and intestinal
stress in mice (100, 101). The intraperitoneal injection of LPS increases the level of the
plasma inflammatory cytokines (102). Six percent of the subcutaneously injected LPS is
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still retained at the injection site 32 days after the injection (103). The subcutaneous LPS
injection induces both the acute and chronic inflammatory responses. The LPS injection
will increase gut leakiness, endotoxemia and systemic inflammation. The combination of
the high fat diet and the LPS injection should increase the severity of gut leakiness,
endotoxemia and systemic inflammation (Figure 1.1) and should make it easier to detect
the potential beneficial effects of the polar lipids on these endpoints. The mouse model of
the LPS stress and the high fat diet is a great platform for studying the effects of the milk
polar lipids on gut permeability and systemic inflammation.

Dissertation Outline
During this dissertation research, I explored the effects of milk polar lipids on gut
permeability, systemic inflammation, and lipid metabolism during inflammation and
obesity. The following hypotheses were tested (Figure 1.1): 1) Dietary milk polar lipids
will reduce liver lipid levels and affect the expression of genes associated with fatty acid
synthesis and cholesterol regulation in the liver in both C57BL/6J ob/ob and wild type
mice fed a diet with 34% fat by energy; 2) Dietary milk polar lipids will reduce intestinal
permeability and systemic inflammation in C57BL/6J ob/ob mice fed a diet with 34% fat
by energy; 3) Dietary milk polar lipids will improve intestinal barrier integrity, lipid
metabolism and systemic inflammation during acute and chronic systemic inflammation
induced by LPS injected subcutaneously; 4) Dietary milk polar lipids will prevent gut
permeability increase and subsequent systemic inflammation during the development of
DIO in C57BL/6J wild type mice fed a diet with 34% fat by energy.
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To begin with, I tried to explore the effects of dietary milk polar lipids isolate on lipid
metabolism and gene expression in a rat model. I obtained the lipid profiles of liver,
gonadal adipose and skeletal muscle samples from a previous rat study on the effects of
milk polar lipids isolate on the development of aberrant crypt foci in the colon. I also
analyzed microarray gene expression data of those tissue samples. The results are
reported in Chapter 2. The milk polar lipids reduced liver lipid levels and the reduction of
liver lipids coincided with the increase of lipids in the plasma. The effects of the milk
polar lipids on tissue gene expression were complex in the rats.

To test the aforementioned hypotheses, I used three mouse models, a genetic obesity
model, a LPS-induced inflammation model, and a diet-induced obesity model. The first
hypothesis was tested in all three models. I analyzed the liver samples from all three
mouse studies. As reported in Chapters 3, 4, and 5, the milk polar lipids reduced the liver
lipid level and slightly affected gene expression associated with the liver lipid
metabolism in all three mouse models.

To test the second hypothesis, I used the ob/ob mouse model. The ob/ob mice were
fed moderately high-fat diets. As reported in Chapter 3, the milk polar lipids did not
prevent the increase of gut permeability. The milk phospholipids increased the colon
permeability and the plasma IL-6 level, decreased the liver mass and the liver cholesteryl
ester level, and increased the plasma levels of FFA, DG, SM, and PL. The milk
gangliosides decreased ZO-1 and increased occludin in the colon mucosa but had little
effect on gut permeability, systemic inflammation, and lipid metabolism.
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To test the third hypothesis, I used a LPS-induced inflammation model. Lean
C57BL/6J mice were injected subcutaneously with LPS. The effects of the milk polar
lipids were tested during acute and chronic inflammation induced by the injected LPS. As
reported in Chapter 4, the subcutaneous injection of the LPS at 5 mg/kg body weight
successfully induced leaky gut and acute and chronic systemic inflammation. The milk
phospholipids decreased occludin expression in jejunum mucosa and increased ZO-1 &
occludin in colon mucosa; increased plasma LPS; decreased liver mass, muscle TG, liver
expression of Acacb & Hmgcr and plasma CE; decreased PC & PE in ileum mucosa and
PE & GG in colon mucosa. The milk gangliosides decreased adipose PE, PC & SM,
hepatic FFA & PI; increased liver expression of Acaa2. LPS stress in combination with
high fat diets increased gut permeability and plasma proinflammatory cytokine levels.
LPS stress reduced plasma insulin level, blocked the accumulation of body fat, and
increased plasma IL-6 level. The experimental feeding increased plasma LPS but did not
raise plasma cytokine levels.

To test the last hypothesis, I used a diet-induced obesity model. C57BL/6J lean mice
were fed the AIN93G based diets with 34% fat by energy. As reported in Chapter 5, the
milk phospholipids promoted body fat accumulation and increased obesity; increased gut
permeability and plasma LPS; decreased occludin in jejunum mucosa; increased liver PE,
PC & SM and plasma TG; decreased plasma FFA & PC; decreased PC & SM in colon
mucosa. The milk gangliosides decreased adipose SM, plasma FFA & PC; increased liver
PE & SM; increased ZO-1 in colon mucosa. The experimental feeding increased body fat
and plasma CE; increased colon permeability and plasma levels of LPS, leptin, resistin,
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insulin and glucose; decreased insulin sensitivity as indicated by the increased HOMA-IR;
increased plasma IL-6 before the establishment of DIO; decreased permeability of the
small intestine.

In addition to testing the aforementioned hypotheses, I also tried to explore the
dynamic changes of gut permeability, systemic inflammation, and lipid metabolism
during genetic obesity, the LPS-induced inflammatory response, and diet-induced obesity.
The endpoints were measured at multiple time points. Often times the measurements did
not stay in one direction. The repeated measurements also indicated that dietary
supplementations had different effects at different time points.

In this dissertation, I demonstrated that repeated measurements are important for
monitoring the dynamic changes of biological endpoints and evaluating the effects of
dietary supplementations. The milk polar lipids in general did not have strong positive
effects on gut permeability and systemic inflammation during obesity and the acute and
chronic inflammatory responses. The milk polar lipids tended to have more positive
effects when the animals were under more stressful conditions such as preexisting obesity
and the LPS-induced inflammation. Several of the unexpected findings are quite
interesting. The milk phospholipids promoted body fat accumulation in C57BL/6J lean
mice. The milk polar lipids decreased the polar lipid levels in the intestinal mucosa and
sometimes in the liver and the skeletal muscle. The LPS absorbed through the gut did not
induce strong systemic inflammation while the LPS injected subcutaneously stimulated
much stronger inflammation. As described in Chapter 6, many hypotheses can be
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generated from the data collected in this dissertation. Further studies are needed to test
those hypotheses and reveal the mechanisms for the observed new findings.
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Table 1.1 Major components of MFGM in bovine milk (adapted from Ref (7)).

Lipids
Triglycerides
Diglycerides
Monoglycerides
Sterols
Sterol esters
Free fatty acids
Hydrocarbons (squalene
and phytene derivatives)
Phospholipids
Polar lipids
Sphingomyelin
Phosphatidylcholine
Phosphatidylethanolamine
Phosphatidylinositol
Phosphatidylserine
Lysophosphatidylcholine
Proteins
Mucin 1
Xanthine oxidoreductase
PAS III
CD 36
Butyrophilin
PAS 6/7
Adipophilin
Fatty acid binding protein

%
62
9
Trace
0.2-2
0.1-0.3
0.6-6
1.2
26-31
%
22
36
27
11
4
2
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Figure 1.1 Complex links between dietary lipids, leaky gut, endotoxemia, obesity,
NAFLD and metabolic inflammation and the effect of the LPS injection. T shaped arrows
indicate the hypothesized effects of polar lipids on NAFLD (①), leaky gut (②, ④),
endotoxemia (③), and systemic inflammation (②, ③, ④). Milk polar lipids decrease gut
permeability and NAFLD and therefore decrease endotoxemia and metabolic
inflammation in mice during the high fat diet feeding and during the LPS stress in
combination with the high fat diet. SQ: subcutaneous injection. NAFLD: nonalcoholic
fatty liver disease. LPS: lipopolysaccharide.
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CHAPTER 2
DIETARY FAT COMPOSITION INFLUENCES TISSUE LIPID PROFILE AND
GENE EXPRESSION IN FISCHER-344 RATS

Abstract
The AIN-76A diet causes fatty liver in rodents when fed for long periods of time. The
aim of this study was to utilize fatty acid analysis and transcriptomics to investigate the
effects of different fat sources in the AIN-76A diet on tissue lipid profiles and gene
expression in male, weanling Fischer-344 rats. Animals were fed isocaloric diets that
differed only in the fat source: 1) corn oil (CO) 2) anhydrous milk fat (AMF) and 3)
AMF supplemented with 10% phospholipids from the milk fat globule membrane
(AMF-MFGM). There were no differences in food intake, body weight, growth rate or
body fat composition among the groups, and the fatty acid compositions of red blood
cells (RBCs), plasma, muscle and visceral adipose tissues reflected the dietary fat sources.
Modifying the fat source resulted in 293 genes differentially regulated in skeletal muscle,
1,124 in adipose and 831 in liver as determined by analysis of variance (ANOVA). While
tissue fatty acid profiles mostly reflected the diet, there were several quantitative
differences in lipid classes in the liver and plasma. The AMF diet resulted in the highest
level of hepatic triglycerides, but the lowest level in plasma. The CO diet decreased
DGAT expression and activity and resulted in significant accumulation of hepatic
unesterified fatty acids, a potential trigger for steatohepatitis. These results indicate that
the fatty acid composition and presence of polar lipids in the AIN-76A diets have
significant effects on lipid partitioning, gene expression, and potentially the development
of liver pathology.
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Reprinted with modifications from Zhou AL, Hintze KJ, Jimenez-Flores R, and Ward
RE. Dietary Fat Composition Influences Tissue Lipid Profile and Gene Expression in
Fischer-344 Rats. Lipids. 2012. 47(12):1119-30. doi: 10.1007/s11745-012-3729-3.
Robert Ward and Korry Hintze raised the rat, collected the tissue samples and obtained
the microarray raw data. Albert Lihong Zhou did the lipid profiling of the diets and the
tissues, carried out the RT-PCR, histology and enzyme assay, processed the microarray
data, carried out data analyses and statistical analyses, interpreted all of the data and
prepared the first draft of the manuscript. Robert Ward revised the manuscript. Korry
Hintze provided the reagents for the RT-PCR experiment. The only contribution to this
work from Rafael Jimenez-Flores was to provide the testing material, the MFGM
isolate.

Introduction
The AIN-76 diet is a purified rodent diet that was developed in the late 1970’s by an
ad hoc committee formed by the American Institute of Nutrition (AIN) (1). One rationale
for developing this diet was to provide researchers with a nutritionally adequate diet that
would allow for standardizing studies between laboratories. Not long after this diet was
developed several groups reported undesirable physiological effects linked to the diet,
such as hemorrhagic deaths (2), nephrocalcinosis (3) and fatty liver (4). An amended
formulation of the diet (AIN-76A) was developed in 1980 with an increased vitamin K
content to address the hemorrhagic effect (5). In 1993 two revised diets were formulated
to replace the AIN-76A, a version for growing animals (AIN-93G) and a maintenance
formula for mature animals (AIN-93M). These revised diets contained a higher
calcium:phosphorous ratio (from 0.75 to 1.3) to prevent the nephrocalcinosis found in
female rats consuming the AIN-76A diet (1). In addition, the carbohydrate composition
was changed from 50% sucrose and 15% cornstarch in the AIN-76A formula to ~40%
cornstarch, 15% dextrinized cornstarch and 10% sucrose in the AIN-93G diet. This
change represents a 5-fold decrease in the fructose content of the diet and is not
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associated with the accumulation of hepatic lipids caused by long term feeding of the
high sucrose levels (6). Despite the availability of the improved rodent diets, the
AIN-76A remains popular in specific research fields, such as in studies investigating the
effects of diet on colon cancer using the aberrant crypt foci model (ACF). In fact, in a
database maintained to compare the efficacy of diet modulation on the incidence of ACF,
the overwhelming majority of studies have utilized the AIN-76A (7) .

The propensity of the AIN-76A diet to result in accumulation of hepatic lipids is
potentially of interest to human nutrition, as it is estimated that between 20% and 30% of
adults in Western countries have nonalcoholic fatty liver disease (NAFLD) and this level
rises to between 70% and 90% in obese individuals and those with diabetes (8). To test
the hypothesis that high levels of dietary fructose are responsible for the accumulation of
hepatic lipids, Bacon et al. tested the effects of modifying the sucrose content of the
AIN-76A diet in a three week feeding study in rats (9). According to the results, diets
containing greater than 25% sucrose resulted in significantly higher hepatic triglycerides
(TG) than ones with less than 20% sucrose or chow.

We recently conducted an aberrant crypt foci (ACF) study utilizing the AIN-76A diet
to investigate the potential chemopreventive effects of a complex milk fat fraction (10).
In the study we used three diets with different fat compositions: 1) corn oil (CO), 2)
anhydrous milk fat (AMF), and 3) anhydrous milk fat supplemented with milk fat globule
membrane (AMF-MFGM). CO diet is the standard fat source for the AIN-76A diet, and
for the AMF diet, the 5% mass of fat was replaced with AMF. Formulation of the
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AMF-MFGM diet was achieved by utilizing an isolate of MFGM (providing 10%
phospholipids of total fat) that was isolated from cream, and which also contained protein,
carbohydrate and minerals in addition to the fat. The details of the diet formulation have
been reported previously (10) and are shown in Table 2.1.

MFGM is derived from the apical surface of mammary epithelial cells and surrounds
the fat droplets in milk (11). It is composed primarily of TG, proteins, and phospholipids
(PL) (12). The composition of the polar lipids of MFGM can vary according to the
method of isolation, but the major constituents are phosphatidylcholine (~32%),
phosphatidylethanolamine (32%), sphingomyelin (~24%), phosphatidylinositol (~4%),
phosphatidylserine (~3%) and gangliosides (~3%) (13). A large amount of this material is
produced in the US each year as a byproduct of butter production, and is available as a
food ingredient. Due to its unique lipid profile and membrane protein profile, MFGM has
been suggested as a potentially bioactive food ingredient with novel nutritional
functionalities (14). Despite this supposition, few studies have been conducted in vivo
with either animal models or humans to evaluate the potential of this material as a
bioactive ingredient.

The goal of this study was to investigate lipid metabolism in rats fed a diet known to
induce hepatic stress. Our approach involved subjecting lipid metabolizing tissues to two
different, yet comprehensive analytical techniques (lipid and gene expression profiling)
to understand how the dietary fats affected lipid metabolism.
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Materials and Methods

Animals and diets
Eleven animals used in this study were among a group of sixty-three male, weanling
Fischer-344 rats (Charles River Laboratories) used in another study (10). They were
randomly assigned to one of three isocaloric dietary treatments that differed only in the
fat source (10). After a 7 day acclimation period on standard chow diets, the rats were
individually housed in a room controlled for temperature, humidity, and light cycle and
were given free access to experimental diets and deionized water. Food intake and body
weight were measured weekly. All experimental protocols involving animals were
approved by the Utah State University Institutional Animal Care and Use Committee.

Animals were fed experimental diets for twelve weeks. After MRI analysis of body
composition (EchoMRI-900™), rats were sacrificed by cardiac puncture following
ketamine/xylazine anesthesia. The liver, the gonadal adipose tissue, and the skeletal
muscle and the blood samples were collected, flash frozen in liquid nitrogen, and stored
at -80 oC until the time of analysis.

Lipid extraction
Tissue samples were removed from the freezer and a sample of tissue was cut into
small pieces with a razor and placed in a mortar with liquid nitrogen and ground to obtain
a fine homogenous powder. About 200 mg of the tissue powder from each sample was
weighed and put into a glass tube with screw cap. Surrogate standards, including
sphingomyelin, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine,
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diglycerides (DG), free fatty acids (FFA), TG, and Cholesteryl esters (CE), were prepared
in chloroform. 100 µl surrogate standards for different lipid classes were added to each
sample and weights were recorded. Lipids were extracted by the method of Folch et al.
(15) with slight modifications. Samples were mixed with 5 ml chloroform/methanol (2:1
with butylated hydroxytoluene, BHT). The whole mixture was sonicated and then
agitated for 15-20 minutes in an orbital shaker at room temperature. The mixture was
washed with 0.2 volumes (1 ml for 5 ml solvent mixture) of 0.9% NaCl solution and
vortexed for 20 seconds. Subsequently, the mixture was centrifuged at 1,500 × g for 10
minutes to separate the two phases. The lower chloroform phase containing lipids was
collected and evaporated under a nitrogen stream and then reconstituted in a small
volume of hexane with BHT in a 4ml amber vial and stored at -80 ºC until further
analysis.

Separation and recovery of different lipid classes
Individual lipid classes of the extracted lipid were separated using thin layer
chromatography (TLC). Extracted lipid from each tissue was diluted by hexane with
BHT such that 20 µl of solution contained around 2.5 mg of lipid. Aliquots of 20 µl were
spotted on a 20 × 20 cm silica gel 60 Å analytical plate (500 µm layer) (Whatman Inc.,
Florham Park, NJ). Lipid class standards were also spotted for detecting target bands.
Total lipid classes were separated by developing the plate in a solvent system containing
hexane, diethyl ether, and formic acid in the ratio of 80:20:2 (v/v). The TLC plate was
then sprayed with 0.05% primulin in acetone:water (8:2 v/v). Individual lipid bands on
the TLC plate were detected under a hand-held UV lamp and the margins were marked
with a pencil. Target lipid class bands were scraped from the TLC plate using a small
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razor blade and collected into glass tubes with screwed caps. Recovered lipid classes
from total lipid TLC plate were: PL, DG, FFA, TG, and CE.

Fatty acid methyl esters
Recovered lipid classes were transesterified into fatty acid methyl esters (FAMEs)
using the method of Curtis et al. (16) with slight modifications. In each tube, 0.8 ml
hexane and 1.2 ml 10% (v/v) acetyl chloride in methanol were added. Tubes were
capped, vortexed for 20 seconds and placed in 100 °C oven for 40 minutes. Upon
completion of incubation period, samples were removed and allowed to cool down to
room temperature. Then 2 ml 6% sodium carbonate solution and 0.4 ml hexane were
added into each tube. On subsequent vortexing and centrifuging of tubes two distinct
phases were obtained. The top organic layer was removed and transferred to gas
chromatography (GC) vials. Solvent was evaporated under a nitrogen stream and fatty
acid methyl esters were collected in 100 µl of hexane with BHT and transferred to GC
vial inserts. The samples were subsequently analyzed by GC using a GC2010 (Shimadzu
Scientific Instruments, Columbia, MD).

GC data analysis
For each GC run, standard curves were generated using commercially available
FAME standards (Nu-Chek Prep, Elysian, MN). To establish the linearity of the detector
response, a three point calibration was generated with every sample set. The calibration
standard, GLC-463, contained 42 fatty acids representing most of the common species
found in mammalian tissues and dairy products. Chromatograms of sample FAMEs were
compared with those of FAME standards to identify target fatty acids. The peak area for
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each fatty acid was then normalized to the peak area and concentration of the
corresponding surrogate standard. Next, the molar concentration of the analytes was
calculated and then converted to moles of the corresponding lipid classes through
molecular weight calculations. The molar concentration of lipid classes was normalized
to tissue sample weights to obtain concentrations (µmole/g tissue) in each tissue. Lastly,
the mole percentage of each fatty acid species was calculated.

Gene expression analysis
Total RNA was extracted from liver, muscle, and adipose tissue as previously
described (10). Tissue samples were homogenized in Trizol with a tissue homogenizer.
Total RNA was extracted using the RNAqueous kit (Ambion) according to the
manufacturer’s protocol. Frozen total RNA was sent to Genome Quebec for analysis.
Microarray data were generated by Genome Quebec using the Illumina platform
(Illumina, Inc., San Diego, CA). Data were analyzed using FlexArray 1.6, a custom
statistical software program developed by Genome Quebec (17). The expression data
were filtered to remove feature ids that have not been detected. Next, a background
adjustment and normalization were carried out using the Lumi algorithm (based on lumi
Bioconductor package) in FlexArray 1.6. Background correction was carried out by using
negative controls. Variance was stabilized by the Variance-Stabilizing Transformation
(VST) method and subsequently a robust spline normalization was conducted. Analysis
of variance (ANOVA) was conducted to evaluate significant diet effects on gene
expression across treatment groups. The Cyber-T algorithm was employed to identify
differentially regulated genes (CT gene lists) among tissues between treatment groups
from ANOVA gene lists (18) followed by the Benjamini-Hochberg False Discovery Rate
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multiple testing correction (19). The CT gene lists were then subjected to KEGG pathway
analysis using ArrayTrack v.3.5.0 (NCTR/FDA) (20).

Real time PCR
Total RNA was extracted from liver samples using the RNAeasy Mini-Kit (Qiagen,
Valencia, CA). RNA quality was checked and the concentration measured by NanoDrop
1000 (Thermo Fisher, Waltham, MA). One microgram RNA was converted to cDNA
using high capacity cDNA reverse transcription kit (Life Technologies, Carlsbad, CA).
Validated and predesigned TaqMan primers and probes (Life Technologies) were used to
quantify cytochrome P450, family 8, subfamily b, polypeptide 1 (Cyp8b1, ID:
Rn00579921_s1), 1-acylglycerol-3-phosphate O-acyltransferase 2 (Agpat2, ID:
Rn01438505_m1), and angiopoietin-like 4 (Angptl4, ID: Rn01528817_m1). Actin, beta
(Actb, ID: ID Rn00667869_m1) was used as an endogenous control. Real-time PCR
amplifications were carried out in a DNA Engine Opticon® 2 Two-Color Real-Time
PCR Detection System (Biorad, Hercules, CA). PCR results were analyzed with the
Opticon Monitor 3 Software (Biorad). The comparative Ct method was used to quantify
gene expression. ∆Ct was obtained by normalizing to actin, beta. ∆∆Ct was determined by
the arithmetic formula described by López-Parra et al. (21). Symmetrical raw fold change
was obtained by comparing ∆∆Ct values of two groups compared.

Liver fat analysis by histology
Cryostat sections of 6 µm thickness were made from liver samples taken out of 80 °C freezer. The tissue sections were brought to room temperature on glass slides. The
slides were dipped a few times in 60% triethyl phosphate and then stained in 0.5% Oil
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Red O (in 60% triethyl phosphate) for 15 minutes. After being rinsed in water for 2
minutes, the slides were counterstained in Harris modified method hematoxylin stain
(Thermo Fisher, Waltham, MA) for 2 minutes. The slides were placed in saturated
lithium carbonate solution for 10 seconds, rinsed in water for 5 minutes, and held in
water. The slides were mounted with warm glycerin jelly and observed with light
microscopy. Color images were captured with a digital camera attached to the
microscope. Oil Red O stained areas in randomly sampled regions from each slide were
quantified by ImageJ (22). The fat content of each sample was expressed by
quantification of Oil Red O–stained areas as a percentage of whole area.

Liver diglyceride acyltransferase (DGAT) enzyme assay
The microsomal fraction of the liver was obtained by the methods of Ko et al. (23)
and Coleman (24). Rat liver (approximately 1.5 g) was minced and then homogenized in
15 ml of STE buffer (0.25 M sucrose, 10 mM Tris-HCl, pH 7.4, 1.0 mM EDTA) with a
Teflon-glass homogenizer at medium speed. The homogenate was centrifuged at 14,000
× g for 20 minutes at 4 °C. The supernatant was centrifuged at 100,000 × g for 1 h at 4 °C
to obtain a microsomal pellet. The pellet was suspended in STE buffer without EDTA
and centrifuged at 100,000 × g for 1 h at 4 °C. The final pellet was resuspended in STE
buffer without EDTA. Total protein in final solution was quantified by the Bradford
Assay. The microsomal fractions were stored in aliquots at -80 °C.

A fluorescent DGAT assay was carried out as described by McFie and Stone (25).
Briefly, a master mix was prepared in a test tube containing: 20 µl of 1 M Tris-HCl (pH
7.6), 4 µl of 1 M MgCl2, 10 µl of 4 mM dioleoyl-sn-glycerol, 10 µl of 12.5 mg/ml bovine
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serum albumin, 10 µl of 500 µM NBD-palmitoyl CoA and 96 µl of water per reaction.
Tubes were pre-incubated in a 37 °C water bath for 2 minutes and 50 µl of protein sample
was added to start the reaction, which was held at 37 °C for 10 minutes with occasional
shaking. The reaction was terminated by addition of 4 ml CHCl3/MeOH (2:1, v/v).
Samples were added 800 µl of water and allowed to sit at room temperature for 1 h.
Tubes were centrifuged at 3000 × g for 5 minutes to separate aqueous and organic phases.
The organic phase was removed via pipette and dried under stream of nitrogen. Lipids
were resuspended in 50 µL CHCl3/MeOH (2:1) and spotted on a 20 x 20 cm TLC plate.
TLC plates were developed in the solvent system, hexane/diethyl ether/acetic acid
(80:20:1, v/v/v). The plates were air dried for 1 h and scanned by Typhoon Trio+ Laser
Imager 7 (GE Healthcare, Waukesha, WI). The following settings were used: Excitation Blue (488 nm) LED laser light source; Emission – 520 nm BP emission filter.
Fluorescence was quantified by ImageJ (22). The newly synthesized NBD-TG was
quantified as units (fluorescence intensity) of NBD-TG formed per minute per mg protein.

Statistical analysis
A one-way ANOVA was performed using SAS software version 9.2 (SAS Institute
Inc.) to perform comparisons among groups or using FlexArray 1.6 for gene expression
among groups and tissues. Group means were compared using Cyber-T algorithm for
gene expression data and Ryan-Einot-Gabriel-Welsch Multiple Range Test for other data.
Data are reported as Mean ± Standard Error of the Mean (SEM).
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Results

Fatty acid profile of diets
The most abundant fatty acids of the test diets are shown in Figure 2.1. Both the milk
fat based diets have similar fatty acid profiles, and are very different from the CO diet.
The milk fat diets both have significant contributions of saturated fatty acids (~65%)
whereas in the CO diet the percentage is much lower (~17.5%). All diets have similar
levels of monounsaturates, with oleic acid contributing approximately 25%. The other
notable difference is in the polyunsaturated fatty acid content (PUFA) content (CO 54%,
AMF 4.5% and AMF-MFGM 6%) and n6:n3 ratio (CO 54:1, AMF 6:1, AMF-MFGM
7:1).

Food intake, body weight, growth rate and body fat composition
There were no significant differences in terms of food intake, final body weight,
growth rate or body fat composition (MRI analysis) among groups (Figure 2.2) (10).

Fatty acids profile of RBCs
The RBC fatty acid profile was measured to compare the CO diet to the milk fat
based diets, and to determine if the higher polar lipid content of the AMF-MFGM had an
effect compared with the AMF diet. RBC fatty acids that were significantly affected by
the diets and present at least one percent of total fatty acids are shown in Figure 2.3. Not
surprisingly, the CO cohort had a higher percentage of 18:2n-6, 20:4n-6 and 22:4n-6, all
n6 fatty acids, presumably due to the high linoleic acid content of the diet. In addition,
these animals had lower percentages of 16:1n-7, 18:1n-9, 18:1n-7, 20:3n-9, 20:5n-3,
22:5n-3 and 22:6n-3 compared with the animals fed the milk fat diets. The RBCs from
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animals fed the two milk fat based diets had remarkably similar fatty acid profiles with
two statistically relevant differences. Namely, the AMF-MFGM fed animals had a higher
percentage of 18:1n-7 and a lower percentage of 20:3n-9.

Fatty acids profile of skeletal muscle tissue and visceral adipose tissue
As with the RBCs, there were large differences between the fatty acid profile in
skeletal muscle and visceral adipose tissue of the rats fed the CO diet versus the milk fat
diets, which were virtually identical (Figure 2.4 & 2.5). In skeletal muscle, the CO fed
animals had significantly less 16:1n-7, 18:1n-9, and 20:3n9, and more 18:2n-6, 20:4n-6,
and 22:4n-6 (Figure 2.4). Unlike skeletal muscle, the contribution of long chain fatty
acids to the adipose lipids was low (Figure 2.5). However, among the major fatty acids
(> 1% total), the CO animals had less 16:0, 16:1n-7, 18:0, 18:1n-9 and more 18:2n-6. The
only fatty acid that differed among the animals fed the milk fat diets was 20:3n9, which
in both tissues was slightly lower in the AMF-MFGM group.

Fatty acids profile of liver tissue
Fatty acids in liver tissue which were significantly affected by the CO, AMF and
AMF-MFGM diets and which contribute at least 1% of fatty acids in one tissue are
presented in Figure 2.6. Animals from the CO group had less 16:1n-7, 18:1n-9, 20:3n-9,
and 22:6n-3 and more 18:2n-6 and 20:4n-6. Unlike the RBCs, skeletal muscle, and
adipose tissues, supplementation of the AMF diet with MFGM resulted in several
differences in the fatty acid profile of the liver. For example, of the six fatty acids that are
significantly affected across the diets and present at least 1%, five are significantly
different in livers of the animals fed the AMF and AMF-MFGM diets. Thus, the
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increased polar lipid concentration of the AMF-MFGM diet appears to have significant
effects in liver lipid metabolism and partitioning. The largest differences are in 18:1n-9,
which is higher in the AMF animals, and 20:4n-6 and 22:6n-3, which are higher in the
AMF-MFGM cohort.

Plasma, visceral adipose and liver lipid classes
To better understand the differences in lipid partitioning as affected by the CO, AMF
and AMF-MFGM diets, plasma, adipose and liver lipid classes were analyzed. Lipid
classes with significant differences are shown in Figure 2.7. Interestingly, the animals
consuming AMF as the fat source had less total PL in plasma than animals fed the CO
and AMF-MFGM diets. Additionally, there was less TG than the animals fed the
AMF-MFGM diet. In the visceral adipose, there was more TG in the animals fed CO than
those fed the AMF-MFGM. In the liver, there was more FFA in the animals fed the CO
diet than in those fed the AMF-MFGM diet, and a similar trend for the AMF animals,
although this was not significant. On the other hand, the CO diet resulted in less
accumulated TG than the AMF diet, with the AMF-MFGM diet in between. Lastly, both
the CO and the AMF-MFGM diets resulted in lower hepatic CE than did the AMF diet.

Tissue gene expression
In total, 293, 1,141, and 831 genes were differentially expressed, respectively, in
skeletal muscle, adipose, and liver at p < 0.05. To identify metabolic pathways that were
affected across the three diets all the genes that were differentially regulated according to
the ANOVA analysis were analyzed with the program ArrayTrack, a free software tool
developed by the National Center for Toxicological Research (NCTR) and the United
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States Food and Drug Administration (FDA). All three diets were compared and the data
generated from this analysis are summarized in Table 2.2. On a diet comparison basis, the
fewest number of pathways affected across the three tissues were between the two milk
fat fed animal groups (22 pathways) and the most pathways were affected between the
CO and AMF-MFGM groups (40 pathways). In specific tissues, there were 18 pathways
differentially affected in skeletal muscle, 31 in adipose and 40 in the liver. In specific
diet/tissue comparisons, the fewest number of pathways were affected in skeletal muscle
between the CO and the AMF diets (2). There were 16 pathways affected between the
AMF and CO diets in the liver and 16 pathways between the AMF-MFGM and CO diets
in adipose. In the lower half of Table 2.2 the pathways that were significantly affected
across at least two diet combinations are shown. For example, in the muscle tissue, the
circadian rhythm pathway (KEGG rno 04710) was significantly affected between all
three diets, where as adipocytokine signaling (rno00020) was only affected in the diet
combinations in which AMF was compared. Similar to the fatty acid data of the selected
tissues, there were fewer pathways affected in the muscle and adipose tissue compared
with the liver. A striking feature of the pathway analysis shown in the bottom half of
Table 2.2 is that only 3 pathways were different in the liver between the two milk fat
diets, whereas > 10 were affected when these diets were compared with the CO diet.

Although the two milk fat diets were nearly identical at the fatty acid level, there were
several differences in the liver and plasma lipid profiles of the rats fed the AMF and
AMF-MFGM diets. Therefore, the expression of several genes of interest was
determined using RT-PCR and the results are shown in Table 2.3. The three genes
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selected were chosen from the KEGG (Kyoto Encyclopedia of Genes and Genomes)
pathways differentially affected by the milk fat diets in Table 2.2. The results of the
RT-PCR in Table 2.3 are expressed relative to actin, beta, and thus a smaller number
indicates a higher expression level. Comparing the two milk fat groups, all three genes
are more highly expressed in the livers of the AMF-MFGM rats compared with the AMF
group.

Liver fat analysis by histology and DGAT assay
In general, both the lipid analysis and the gene expression profiling indicated the diets
had the greatest effect on the liver. Although there was not a quantitative difference in the
total lipid content of the livers, there were significant differences in distributions across
lipid classes (Figure 2.7). For example, there is more triglyceride in the livers of rats fed
AMF compared with the CO, yet the total fatty acid was not different. Interestingly,
expression of diglyceride O-acyltransferase 2 (DGAT2), was lower in the CO fed animals
than in the other two groups. Consequently, the livers were stained with Oil Red O
(Figure 2.8) and DGAT activity was measured via enzymatic assay of the microsomal
fraction, and the results are shown in Figure 2.9. There was significantly less staining of
the hepatic tissue of the CO fed mice (Figure 2.9a), and this corresponded with lower
DGAT activity (Figure 2.9b).

Discussion
The main focus of this work was to utilize tissue fatty acid profiling and
transcriptomics to determine the effects of changing the lipid source of the AIN-76A diet
on lipid metabolism. This work was conducted on key tissues involved in lipid
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metabolism, storage and processing (skeletal muscle, visceral adipose and liver) as well
as plasma. The fat sources used in formulating the diets (corn oil, anhydrous milk fat and
anhydrous milk fat supplemented with milk fat globule membrane) were originally
selected for an ACF study previously reported (10). In that study, as in most ACF studies,
the CO diet was selected as a control, whereas the AMF-MFGM diet was included to
determine potential cancer protective effects of specific lipids associated with this
material, such as sphingomyelin and plasmalogens. The AMF diet was included to
control for the potential that other lipids in milk fat might affect the development of ACF,
such as butyrate and conjugated linoleic acid. While it was expected that fat sources like
CO and AMF that vary widely in fatty acid composition would affect both lipid
partitioning between tissues as well as gene expression, it was unclear what effect the
inclusion of polar lipids would have between the two milk fat based diets as they are so
similar at the fatty acid level.

The membrane composition of RBCs reflects dietary fat sources, and several groups
have investigated the correlation of RBC fatty acid profiles with disease susceptibility in
humans. For example, Harris and Von Schacky have shown that the omega-3 index, the
combined percentage of EPA (20:5n-3) and DHA (22:6n-3) in RBCs, correlates in
humans with risk of coronary heart disease (CHD) with values above 8% being
associated with the most protection and values below 4% with the least (26). A similar
metric, the percent contribution of omega-6 fatty acids to highly unsaturated fatty acids
(HUFA, ≥ 20 carbons and ≥ 3 double bonds),%n6 HUFA, was shown by Lands to
correlate with CHD mortality in several human populations with levels below 40% being
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protective (27). The omega-3 indices were 0.9 for the CO diet, 2.5 for the AMF diet and
2.0 for the AMF-MFGM diet, while the % n-6 HUFA levels were 96%, 79% and 83%,
respectively. While these metrics may not be applicable in rodents, it is interesting
nonetheless that all three diets result in very low levels of n-3 long chain PUFA in RBCs
which likely affect many physiological processes.

One interesting fatty acid which is present at significant levels in the RBCs, muscle,
adipose and liver of the milk fat fed animals, but not those consuming CO is 20:3n-9.
This fatty acid is an elongation product of oleic acid and has been shown to be a sensitive
marker of PUFA intake. According to Lands, 20:3n-9 correlates with low PUFA intakes
and a value of approximately 10% in the HUFA indicates PUFA insufficiency (27). To
our knowledge, no studies have provided data on the % contribution of 20:3n-9 to tissue
HUFA for RBCs, muscle, adipose and liver which are shown in Table 2.4. Animals fed
the AMF diet have the highest levels of this fatty acid across all tissues measured, while
those consuming the AMF-MFGM diets also had high levels. Interestingly, the HUFA
percentage of 20:3n-9 in adipose was high for the CO fed animals, albeit not as high as
the other groups. This may be a result of the very low concentration of HUFA in adipose,
as the lipids in this tissue are primarily less than 18 carbons in length.

The lipid profiles of the RBCs, muscle, adipose and liver reflect the fat sources of the
three diets, and there were few differences between those fed the AMF and AMF-MFGM.
However, there were quantitative differences across lipid classes in both plasma and the
liver. Pathway analysis of the gene expression data indicated that a fewer number of
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pathways was affected in skeletal muscle than in liver. There were no differences in total
liver fatty acids between treatments, but there was in the distribution of fatty acid across
lipid classes (Figure 2.7). One striking feature is the high FFA and low TG in the livers of
the CO fed rats compared with those fed the AMF-MFGM diet. To further investigate
this finding we compared oil red O staining in livers across the three treatments, and the
results are shown in Figure 2.9a. In the rats fed the CO diets there is less oil red O
staining. According to O’Rourke et al., oil red O staining of tissues is well correlated with
triglyceride content (28). The inverse relationship between the hepatic TG and FFA
suggests the differences may be due to triglyceride synthesis activity. According to the
gene expression profiling, DGAT2, the enzyme responsible for the final step in TG
synthesis from diglycerides and FFA was 1.25 fold lower in the CO fed rats compared
with those fed AMF and 1.46 fold lower compared with those fed AMF-MFGM. These
differences are modest, and it was not clear if their expression would translate into
physiological differences. Thus, the triglyceride synthetic activity in liver microsomal
fractions was measured using a functional assay and the results are shown in Figure 2.9b.
In agreement with the oil red O staining, the DG activity measure suggests the
differences in FFA, DG and TG levels in the liver may be partially explained by the
conversion of FFA and DG into TG.

While excess hepatic TG storage has typically been viewed as a negative
physiological response, it may be protective under some metabolic situations. For
example, in a mouse model of nonalcoholic steatohepatitis (NASH), Yamaguchi et al.
evaluated the effects of hepatic DGAT2 expression on disease development using an
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antisense nucleotide treatment (29). While reducing expression of DGAT2 did prevent
hepatic steatosis, the increase in FFA was associated with markers of lipid
peroxidation/oxidant stress and fibrosis. From this study the authors concluded that
accumulation of hepatic TG is actually protective against progressive liver damage in
NAFLD. It is unclear why the CO diet resulted in lower DGAT expression and activity in
the CO fed rats. However, one distinguishing feature of this diet is the PUFA content
primarily in the form of linoleic acid. Interestingly, reviewing the fatty acid composition
of diets used to study NASH, Romestaing et al. drew the conclusion that dietary PUFA
with a high omega-6 to omega-3 ratio may be a causative factor via effects on lipid
peroxidation and proinflammatory cytokine production (30).

There are several differences in the plasma and hepatic lipid profiles of the animals
fed the two milk fat diets, which is surprising considering the similarity of these diets at
the fatty acid level. According to the KEGG pathway analysis conducted on the hepatic
gene expression and shown in Table 2.2, the two milk fat diets affected PPAR signaling
(rno03320), C21 steroid hormone metabolism (rno00140) and glycerophospholipid
metabolism (rno00564). The affected PPAR signaling in both the liver and skeletal
muscle were through PPARα receptor. The involved genes were associated with
lipogenesis, cholesterol metabolism and fatty acid transport in the liver and with
lipogenesis in skeletal muscle. Consequently, the expression of three genes from these
pathways was validated using RT-PCR. The genes Cyp8b1, Agpat2 and Angptl4 were
selected from the differentially expressed genes in the pathways determined by the gene
expression profiling. They were chosen due to their physiological function and potential
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to affect tissue lipid partitioning, and the results are shown in Table 2.3. The function of
these genes is discussed below including their potential roles in affecting lipid
metabolism across the two milk fat groups. Of course these findings are only correlations
and positive confirmation of their roles will need to be tested explicitly for confirmation.

Cyp8b1 is a cytochrome P450 enzyme which is a component of the primary bile acid
biosynthesis and PPARα signaling pathways in the liver. It is involved in the synthesis of
cholic acid (31). Cyp8b1 controls the ratio of cholic acid to chenodeoxycholic acid in bile
salts, and as cholic acid is less effective in solubilizing cholesterol it may affect its
absorption (32). The AMF-MFGM diet was associated with a lower hepatic cholesteryl
ester content (Figure 2.7). Milk polar lipids affect both the absorption and fecal excretion
of cholesterol when fed both acutely and chronically. For example, Noh and Koo found
that infusion of milk sphigomyelin via a duodenal catheter resulted in decreased
cholesterol, fat and vitamin E absorption (33). In a chronic feeding study Kamili et al. fed
mice high fat diets for 5 weeks which were supplemented with two different formulation
of milk phospholipids at 1.2% by weight (34). Both milk polar lipid preparations resulted
in significant decreases in liver cholesterol and triglyceride which was accompanied by
an increase in fecal cholesterol excretion. Data from the present study indicates that the
decreased cholesterol absorption and increased fecal excretion resulting from luminal
milk polar lipids in those previous studies may be mediated, at least in part, by the ratio
of bile acids.
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Agpat2 is an enzyme responsible for the conversion of lysophosphatidic acid to
phosphatidic acid, a step in PL synthesis and is a component of KEGG pathway
glycerophospholipid metabolism. The expression of Agpat2 was higher in the
AMF-MFGM group than the AMF group (Table 2.3) but there was not a significant
difference in hepatic PL. There was, on the other hand, a significant increase in plasma
PL in the AMF-MFGM. The increased plasma PL may result from increased hepatic
synthesis and secretion. Previous studies with milk polar lipids have also shown the
ability of these constituents to increase both plasma PL and TG. For example, Wat et al.
(35) fed mice both a low fat, non purified diet and a high fat diet formulated with and
without a 2.5% PL-rich milk fat extract. In the mice fed the low fat, non purified diet, the
milk PL increased the plasma TG by 20% and the plasma PL by 5% over the control
mice fed the low fat diet. However, in the mice fed the high fat diets, the PL-rich extract
actually reduced both the plasma TG and PL to levels similar to the low fat control. The
increased plasma lipid concentration in the rats fed the AMF-MFGM diet, compared with
those fed the AMF diet may be a result of either more lipid exported from the liver, or
from reduced clearance via peripheral tissues.

Expression of Angptl4 was also verified by RT-PCR. Angptl4 is a component of the
PPARα signaling pathway. It is an angiopoietin-like protein which increases plasma TG
via suppression of lipoprotein lipase (36). Interestingly, there were significant differences
in plasma TG between the two milk fat fed groups (Figure 2.7). Also known as fasting
induced adipocyte factor (Fiaf), Angptl4 is highly expressed in the gut epithelium in
germ-free mice and prevents accumulation of fat into adipocytes, whereas
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conventionalization with a microflora suppresses this effect (37). Although it is not clear
if hepatic expression of Angptl4 in the AMF-MFGM fed rats contributed to the increase
in plasma TG, this finding indicates a potential mechanism via which this effect was
mediated.

Despite the fact that it is still commonly used in ACF studies with rodents (7), the
high sucrose content of the AIN-76A diet has been long known to cause fatty liver in
animals fed the diet for long periods of time (9). Therefore, when reviewing the different
effects of the fat sources on tissue lipid composition and gene expression it is necessary
to keep in mind these changes are in the context of an overall metabolically stressful diet.
From the data presented here, a few hypotheses may be drawn that can be tested in
studies designed specifically for their evaluation. For example, compared with the milk
fat diets, the CO diet caused a significant increase in hepatic free fatty acids, a potential
trigger for the development of NASH from NAFLD. It may be hypothesized that high
dietary n6 PUFA facilitates the development of NASH from NAFLD by increasing
hepatic free fatty acids. Conversely, compared with the CO and AMF-MFGM diets, the
AMF diet resulted in more hepatic TG storage which in itself may be undesirable. It may
be hypothesized that dietary saturated fatty acids increases hepatic TG and facilitate the
development of hepatic steatosis. Supplementing the AMF diet with polar lipids from
milk appears to reduce the accumulation of hepatic TG yet appears to achieve this effect
via promotion of lipid export into plasma. The long term physiological significance of
this is unknown. It may be hypothesized that dietary polar lipids increase hepatic TG
export into the circulation to be stored in adipose tissue and to be utilized by the muscle.
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In conclusion, the fat source of the AIN-76A diet affects the tissue profile of key tissues
involved in lipid trafficking and storage as well as gene expression networks within these
tissues.
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Table 2.1 Composition of dietary treatments.

a

Diets were prepared by Dyets.com. bFour grams of lactose was added to the control and AMF
diets to balance lactose in MFGM isolate. cMFGM isolate is 68% protein, 20% fat, 4% ash, and
4% lactose. The casein to whey ratio is 80:20. The triglyceride to polar lipid ratio is 3:1. dMineral
composition of MFGM isolate was determined by ICP-AAS. Minerals were adjusted in
AMF-MFGM diet accordingly. eAmount derived from MFGM portion of the diet in parentheses
(mg/kg diet).
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Table 2.2 Metabolic pathways significantly affected across all three diet combinations
(CO = corn oil; AMF = anhydrous milk fat; AMF-MFGM = anhydrous milk fat-milk fat
globule membrane; KEGG = Kyoto Encyclopedia of Genes and Genomes).
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Table 2.3 Differentially expressed genes by ANOVA in liver from rats fed with diet
containing corn oil (control), anhydrous milk fat (AMF) and milk fat globule membrane
(AMF-MFGM) (unit: ∆∆Ct).

Genes
Cyp8b1
Agpat2
Angptl4

CO
-0.94±0.26b
1.93±1.03ab
2.90±0.93b

AMF
-0.10±0.16a
2.82±0.42a
4.19±0.26a

MFGM
-2.49±0.41c
1.14±0.48b
2.34±0.67b

a, b, c

Means in a row with different superscripts are significantly different (p < 0.05). The
data represent mean ± SEM (n = 4, 3, 4 for CO, AMF, AMF-MFGM).

Table 2.4 %20:3n-9 in highly unsaturated fatty acids (HUFA) in RBCs, skeletal muscle,
adipose, and liver as a function of diet.

%20:3n-9 in HUFA
RBCs
Muscle
Adipose
Liver
a,b,c

CO
NDb
0.51±0.05c
7.92±0.24c
0.53±0.02c

AMF
11.05±0.15a
20.01±0.26a
43.08±1.37a
15.65±0.84a

AMF-MFGM
8.60±1.39a
12.44±0.16b
31.40±0.21b
8.64±0.49b

Means in a row with different superscripts are significantly different (p < 0.05), ND
= not detected. The data represent mean ± SEM (n = 3).
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Figure 2.1 Fatty acid profile of experimental diets. Only fatty acids present at > 1% of
total fatty acids are shown. The data represent mean ± SEM (n = 2). Means in a row with
different superscripts are significantly different (p < 0.05).
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Figure 2.2 Effect of experimental diets on food intake (a), total weight gain (b) and body
fat composition (c). Values are mean ± SEM (n = 17, 16, 16 for CO, AMF,
AMF-MFGM). Experimental diets did not significantly affect consumption, weight gain
or body fat percentage.
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Figure 2.3 Red blood cell (RBC) fatty acids from rats fed CO (corn oil), AMF
(anhydrous milk fat) and AMF-MFGM (anhydrous milk fat-milk fat globule membrane).
The data represent mean ± SEM (n = 3). Only fatty acids present at greater than 1% of
total fatty acids are shown. Means in a row with different superscripts are significantly
different (p < 0.05).
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Figure 2.4 Fatty acid profile of skeletal muscle from rats fed CO (corn oil), AMF
(anhydrous milk fat) and AMF-MFGM (anhydrous milk fat-milk fat globule membrane).
The data represent mean ± SEM (n = 3). Only fatty acids present at greater than 1% of
total fatty acids are shown. Means in a row with different superscripts are significantly
different (p < 0.05).
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Figure 2.5 Fatty acid profile of visceral adipose tissue from rats fed CO (corn oil), AMF
(anhydrous milk fat) and AMF-MFGM (anhydrous milk fat-milk fat globule membrane).
The data represent mean ± SEM (n = 3). Only fatty acids present at greater than 1% of
total fatty acids are shown. Means in a row with different superscripts are significantly
different (p < 0.05).
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Figure 2.6 Fatty acid profile of liver tissue from rats fed CO (corn oil), AMF (anhydrous
milk fat) and AMF-MFGM (anhydrous milk fat-milk fat globule membrane). The data
represent mean ± SEM (n = 4). Only fatty acids present at greater than 1% of total fatty
acids are shown. Means in a row with different superscripts are significantly different (p
< 0.05).
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Figure 2.7 Quantitation of lipid classes from plasma, visceral adipose and liver. PL =
phospholipids, TG = triglycerides, FFA = free fatty acids, CE = Cholesteryl esters. The
data represent mean ± SEM (n = 3 for plasma and adipose, n = 4 for liver). Means in a
row with different superscripts are significantly different (p < 0.05).

Figure 2.8 Liver histological slides (light microscope, 18x) by Oil Red O Staining from
rats fed CO (corn oil), AMF (anhydrous milk fat) and AMF-MFGM (anhydrous milk
fat-milk fat globule membrane).
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Figure 2.9 Hepatic Oil Red O Staining (A) and hepatic DGAT activity (B) in liver tissue
from rats fed CO (corn oil), AMF (anhydrous milk fat) and AMF-MFGM (anhydrous
milk fat-milk fat globule membrane). The data represent mean ± SEM (n = 4, 3, 4 for CO,
AMF, AMF-MFGM). Means with different superscripts are significantly different (p <
0.05).

70

CHAPTER 3
DIETARY MILK POLAR LIPIDS AFFECT LIPID METABOLISM, GUT
PERMEABILITY AND SYSTEMIC INFLAMMATION IN C57BL/6J OB/OB
MICE

Abstract
Dynamic interactions between lipid metabolism, gut permeability and systemic
inflammation remain unclear in the context of obesity. One objective of this study was to
explore the dynamic changes of gut permeability, inflammation and lipid metabolism in
genetic obesity. Another objective was to test the hypotheses that milk polar lipids will
reduce gut permeability, systemic inflammation and liver lipid levels, and affect the
expression of genes associated with fatty acid synthesis and cholesterol regulation in the
liver in preexisting obesity. Three groups of C57BL/6J ob/ob mice were fed moderately
high fat diets for 2 weeks: 1) modified AIN-93G diet (CO) with 34% fat by energy; 2)
CO with milk gangliosides (GG); 3) CO with milk phospholipids (PL). The GG and the
PL did not affect the total food intake, weight gain or fasting glucose. The PL led to
smaller livers and mesenteric fat depots compared with the CO. No difference was found
in the gut permeability. Dietary polar lipids did not enrich the polar lipids content in the
intestinal mucosa. The GG increased the expression of the tight junction protein occludin
in the colon mucosa compared with the CO. The GG and the PL decreased the expression
of the tight junction protein ZO-1 in the jejunum mucosa compared with the CO. The
moderately high fat diet feeding increased the plasma endotoxin level, which was not
affected by the dietary polar lipids. The PL increased the IL-6 level in the plasma and the
sphingomyelin levels in the plasma and the liver compared with the CO and the GG. The
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increase of the plasma IL-6 level was positively correlated with the sphingomyelin
increase in the plasma and the liver. The PL and the GG decreased the PI level in the
liver and the skeletal muscle. Hepatic expression of 13 genes involved in lipid
metabolism was assessed by RT-qPCR. The GG and the PL differentially regulated the
genes associated with fatty acid and cholesterol metabolism. In conclusion, dietary
supplementation of milk polar lipids may affect lipid metabolism and have unfavorable
effects on systemic inflammation in genetic obesity.

Introduction
Obesity is usually defined as a condition with excessive body fat that has an adverse
effect on health (1). The pathological states associated with obesity include many
comorbidities, such as type 2 diabetes, cardiovascular disease, leaky gut, dyslipidemia,
non-alcoholic fatty liver disease (NAFLD) and systemic inflammation (2-4). The
increased intestinal permeability has been observed in obese animals (5) and humans (2).
Leptin-deﬁcient C57BL/6J ob/ob (ob/ob) mice have more surface area and mass of their
intestinal mucosa for nutrient absorption in proportion to the metabolic mass (6). This
increased surface area is caused by the intestinal hyperplasia (7) and the associated
inappropriate increase and distribution of the tight junction (TJ) proteins leads to the
decrease in the barrier integrity (6). Ob/ob mice also have portal (8) and plasma
endotoxemia, the presence of lipopolysaccharide (LPS) in the blood (9). LPS can activate
the toll-like receptor 4 (TLR4) and initiate inflammation in various tissues (10). The
systemic inflammatory state in obesity is associated with endotoxemia resulting from
increased gut barrier permeability in obese animals (5) and humans (2).
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In obese subjects, the high levels of inflammatory cytokines may alter structure and
localization of the TJ to cause malfunction of the intestinal barrier (11). The adipose
tissue contains adipocytes, ﬁbroblasts, leukocytes, and macrophages. These cells may
jointly produce proinflammatory cytokines, such as tumor necrosis factor-α (TNF-α) and
interleukin-6 (IL-6) (12). Adipocytes are also targets of the proinflammatory signals
such as TNF-α and IL-6 (13). Obesity, systemic inflammation and increased intestinal
permeability may generate a self-perpetuating vicious cycle (Figure 1.1) (14). Lipid
metabolism is involved with this complex cycle. The plasma long-chain saturated fatty
acids (LCSFA, e.g., myristic, palmitic acids) activate the TLR4 in adipocytes and
macrophages and initiate the secretion of proinflammatory cytokines such as IL-6 (10).
The LCSFA may have synergistic effect with LPS on the activation of the TLR4 (10).
Therefore, increased gut barrier permeability, endotoxemia, systemic inflammation, and
lipid metabolism are complexly interrelated events during obesity (Figure 1.1).

The current estimates by the Centers for Disease Control is that about 1/3 Americans
are obese (body mass index, BMI ≥ 30) and 1/3 Americans are overweight (25 ≤ BMI <
30). The burden of the obesity epidemic is well recognized but there are not yet very
effective preventive solutions. The main effective therapy is surgery. Dietary intervention
might have promising potential in fighting against obesity since the excessive food
energy intake (the easily accessible and palatable diet) is one of the main causes of
obesity (15, 16). Rich in nutrients, milk provides protection for the gut and enhances the
immune system of the newborn (17). One fraction of milk, the polar lipids, may play
important roles in biological functions such as maintaining gastrointestinal barrier
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integrity and affecting systemic inflammation, and lipid metabolism. The milk polar
lipids mainly come from the milk fat globule membrane (MFGM) and include
phospholipids (PL) and gangliosides (GG). The most abundant milk polar lipids are
phosphatidylcholine (PC), phosphatidylethanolamine (PE), sphingomyelin (SM),
phosphatidylinositol (PI) and phosphatidylserine (PS) (36%, 27%, 22%, 11% and 4%
respectively of total polar lipids) (18).

A milk isolate, rich in polar lipids, protects against the increase in gut permeability of
fluorescein isothiocyanate-dextran (FITC-dextran) in mice stressed by the LPS (19).
Dairy GG inhibits the degradation of the gut TJ protein occludin during the LPS-induced
acute inflammation (20). Dietary PL reduce liver triglycerides (TG) and cholesterol in
rats (21). The PL-rich MFGM extract supplemented diet reduces hepatomegaly, hepatic
steatosis and hyperlipidemia and positively regulates genes associated with fatty acid
synthesis and cholesterol regulation in mice fed a high-fat diet (22). The effects of the PL
on liver lipid metabolism could be partially due to the choline contributed by the PC
when the diets were high in sucrose, which promote the development of fatty liver
disease (23). The milk sphingolipids, including SM and GG, have been shown to reduce
the uptake of cholesterol (24) and the inflammatory response (25, 26). The
supplementation of milk polar lipids in a high fat diet in the context of preexisting obesity
may facilitate the understanding of the interrelationships among the intestinal barrier
integrity, endotoxemia, systemic inflammation, lipid metabolism and obesity.
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Ob/ob mice fed a standard chow diet have increased intestinal permeability (8). High
fat diets decrease the gut barrier integrity and increase endotoxin absorption, which leads
to the systemic inflammation independent of obesity (27). The ob/ob mice can be used as
an obesity model in exploring the interrelationships among the intestinal barrier integrity,
endotoxemia, systemic inflammation, lipid metabolism and obesity. This study was
designed to test the hypotheses that the dietary milk polar lipids will reduce gut
permeability and liver lipid levels, affect the expression of genes associated with fatty
acid synthesis and cholesterol regulation in the liver, and alleviate the systemic
inflammation that resulted from the preexisting obesity and may be sustained and/or
exacerbated by the high fat intake.

Materials and Methods

Diets formulation
Diets based on the AIN-93G rodent diet were used in this study. The fat provided 34%
energy (16.8% by weight). This amount of fat is considered high compared with the 16%
(energy) fat in the regular mouse chow diet (LabDiet 5K52, Table 3.1). The high fat diets
with 30% or more fat as energy have successfully induced obesity in the C57BL/6J mice
(28). Data from the National Health and Nutrition Examination Survey (NHANES
2007-2008) indicates that the mean amount of fat consumed per individual American was
34% by energy. Thus, using diets with 34% (energy) fat emulates the real dietary
practices in America. The current estimates by the Centers for Disease Control is that
about 1/3 Americans are obese (BMI ≥ 30) and 1/3 Americans are overweight (25 ≤ BMI
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< 30). So it could be common practice to have diets with 34% (energy) fat in the
background of obesity.

Three diets based on the AIN-93G rodent diet were formulated (Table 3.1) so that
they were identical in the macro and micro nutrient except for the fat source, which were
provided by soybean oil + lard (CO diet), soybean oil + lard + milk GG (GG diet),
soybean oil + lard + milk PL (PL diet), respectively. The milk polar lipids were provided
as a semi-purified milk PL concentrate or a semi-purified milk GG concentrate prepared
from the dried milk cream by ethanol extraction (Fonterra (USA), Inc., Rosemont, IL).
The GG was supplemented at 0.2 g/kg diet, including 0.17 g of ganglioside GD3 and 0.03
g of ganglioside GM3. The GG diet also contained small amount of PC, PS, PE and SM
(0.55, 0.48, 0.21 and 0.2 g/kg diet). The PL was supplemented at 10 g/kg diet, including
2.9 g of SM, 5 g of PC, 1.6 g of PE and 0.6 g of PS. The mineral contents of the diets
were verified by the Utah Veterinary Diagnostic Laboratory. The fatty acid composition
of the diets was analyzed by Gas Chromatography (GC) as described previously (29).

Animals
Five-week-old male C57BL/6J ob/ob mice (n = 18; Jackson Laboratory) were housed
singly in cages at a constant temperature of 22 ± 1 °C with a 12-h light/dark cycle. They
were allowed ad libitum access to diet and water. After 2 weeks feeding on chow (for the
acclimatization and the baseline data collection), mice were randomly assigned to one of
the following treatments: 1) CO diet (n = 6); 2) GG diet (n = 6); 3) PL diet (n = 6). The
mice were fed the experimental diets for 2 weeks. The diet intake and body weight were
measured every other day. The body composition was assessed at the baseline, day 4 and
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day 13 by using the magnetic resonance imaging (MRI) with an EchoMRI-900 Body
Composition Analyzer (EchoMRI, Houston, TX). The experiments were conducted
in conformity with the Public Health Service Policy on Humane Care and Use of
Laboratory Animals and were approved by the Utah State University Institutional Animal
Care and Use Committee.
Assessments of intestinal barrier integrity
To assess the intestinal permeability, 4000 Da FITC-dextran (Sigma-Aldrich Co. LLC,
St. Louis, MO) suspended in phosphate buffered saline was gavaged and the blood
samples were collected through cheek bleeding 5 h after the gavage. The plasma
concentrations of FITC-dextran were determined by measuring fluorescence at 530 nm
(30).

The gut permeability was also assessed by using the differential sugar absorption test
(DST). Three classes of sugar probes are usually used for the DST (31). The Class 1
probes, such as sucrose (molecular weight (MW): 342.3 Da), are metabolized in the
stomach and the proximal small intestine. The class 2 probes, such as lactulose (MW:
342.3 Da) and mannitol (MW: 182.2 Da), can stay in the gut before they are degraded by
bacteria in the colon. The class 3 probes, such as sucralose (MW: 397.64 Da), remain
intact throughout the gut. Sucrose, lactulose and sucralose have similar size and are
absorbed exclusively through the paracellular route (31). As a non-metabolizable small
molecule, mannitol is absorbed from the gut by passive diffusion and solvent drag and
the absorption reflects the background gut permeability (32). By using the
aforementioned four sugars together, information regarding site-specific gut permeability
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may be obtained. The absorption of sucrose reflects the permeability of the stomach and
the proximal intestine. The absorption of lactulose reflects the permeability of the small
intestine. The absorption of sucralose reflects the permeability of both the small intestine
and the colon. When there is no small intestinal damage as revealed by the lactulose
absorption, the sucralose absorption may detect the colonic damage (31). The
Sucrose/Lactulose ratio can be used to decide if the intestinal damage is more
severe proximally or distally. For example, the Sucrose/Lactulose ratio increases during
active celiac disease and severe malaria (33, 34).

The DST was carried out according to the method of Arrieta et al. (35). After a 4 h
fast of food and water, the mice were gavaged with 0.2 ml of a sugar probe solution
containing 100 mg of sucrose, 12 mg of lactulose, 8 mg of mannitol and 6 mg of
sucralose. Immediately after the gavage the mice were housed in the metabolic cages to
collect the 24-h urine. During the collection period, the urine sample was preserved by
the addition to the collection vessels of 5 mg sodium ﬂuoride. The urinary sugars were
quantified by the method of Farhadi using GC (36).

Tissue sample collection
The mice were sacrificed by CO2 asphyxiation after a 4h fast. After the blood
collection, the liver, the quadriceps muscle, the intestinal and colonic mucosa, the feces
and the adipose tissue samples were collected. The adipose depots included the gonadal,
retroperitoneal, mesenteric, and subcutaneous depots. Each category of tissue was saved
separately and the tissue mass was recorded. The tissue samples were flash frozen and
stored at -80 °C until further analysis.
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Biochemical analyses of plasma
The blood was obtained by cheek bleeding and collected in heparin containing tubes
(BD, Franklin Lakes, NJ). The plasma samples were obtained after centrifugation at
12, 000 x g for 10 minutes and stored at -80 °C. The plasma levels of insulin, leptin,
resistin, monocyte chemotactic protein-1 (MCP-1), IL-6, TNF-α and plasminogen
activator inhibitor-1 (PAI-1) were determined by using the MILLIPLEX mouse
adipokine kit (Millipore, Billerica, MA). The plasma glucose level was measured by
using the Cholestech L.D.X system (Cholestech Corp, Hayward, CA). The homeostasis
model assessment-estimated insulin resistance (HOMA-IR) index was calculated from
the fasting glucose and insulin levels (fasting glucose*fasting insulin/22.5) (37, 38). The
plasma endotoxin levels were measured by the fluorescence endotoxin assays kit (Lonza
Inc., Allendale, NJ).

Western Immunoblotting for zonula occludens (ZO)-1 and occludin proteins
The small intestine (without the duodenum) and the colon were excised after the
mouse was sacrificed. The proximal 1/3 segment of the small intestine (jejunum), the
distal 2/3 segment of the small intestine (ileum) and the entire length of the colon were
collected and opened longitudinally. The intestine was washed with ice-cold 0.9% saline
solution to remove the visible mucus and dietary debris. Then the moisture was
carefully removed with tissue paper. The intestine segments were gently scraped twice
with a glass microscope slide to obtain the mucosa, which were flash frozen and stored at
-80 °C until further analysis. Mucosal samples were homogenized in 500 µL ice-cold
tissue protein extraction reagent (contains a proprietary detergent in 25 mM bicine, 150
mM sodium chloride; pH 7.6) with 1% protease inhibitor and 1% phosphatase inhibitor
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(Pierce Biotechnology, Rockford, IL). The homogenates were centrifuged at 10,000 x g
for 5 minutes to collect the supernatants. The protein samples were suspended in the
sodium dodecyl sulfate (SDS) sample buffer (Invitrogen, Grand Island, NY) and were
boiled at 100 °C for 5 minutes. The proteins were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis using 6% (ZO-1) or 8% to 16% (occludin, β actin)
Tris-glycine polyacrylamide gradient gels and subsequently transferred to nitrocellulose
membranes (Invitrogen, Grand Island, NY). The membranes were blocked with 5%
bovine serum albumin (BSA) in Tris-buffered saline (TBS, 0.0242% Tris base, 0.08%
NaCl; pH 7.6)/0.1% Tween 20 for 1 h. The primary antibodies specific for ZO-1
(1:500; Zymed, Grand Island, NY), occludin (1:500; Santa Cruz Biotechnology, Santa
Cruz, CA), or β actin (1:500; Cell Signaling, Danvers, MA) were incubated with the
membranes overnight at 4 °C in 5% BSA with Tris-buffered saline/ Tween 20. The
membranes were washed and incubated for 1 h at the room temperature with the
secondary antibody horseradish peroxidase-linked antirabbit IgG (1:2000; Cell Signaling,
Danvers, MA) prepared in the blocking solution. After thorough washing, the Pierce
Supersignal West Pico Chemiluminescent Kit was applied for antibody detection with
Kodak 2000R Image Station (Raytest USA Inc., Wilmington, NC). The mean pixel
density was estimated using ImageJ (NIH, Bethesda, MD). The data were expressed as
the relative band density from the Western blots. The relative band density was calculated
by dividing the pixel density of the target protein by the mean pixel density of beta actin.

Liver gene expression analysis
The expression of genes associated with lipid metabolism in the liver was analyzed
by the real-time quantitative polymerase chain reaction (RT qPCR) assays. The total
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RNA was extracted from the liver tissue by using the TRI reagent (Sigma-Aldrich Co.
LLC, St. Louis, MO) and the SurePrep RNA Purification Kit (Thermo Fisher Scientific
Inc., Waltham, MA) according to the manufacturer’s instructions. The genomic DNA in
the RNA samples were eliminated with the RNase-free DNase I solution (Thermo Fisher
Scientific Inc., Waltham, MA). The RNA (1 µg) was reverse transcribed into the cDNA
using the QuantiTect® Reverse Transcription Kit (Qiagen, Valencia, CA) and MJ
Mini™ Thermal Cycler (Bio-Rad, Hercules, CA). RT qPCR was then performed with the
EvaGreen® method using the Biomark™ 48.48 Dynamic Arrays (Fluidigm, South San
Francisco, CA). Primer sequences were as in Table 3.2. These mouse primers were
selected from the Primer Bank developed by the Massachusetts General Hospital and
Harvard Medical School (39). The primers were verified with the corresponding mRNA
sequences from the GenBank maintained by the National Center for Biotechnology
Information. The cycle threshold (Ct) values for the genes of interest were normalized
with the Ct values for peptidylprolyl isomerase A. The relative gene expression was
calculated by using the 2−ΔΔCt method.

Tissue lipid profiling
The tissue samples were removed from the freezer, an unbiased sample of the tissue
was cut into small pieces with a razor and placed in a mortar with liquid nitrogen and
ground to obtain a fine homogenous powder. About 50 mg (20 mg for the intestinal
mucosa) of the tissue powder from each sample were weighed and put into a glass test
tube with a screw cap. The lipids were extracted by the method of Folch et al. (40) with
slight modifications. The samples were mixed with 1.5 ml Folch solution
(chloroform/methanol, 2:1, v/v). The whole mixture was sonicated and then agitated for
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15-20 minutes in an orbital shaker at room temperature. The agitated mixture was
vortexed for 30 seconds and washed with 0.2 volumes (0.3 ml for 1.5 ml solvent mixture)
0.9% NaCl solution. The washed mixture was vortexed for 20 seconds and centrifuged at
1,500× g for 10 minutes to separate the two phases. The lower chloroform phase
containing lipids was collected and evaporated under a nitrogen stream. The lipids were
reconstituted in a small volume of Folch solution in a 2 ml amber vial, topped with
nitrogen and stored at -80 ºC until further analysis.
The individual lipid classes of the extracted lipid were separated using high
performance thin layer chromatography (HPTLC). The extracted lipid from each tissue
was diluted by the Folch solution such that 5 µl of the solution contained 2.5 mg of the
lipid. The HPTLC plate (10 × 20 cm silica gel, 3µm particle, 100 µm layer) (Scientific
Adsorbents Inc., Atlanta, GA) was pre-washed with 100 ml of chloroform/methanol (1:1
v/v) and activated in the 100 °C oven for 10 minutes. The lipid class standards were
spotted for detecting the target bands. The aliquots of 5 µl lipid sample or plasma sample
were spotted 1 cm from the bottom of the plate and the plate was air dried. The plate
development was carried out by the method of Kupke (41). The plate was first developed
in a solvent system containing chloroform-methanol-water (60:30:5 v/v/v) until the
solvents reached the middle of the plate. The plate was dried for 30 minutes before a
second development in the same solvent system. Then the plate was dried and developed
in another solvent system containing hexane-diethyl ether-acetic acid (80:20:1.5 v/v/v)
until the solvents reached 0.5 cm from the top of the plate. After being dried, the plate
was sprayed until translucent with a 10 % (w/v) cupric sulfate solution in 8% (w/v)
orthophosphoric acid (42). The plate was heated in an oven at 145 °C for 10 minutes (43).
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The plate was scanned with a document scanner EPSON Stylus NX400 (Epson America
Inc., Long Beach, CA) and the lipid bands were quantified with ImageJ (NIH, Bethesda,
MD). The detected lipid classes from the HPTLC plate were: PE, PC, PS, and PI, SM,
diglycerides (DG), free fatty acids (FFA), TG, and cholesteryl ester (CE).

GG analysis of intestinal mucosa
The total GG content in the intestinal mucosa was determined by measuring the
gangliosides bound sialic acid with Gas Chromatography–Mass Spectrometry (GC-MS).
The gangliosides were extracted and purified by using the Sep-Pak C18 reverse-phase
cartridges (Waters, Milford, MA) according to the method of Schnabl et al. (44). The
gangliosides were derivatized by trimethylsilylation. One hundred microliter ganglioside
samples with 5 µg phenyl N-acetyl-alpha-D-glucosaminide as internal standard were
dried and treated with 700 µl of 0.05 N fresh methanolic HCl by heating for 1 hr at 80 °C.
The mixture was cooled and extracted with 0.5 ml of hexane to remove the liberated fatty
acid esters. The methanolic layer was dried under a nitrogen stream. The
trimethylsilylation derivatization reagent was formed according to the method of Carter
and Gaver (45). Hexamethyldisilazane (2.6 ml) and dry pyridine (2 ml) were mixed.
Trimethylchlorosilane (1.6 ml) was then added. The mixture was shaken and the opaque
solution was centrifuged to give a clear colorless supernatant solution, which was stored
in the dark. The silylation reagent (50 µl) was added to the samples in the small ample
vials. The samples were agitated well with a Vortex vibrator and allowed to stand for 15
minutes. The derivatized samples were transferred into the GC inserts and 1 µl was
injected per assay into a DB-5 GC Column installed on a Shimadzu GC-2010 coupled
with a Mass Spectrometer. The quantification was achieved from the standard curve
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generated by concurrent analysis of a series of ganglioside GD3 standards in different
concentrations.

Statistical analyses
One-way or mixed models analysis of variance (ANOVA) was performed by SAS 9.2.
The group means were compared by the Ryan-Einot-Gabriel-Welsch Multiple Range
Test or the Least Squares Means Contrast in SAS. The data were reported as Mean ±
Standard Error of the Mean (SEM).
Results
Dietary polar lipids supplementation did not affect the daily food intake and weight
gain (Figure 3.1a). There were no significant differences in the tissue masses of total,
subcutaneous, and visceral adipose depots. The PL and GG groups had less mesenteric
adipose depot as percentage of body weight compared with the CO group (GG vs CO: p
= 0.05, PL vs CO: p = 0.06, Figure 3.1b). The PL group accumulated more body fat as
revealed by the MRI scan (Figure 3.2a) compared with the GG and CO groups. Body
weight gain was mainly contributed by fat accumulation (Figure 3.2b). The PL and GG
groups had higher rate of body fat increase compared with the CO group (Figure 3.2b).

One mouse in the GG group died during the second MRI scan. After staying in the
metabolic cage for 24h for the final DST, two mice in the CO group, one mouse in the
GG group and one mouse in the PL group died. They consumed less food compared with
those that survived (0.34 ± 0.12 g vs 1.83 ± 0.62 g) in the metabolic cage and they had a
similar symptom, diarrhea of not fully digested food. One mouse in the PL group
developed an anal ulcer after the final DST and was sacrificed and not included in the
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following analyses. The remaining mice were sacrificed 3 days after the final DST.
Postmortem pathological examination of the dead mice was done by the Utah Veterinary
Diagnostic Laboratory. The pathological examination revealed that there was no evidence
of infectious disease in any tissues or organs. The hepatic lipidosis was severe and
considered the primary cause of mortality. There was also renal lipidosis. For the final
tissue analyses, the mice sacrificed at the end were used (CO (n = 3); GG (n = 4); PL (n =
4)).

Tissue lipid profiles and gene expression
Dietary polar lipids, especially the PL, lowered liver mass and liver weight
percentage (normalized by body weight) (diet effect p = 0.02, Figure 3.3a). PL decreased
liver weight percentage by 2.6% compared with CO (p = 0.006). Dietary polar lipids,
especially the PL, decreased CE and PI in the liver and decreased PI in the skeletal
muscle (p < 0.05, Figure 3.3b). Compared with the CO, the GG and the PL down
regulated the hepatic expression of the fatty acid oxidation gene Acaa2 and the fatty acid
synthesis gene Acacb. The PL up regulated the hepatic expression of the cholesterol
esterifying gene Acat2 (p < 0.05, Figure 3.4) compared with the CO and the GG. The
polar lipids did not affect the following genes associated with lipid metabolism in the
liver: the fatty acid synthesis genes: Elovl5, Slc27a5, Me1 and Scd1; the fatty acid
oxidation genes: Acox3 and Cpt2; the cholesterol regulation genes: Hmgcr, Ldlr, Scarb1
and Cyp7a1.
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The PL group had higher plasma levels of FFA (Figure 3.5a) and DG (Figure 3.5b)
compared with the GG and CO groups. The PL group had higher plasma SM (Figure 3.5c)
and total phospholipids (Figure 3.5d) levels compared with the GG and CO groups.

Gut permeability
The plasma FITC-dextran level decreased significantly during the feeding period
(Figure 3.6a). The polar lipids did not affect the plasma FITC-dextran or the LPS level.
There was no change in the urinary ratios of Lactulose/Mannitol, Sucrose/Lactulose and
Lactulose/Sucralose but the urinary Sucralose/Mannitol ratio increased (Figure 3.6b).
There was no significant dietary treatment effect on the urinary sugar ratios. The plasma
LPS level was increased by 3-4 fold during the study (Figure 3.6c).

The PL and the GG decreased ZO-1 in jejunum mucosa compared with the CO
(Figure 3.6d). The expression of the TJ protein ZO-1 was not affected in the mucosa of
the ileum and the colon (Figure 3.6d). The GG slightly increased the occludin expression
in the colon mucosa compared with the PL and the CO (Figure 3.6d). The polar lipids did
not affect the expression of occludin in the mucosa of the small intestine (Figure 3.6d).

Plasma biochemistry
The PL increased plasma IL-6 level from 41 to 745 pg/ml (p = 0.001). The plasma
IL-6 level did not change in the CO group (18 vs 16 pg/ml). The GG increased plasma
IL-6 level from 44 to 133 pg/ml. The plasma IL-6 level in the PL group was significantly
higher than that in the GG and CO groups (Figure 3.7a, p = 0.02, 0.01, respectively). The
correlation between the plasma IL-6 level and the plasma SM level was strong (r = 0.978,
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p < 0.0001) while the correlation between the plasma FFA and IL-6 levels was not
significant (r = 0.338, p = 0.34). The correlation between the plasma LPS and IL-6 levels
was negative and not significant (r = -0.459, p = 0.16).

Compared with baseline value, there was an increase of the plasma levels of PAI-1,
resistin and leptin. The plasma PAI-1 level increased 2-5 fold (time effect p = 0.0007,
Figure 3.7b). The plasma resistin level increased 1-2 fold (time effect p < 0.0001, Figure
3.7c). The plasma leptin level increased slightly (time effect p = 0.049, Figure 3.7d). No
statistically significant dietary treatment effect was observed in the plasma levels of
PAI-1 and leptin. The GG increased the plasma resistin level compared with the CO and
the PL (diet x time effect p = 0.03, Figure 3.7c).

The plasma levels of insulin, MCP-1 and TNF-α did not change significantly over
time and were not significantly affected by dietary polar lipids supplementation (Table
3.3). There was no treatment effect on the fasting glucose and HOMA-IR at the end of
the study (Table 3.3).

Symptoms related to diabetes
One mouse in the GG group (GO3) and one mouse in the PL group (PO4) developed
obvious diabetic symptoms during the study. Compared with the rest of the mice, these
two mice had wetter beddings, consumed more food, had much higher volume of urine,
and had higher fasting glucose, insulin and HOMR-IR (Table 3.4). Compared with the
other mice, the level of obesity was lower in the diabetic mice (GO3 and PO4) as
indicated by the plots of body fat against fat-free mass (Figure 3.8a-f). When all
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measurements at 6 time points (at day -15, -11, -7, -3, 4, 13) are included, there is
obvious separation of the diabetic mice (GO3 and PO4) from the rest of the mice (Figure
3.8a). The slope for the obese mice was 0.94. From day -15 to day 4, GO3 and PO4 were
gradually separated from the rest of the group (Figure 3.8b-e). The slope decreased to
0.71 at day -3 and returned to 1.17 at day 4. When the slope decreased to 0.57 at day 13,
GO3 and PO4 were not separated from the rest of the group (Figure 3.8f).

Discussion
This study was designed to test the hypotheses that milk polar lipids reduce liver lipid
levels and affect gene expression associated with liver lipid metabolism, prevent the
increase of gut permeability, and reduce plasma inflammatory cytokines in ob/ob mice.
The milk phospholipids reduced the liver lipids level and slightly affected gene
expression associated with lipid metabolism in the liver. The milk phospholipids
increased the colon permeability and the plasma IL-6 level. The milk gangliosides
decreased ZO-1 and increased occludin in the colon mucosa; did not affect gut
permeability, systemic inflammation, and lipid metabolism.

The MRI scan indicated that the PL group had higher total body fat percentage than
the other two groups (diet effect p = 0.29 at day 13, Figure 3.2a). The adipose depot
measurements revealed that the PL group did not have more subcutaneous fat and had
less visceral fat depots and liver mass compared with the CO group. The PL group had
higher lipid levels in the plasma. There was no significant difference in the level of
muscle lipids among groups. Taken together, the PL may have caused fat redistribution
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from the liver and visceral fat depots into the blood stream. Or the PL could have
prevented fat accumulation in the liver and visceral fat depots from the circulation.

The milk polar lipids, especially the PL, lowered the liver mass, liver CE & PI,
muscle PI and plasma CE. The decrease of the hepatic CE may have resulted from the
reduction of the intestinal cholesterol uptake by the PL (46). The milk PL increased the
SM level in the liver and plasma compared with the CO and the GG. The PL group had
higher amount of SM in the diet and the SM may accumulate in the plasma and the liver.

The plasma TG, DG and FFA levels decreased over time in the CO and GG groups
but not in the PL group. Free fatty acids, especially saturated fatty acids, induce the
expression of proinflammatory cytokines in cultured macrophages and adipocytes
through the activation of the TLR4 (47). Saturated fatty acids may bind to the TLR4 in
the adipose tissue and induce inflammation in the adipose tissue of the C57BL6/J mice
(10). Large amounts of saturated fatty acids are released during the macrophage-induced
lipolysis in the hypertrophied adipocytes cocultured with macrophages. The released
saturated fatty acids bind the TLR4 and thereby induce inflammation in both adipocytes
and macrophages by activating the TLR4/NF-kappaB pathway (48). The higher level of
FFA in the plasma may explain the increase of plasma IL-6 level.

Dietary milk polar lipids decrease the hepatic expression of genes associated with
fatty acid synthesis in the C57BL/6 mice on a high fat diet as demonstrated by Wat et al.
(22). In the present study, the milk polar lipids had complex effects on gene expression
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related to lipid metabolism in the liver. The PL upregulated the cholesterol esterifying
gene Acat2 compared with the CO and the GG. The PL and the GG downregulated the
fatty acid oxidation gene Acaa2 and the fatty acid synthesis gene Acacb compared with
the CO. The beneficial effect of milk polar lipids on hepatosteatosis and lipidemia
reported by Wat et al. (22) may result from, at least partially, the PI, which has
antiobesity effect through regulating gene expression associated with hepatic lipid
metabolism in a mouse model of diet-induced obesity (49). Those beneficial effects of
polar lipids could also be partially due to the choline contributed by the PC when the
mice were fed high sucrose-hepatosteatosis promoting diets (23).The milk polar lipids
concentrates used in the present study did not contain significant amount of PI and the
amount of choline was balanced among diets (Table 3.1). The difference in the
composition of phospholipids may explain the disparity in the findings. The soybean
lecithin and PC downregulate the expression of the cholesterol esterifying gene Acat2 in
the liver (50). In the present study the milk PL upreguated the hepatic Acat2. Different
sources of phospholipids may have different effects on the Acat2 expression in the liver.

When the ob/ob mice were fed moderately high fat diets (34% energy), gut
permeability to FITC-dextran (4000 Da) decreased. The decrease of gut permeability to
large molecules may be due to the gut maturation during development when the mice
were 7-9 weeks old. Although the C57BL/6J mice reach sexual maturation by day 35,
fast maturational growth continues for most biologic processes and structures from week
5 until week 13 (51). The colon permeability to sucralose (Figure 3.6b) and the gut
permeability to the LPS (Figure 3.6c) increased. The rise of urinary Sucralose/Mannitol
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ratio without the Lactulose/Mannitol ratio being affected indicated that the permeability
of the colon increased (31). This may explain the increase of the plasma LPS through
enhanced LPS absorption from the colon. A diet with 34% energy by fat would represent
the average American fat intake (34% by energy, NHANES 2007-2008) and be
considered high fat diet compared with regular rodent chow diet. The high fat diet may
have also contributed to the increase of gut permeability during the digestion (27).

The GG decreased TJ protein ZO-1 in the jejunum mucosa and increased occludin in
the colon mucosa compared with the CO. But the GG did not affect the permeability of
the small intestine or the colon. The change of TJ protein content in the intestinal mucosa
may not necessarily result in the change of gut permeability since the distribution of the
TJ proteins also plays an important role in affecting gut permeability (6).

The phospholipids fed group had a higher IL-6 level in the plasma compared with the
other two groups at the end of the experiment. During the experimental feeding, the
plasma fatty acid levels stayed constant in the PL group. The change of fatty acid profile
is yet to be verified. The increased plasma IL-6 level could be due to the activation of the
TLR4 (10) by the increased plasma saturated fatty acids level, which may be contributed
by the dietary intake since 60% of the fatty acids in the dairy PL are saturated (22). The
increased plasma SM level could also cause the increase of IL-6 level through stimulating
the adipocytes (52). The correlation between the plasma IL-6 level and the plasma SM
level was strong (r = 0.978, p < 0.0001) while the correlation between the plasma FFA
level and the IL-6 level was not significant (r = 0.338, p = 0.34). Although the plasma
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LPS level increased and the LPS has the potential to activate the TLR4 and initiate
inflammation, the plasma IL-6 level did not increase in the CO and GG groups in which
the LPS level increased similarly as in PL group. The correlation between the plasma
LPS level and the IL-6 level was negative and not significant (r = -0.459, p = 0.16).
These results indicate that the plasma SM may have a bigger influence on the systemic
inflammation than the plasma FFA and LPS in the ob/ob mouse model. One of the main
concerns of the increased gut permeability is the resultant increase of the LPS absorption.
The findings of this study support the suggestion that the plasma lipids levels may play
more important roles in the inflammatory response than the gut permeability in the ob/ob
mouse model. Dietary supplementation of the milk PL may pose negative effects by
raising the plasma SM level in the ob/ob mice.

The dietary GG did not significantly affect the GG contents in the intestinal mucosa.
The GG fed group had higher tight junction protein occludin level in the colon mucosa.
The increase of occludin level was not accompanied by an increase of the colon barrier
integrity. The PL and GG groups had less PC per gram tissue in the mucosa of the small
intestine although the diets had higher amounts of PC compared with the CO group.
There were no differences in other phospholipid classes in the intestinal mucosa among
the groups. These data do not support the hypothesis that the dietary GG and PL may
increase the intestinal barrier integrity through enriching the GG and PL in the intestinal
mucosa.
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The dietary addition of GG (0.02% w/w) was determined according to a previous
study where the dietary GG were observed to protect the tight junction protein occludin
in the intestinal mucosa from degradation during the LPS-induced acute inflammation
(20). In the present study, the GG supplemented group also had a higher level of occludin
in the colon mucosa compared with the CO group. For practicability in general dietary
supplement, the GG was provided as a concentrate that also contains the milk
phospholipids. The amount of phospholipids in the GG diet was about one ninth of that in
the PL diet. Most of the effects of the GG that were similar to the PL may be due to the
phospholipids content in the GG diet. The only unique effect of the GG compared with
the PL in the present study was that the GG group had a higher occludin expression in the
colon mucosa compared with the CO group. Therefore, the GG at the dose used may not
have any significant effect on lipid metabolism, gut permeability and systemic
inflammation in the ob/ob mice when they are fed a moderately high fat diet.

Some mice died after staying in the metabolic cage for 24h during the second DST.
Before the mice were put on the experimental diets, they were fed the chow diet and a
baseline DST was carried out. None of the mice had any abnormal symptoms after the
baseline DST. At that time, they were small enough to easily access the food in the
metabolic cage. After two weeks, their increased size made it difficult to access the food
in the metabolic cages and the dietary intake was reduced significantly (5.9 ± 0.5 vs
1.4 ± 0.5 g, p < 0.0001). Starving has been shown to induce hepatic steatosis (53) in
ob/ob mice sacrificed 24h after the food was withheld. The food restriction in the
metabolic cages in the present study did not kill the mice immediately.
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Mice that died thereafter consumed less food in the metabolic cages and did not
resume normal food consumption after they were returned to the regular cages. It is
unlikely that the animal deaths were mainly due to the high fat diet feeding. Diets with
much higher fat contents, such as 80% (54), 66% (55), and 48% (56) by energy, have
been used, respectively, in 3-6, 3.5-6.5, and 6-8 week old ob/ob mice and no animal death
was reported. The ob/ob mice develop spontaneous liver steatosis and a “second
metabolic hit”, such as a high fat diet, is needed to induce a more severe injury (57).
Non-alcoholic steatohepatitis (NASH) develops in the ob/ob mice on a moderately high
fat diet (35.7% by energy) for 4 weeks (58). The food restriction in the present study was
unintentional and it should have worsened the hepatic lipidosis. Extreme steatosis and
stress in the metabolic cages may have resulted in the animal mortality. Although the
number of animal per group became small after animal mortality, the data on gut
permeability were collected before the animal death.

Two mice developed obvious diabetic symptoms in this study. One of the mice died
after the last DST and the other one developed an anal ulceration. Both mice were not
included in the final analyses. The ob/ob mouse is widely used as an animal model of
type 2 diabetes mellitus (59). Diabetes mellitus is usually defined by the fasting
hyperglycemia. The fasting glucose above 250 mg/dl (13.87 mM) is out of the normal
range for the mouse and may be used as the threshold for a diagnosis of diabetes mellitus
in mice (59). The average fasting glucose level was 16.58 ± 2.61 mM in this study and it
is similar to the 20.2 ± 1.6 mM reported in another study by Prasain et al. using the ob/ob
mice at a similar age of 10 weeks (60). The diet composition in the Prasain’s study was
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not described for the ob/ob mice but was likely the regular rodent chow. The ob/ob mice
in Prasain’s study had plasma insulin level of 541.1 ± 69.6 μIU/ml, which is much higher
than the 89.87 ± 13.87 μIU/ml observed in the present study. The HOMA-IR index is
also much smaller in the present study (499.4 ± 81.5 vs 68.99 ± 11.38). The main
difference between these two studies is the diet. Further studies are needed to clarify the
reasons for the different levels of plasma insulin observed between the Prasain’s study
and the current study.

Most of the mice in this study had a fasting glucose level exceeding 250 mg/dl (or
13.87 mM) yet only two mice developed clinical symptoms of overt diabetes. Currently
there are no standardized criteria defining type 2 diabetes for the mouse. In future studies,
a better diagnosing standard may be developed and the diabetic mice may be excluded for
the preexisting obesity model to reduce confounding factors contributed by the diabetes.

Fenton’s method for defining obesity (61) was supported by the data from the current
study. The level of obesity in the diabetic mice decreased when the diabetic symptoms
became more severe (Figure 3.8a-f). Stresses, such as staying in the metabolic cage,
decreased the level of obesity. After the first two DSTs, the obesity level decreased at day
-3 (Figure 3.8d) and at day 13 (Figure 3.8f).

Summary
The high fat feeding compromised the gut barrier integrity, decreased the plasma
lipids level but had little effect on the level of systemic inflammatory cytokines. The GG
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increased the expression of the tight junction protein occludin in the colon mucosa and
had little effect on lipid metabolism and systemic inflammation. The PL supplementation
increased the total body fat percentage and redistributed lipids from the liver and the
visceral fat depots into the plasma. The PL increased the plasma SM and the
inflammatory cytokine IL-6. The PL increased the gut permeability of the colon. In
summary (Figure 3.9), dietary supplementation of the milk phospholipids resulted in
unfavorable effects on the intestinal barrier integrity and systemic inflammation in the
ob/ob mice. The milk phospholipids reduced the liver mass and lipids in the liver but
increased the lipid levels in the plasma. The milk gangliosides at the current dose affected
the tight junction proteins expression in the intestinal mucosa but did not have significant
effect on the intestinal barrier integrity, lipid metabolism and systemic inflammation in
the ob/ob mice. Future studies may explore which components of the milk phospholipids
are responsible for the observed effects.

The PL supplementation affected lipid metabolism but had little effect on gut
permeability and systemic inflammation. Often times, a few organ systems are assessed
during the dietary intervention. The limitation of these kinds of studies is that the dietary
treatment may benefit one or a few organ systems but could negatively affect other organ
systems. During this study, although as many systems were assessed as conditions permit,
there are still many systems that were not assessed, such as the nervous system,
cardiovascular system, skeletal system, respiratory system, excretory system, endocrine
system, reproductive system and immune system. As a result, only four out of the eleven
organ systems were assessed in some detail. Although the milk polar lipids did not show
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beneficial effects on gut permeability and systemic inflammation in the ob/ob mice, they
may benefit other organ systems that were not tested. The overall effects cannot be
concluded until all systems are taken into consideration. Therefore, the effects of dietary
milk polar lipids on the whole body in the ob/ob mice needs to be further assessed in a
systematic manner.
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Table 3.1 Diets composition (unit: g/kg; Chow: LabDiet 5K52; CHO = carbohydrates).

Ingredient
Casein, Vitamin-Free Test
L-Cystine
Corn Starch
Maltodextrin
Sucrose
Soybean Oil
Lard
Lactose
Cellulose
Nitrogen-free non-carbohydrate
Mineral Mix, AIN-93G
Vitamin Mix, AIN-93
TBHQ, antioxidant
GG concentrate
PL concentrate
Water
Food Color
Choline Bitartrate
Sodium Meta-Silicate, nonahydrate
Sodium Chloride
Potassium Phosphate, monobasic
Potassium Sulfate
Calcium Carbonate
Magnesium Oxide
Protein
Carbohydrate
Fat
Energy density (Kcal/g)

CO
GG
PL
Chow
188
188
188
193 (crude protein)
3
3
3
0
348
348
348
397.9 (crude CHO)
100
100
100
0
100
100
100
6.2
73
73
73
72 (crude fat)
95.30
91.93
83.20
0
6.87
0
5.88
0
34.90
34.90
34.90
43 (crude fiber)
0
0
0
138.1
35
35
35
65 (crude ash)
10
10
10
Crude vitamin
0.04
0.04
0.04
0
0
11.24
0
0
0
0
14.24
0
0.03
0.06
1.45
0
0.15
0.15
0.15
0
Choline adjustment (g/kg)
3.95
3.76
2.50
0
Minerals adjustment (mg/kg)
7.7
0
1.5
0
196.8
20.5
0
0
1259.7 897.3
0
0
281.4
0
644.7
0
8
4.8
0
0
1.1
0
0.1
0
Energy contribution (Kcal%)
16.78
16.78
16.78
22.24
49.02
49.02
49.02
61.73
34.20
34.20
34.20
16.03
4.3
4.3
4.3
3.5
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Table 3.2 Mouse primers sequences for real-time quantitative polymerase chain reaction
(qPCR) assays.

Gene symbol
Gene name
Fatty acid synthesis
Acacb
Acetyl-Coenzyme A
carboxylase beta
Elovl5
ELOVL family member 5,
elongation of long chain fatty
acids carrier family 27
Slc27a5
Solute
(fatty acid transporter),
member
5
Me1
Malic
enzyme
1, NADP(+)dependent, cytosolic
Scd1
Stearoyl-Coenzyme A
desaturase 1
Fatty acid oxidation
Acaa2
Acetyl-Coenzyme A
acyltransferase 2
(mitochondrial 3-oxoacylAcox3
Acyl-Coenzyme
A oxidase 3,
Coenzyme A thiolase)
pristanoyl
Cpt2
Carnitine
palmitoyltransferase 2
Cholesterol regulation
Acat2
Acetyl-Coenzyme A
acetyltransferase 2
Hmgcr
3-hydroxy-3-methylglutarylCoenzyme A reductase
Ldlr
Low density lipoprotein
receptor
Scarb1
Scavenger receptor class B,
member 1
Cyp7a1
Cytochrome P450, family 7,
subfamily a, polypeptide 1
Housekeeping
Gapdh
Glyceraldehyde-3-phosphate
dehydrogenase
Actb
Actin, beta
Ppia

Peptidylprolyl isomerase A

Primers (5'→3': forward; reverse)
TTCTGAATGTGGCTATCAAGACTGA;
TGCTGGGTGAACTCTCTGAACA
GAACATTTCGATGCGTCACTCA;
GGAGGAACCATCCTTTGACTCTT
GGAGGTGGTGATAGCCGGTAT;
TGGGTAATCCATAGAGCCCAG
TCTGACTTCGACAGGTATCTCC;
CGGAATGCCAAACTGTACTGC
GATAGAGCAAGTCCCCGCTG;
CCTGCATTAACCCCCTTCAC
CTGCTACGAGGTGTGTTCATC;
TCCAAAGGGTGTTCGCTTCG
CAGAATGGTGTGCTAGAGCGT;
AGCCTGTCGGCTACAGATTTG
CCTGCTCGCTCAGGATAAACA;
GTGTCTTCAGAAACCGCACTG
CCCGTGGTCATCGTCTCAG;
GGACAGGGCACCATTGAAGG
TGTTCACCGGCAACAACAAGA;
CCGCGTTATCGTCAGGATGA
TGACTCAGACGAACAAGGCTG;
ATCTAGGCAATCTCGGTCTCC
TTTGGAGTGGTAGTAAAAAGGGC;
TGACATCAGGGACTCAGAGTAG
CAGGGAGATGCTCTGTGTTCA;
AGGCATACATCCCTTCCGTGA
AGGTCGGTGTGAACGGATTTG;
TGTAGACCATGTAGTTGAGGTCA
GGCTGTATTCCCCTCCATCG;
CCAGTTGGTAACAATGCCATGT
GGACCAAACACAAACGGTTCC;
CCAGCCATTCAGTCTTGGCA
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Table 3.3 Effects of milk polar lipids on plasma levels of MCP-1, TNF-α, insulin,
glucose, and homeostasis model assessment of insulin resistance (HOMA-IR) in ob/ob
mice (Mean ± SEM; unit: Log10(pg/ml) for cytokines; mM for glucose; arbitrary for
HOMA-IR).

Lipids
Baseline
MCP-1
TNF-α
Insulin
Day 16
MCP-1
TNF-α
Insulin
Glucose
HOMA-IR

CO

GG

PL

1.86±0.09
1.43±0.03
3.62±0.09

1.66±0.14
1.45±0.02
3.34±0.18

1.66±0.05
1.33±0.06
3.57±0.08

1.88±0.31
1.40±0.04
3.50±0.03
15.04±1.01
60.09±1.39

2.09±0.22
1.47±0.12
3.48±0.03
18.94±4.80
76.54±23.37

2.09±0.23
1.53±0.21
3.57±0.07
14.97±7.01
67.82±48.02

Table 3.4 Diabetes associated parameters measured in mice GO3 and PO4 (The data
represent mean ± SEM).

Lipids
Daily food intake (g)
Body weight at day 16 (g)
24h urine at day 13 (ml)
Insulin at day 16 (µIU/ml)
Glucose at day 16 (mM)
HOMA-IR at day 16

Average
4.93±0.29
37.22±1.10
3.06±1.50
89.87±13.87
16.58±2.61
68.99±11.38

GO3 (GG)
5.50
29.00
17.50
96.94
27.75
115.60

PO4 (PL)
7.24
34.00
17.00
117.99
27.75
103.64
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Figure 3.1 Effects of polar lipids on food intake, weight gain and fat depots. The data
represent mean ± SEM (n = 3, 4, 4 for CO, GG, PL). (a) GG and PL did not affect food
intake and weight gain compared with CO. (b) GG and PL decreased mesenteric fat
percentage (by body weight) compared with CO. Means in a row with different
superscripts are significantly different (p < 0.05).
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Figure 3.2 Effects of milk polar lipids on body fat and body weight. The data represent
mean ± SEM (n = 5, 5, 6 for CO, GG, PL). Initial body weight for CO, GG and PL
groups: 34.2 ± 0.8, 31.8 ± 2.8, 35.5 ± 2.4 (g). (a) PL facilitated body fat accumulation. (b)
Body fat increased at faster rate compared with body weight.
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Figure 3.3 Effects of milk polar lipids on liver mass and tissue lipid profile. The data
represent mean ± SEM. (a) GG and esp. PL decreased liver mass. (b) GG and esp. PL
decreased CE & PI in the liver and decreased PI in skeletal muscle. Means in a row with
different superscripts are significantly different (p < 0.05).
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Figure 3.4 Effects of milk polar lipids on gene expression associated with lipid
metabolism in the liver. The data represent mean ± SEM. PL and GG down regulated the
expression of Acaa2 and Acacb compared with CO. PL up regulated the expression of
Acat2 compared with CO and GG. Means in a row with different superscripts are
significantly different (p < 0.05).
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Figure 3.5 Effects of milk polar lipids on plasma lipid profile. The data represent mean ±
SEM (n = 6/group at day 0, n = 3, 4, 4 for CO, GG, PL at day 16). (a) PL group had
higher plasma FFA level. (b)Plasma DG level decreased. (c) Plasma SM increased. (d)
PL group had higher plasma PL level.
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Figure 3.6 Effects of milk polar lipids on gut permeability. The data represent mean ±
SEM (n = 6/group at baseline). (a) Plasma FITC-dextran decreased (n = 3, 4, 4 for CO,
GG, PL). (b) Urinary Sucralose/Mannitol (S/M) ratio increased (n = 5, 4, 4 for CO, GG,
PL). (c) Plasma LPS level increased (n = 3, 4, 4 for CO, GG, PL). (d) PL and GG
decreased ZO-1 expression in jejunum mucosa (n = 3, 4, 4 for CO, GG, PL). Means in a
row with different superscripts are significantly different (p < 0.05).
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Figure 3.7 Effects of milk polar lipids on plasma cytokines. The data represent mean ±
SEM. (a) PL increased plasma IL-6 level. (b) Plasma PAI-1 level increased. (c) Plasma
resistin level increased. (d) Plasma MCP-1 level increased.
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Figure 3.8a-c Body fat plotted against fat-free mass for individual animals during (a) day
-15 through 13 and at (b) day -15 and (c) day -11.
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Figure 3.8d-f Body fat plotted against fat-free mass for individual animals at (e) day -3,
(f) day 4 and (g) day 13.
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Figure 3.9 Summary of major findings in Chapter 3. Horizontal white arrows indicate the
effects of the control diet. Horizontal T-shaped purple arrows indicate undesirable effects.
Horizontal solid purple and blue arrows indicate desirable or neutral effects.
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CHAPTER 4
DIETARY MILK POLAR LIPIDS AFFECT GUT BARRIER INTEGRITY AND
LIPID METABOLISM IN C57BL/6J MICE DURING SYSTEMIC
INFLAMMATION INDUCED BY ESCHERICHIA COLI
LIPOPOLYSACCHARIDE

Abstract
Adiposity is linked to the complications of obesity by metabolic inflammation. High
fat diets can increase gut permeability and lead to endotoxemia and metabolic
inflammation. Milk polar lipids protect the gut barrier integrity. One objective of this
study was to test the hypotheses that dietary polar lipids may prevent the increase of gut
permeability and plasma inflammatory cytokines, reduce liver lipid levels and affect the
expression of genes associated with fatty acid synthesis and cholesterol regulation in the
liver during the acute and chronic inflammation induced by the subcutaneously injected
lipopolysaccharide (LPS). Another objective was to explore the dynamic changes in gut
permeability, plasma inflammatory cytokines and lipid metabolism during systemic
inflammation. Three groups of C57BL/6J mice were fed for 8 weeks: 1) modified AIN93G diet (CO); 2) CO with milk gangliosides (GG); 3) CO with milk phospholipids (PL).
After 2 weeks’ experimental feeding, the mice were injected subcutaneously with LPS to
induce acute and chronic inflammation. The animals were fed the experimental diets for
another 6 weeks. The gut permeability was assessed by the differential sugar tests at
baseline and 24 h, 2 weeks, and 4 weeks after stress. The tight junction protein expression
in the intestinal mucosa was evaluated by Western blot at day 57. The plasma cytokines
and lipids were measured at the baseline, day 34 and 57. The tissue lipid profiles in the
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liver, skeletal muscle, adipose and intestinal mucosa were assessed by high performance
thin layer chromatography at day 57. The GG or the PL did not affect the total food
intake, weight gain or fasting glucose, plasma cholesteryl ester and plasma triglycerides.
The milk polar lipids did not protect the gut barrier integrity at 24 h post LPS injection.
There was no dietary treatment effect on systemic inflammation. The experimental
feeding increased the plasma levels of leptin and resistin and decreased the plasma
insulin level. The increased LPS absorption from the gut was not accompanied by the
increase of plasma proinflammatory cytokines while systemic inflammation increased
after the LPS injection. In conclusion, the milk GG did not affect the gut permeability
and the systemic inflammation, and increased the hepatic gene expression of Acaa2. The
milk PL had complex effects on the gut permeability, did not affect systemic
inflammation, decreased the liver mass, and suppressed the hepatic gene expression of
Acacb and Hmgcr.

Introduction
Obesity is a big health concern in America. In 2009–2010, 16.9% of children and
adolescents, and 35.7% of adults in the United States were obese (1). Metabolic
inflammation is a link between adiposity and the complications of obesity (2). High fat
diets increase intestinal permeability (3). Chronic feeding of high fat diets result in the
increased endotoxin absorption and the low-grade metabolic inflammation (4). Gut
permeability plays an important role in the metabolic inflammation.

The gastrointestinal surface hydrophobicity decreases under the pathological
conditions. Maintenance of the phosphotidylcholine (PC) in the hydrophobic surface may
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play an important role in the promotion of health and the prevention of disease (5). The
phospholipid (PL) concentration and species composition of the intestinal mucus barrier
are signiﬁcantly altered in the patients with ulcerative colitis (6). The alterations in PL
may be important for the pathogenesis of diseases associated with the disruption of
intestinal barrier integrity. It may be hypothesized that dietary PL supplementation may
help maintain the intestinal barrier integrity and therefore reduce the endotoxin
absorption and the metabolic inflammation.

The mouse model of gut leakiness and systemic inflammation induced by
lipopolysaccharide (LPS) is well established. LPS at 2 mg/kg (7) and 10 mg/kg (8) body
weight injected subcutaneously induces endotoxemia and the intestinal stress in mice.
The LPS elevates the serum concentrations of various cytokines in mice, including
interleukin-6 (IL-6), monocyte chemotactic protein-1 (MCP-1), and tumor necrosis
factor-α (TNF-α) (9). Approximately 30% of the subcutaneously LPS injection leaves the
injection site within an hour and the injected LPS is retained at the injection site for more
than a month (10). The LPS retention decreases to 30% of the injected bolus by the post
injection day 4 and then decreases at a slower rate to 6% by the post injection day 32 (10).
Both acute and chronic inflammation may be achieved by injecting LPS subcutaneously.

A chronic high fat diet could increase endotoxemia during the digestion of dietary
lipids and contributes to low-grade metabolic inflammation (4). Endotoxemia caused by
periodontal gram-negative pathogens in patients with severe periodontitis facilitate the
development of obesity in these people (11). The effects of the nutrient uptake on
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metabolism could be used to break the link between the metabolic inflammation and
obesity (2). A milk extract, rich in polar lipids, prevents the increase in intestinal
permeability of fluorescein isothiocyanate-dextran (FITC-dextran) in mice stressed by
intraperitoneal LPS (12). One type of milk polar lipids, sphingolipids, protect against the
bacterial infections in the gut (13-15) and reduce the inflammatory response (16-19).
Sphingomyelin (SM), one subfraction of the sphingolipids, plays an important role in
neonatal gut maturation during the suckling period in rats (20). Another subfraction of the
milk sphingolipids, gangliosides (GG), inhibits the degradation of gut occludin tight
junction (TJ) protein during the LPS-induced acute inflammation (21). The GG affect the
intestinal immune system maturation in mice during weaning (22). Taken together,
dietary milk polar lipids may directly reduce systemic inflammation and may decrease
inflammation by preventing the increase of gut permeability.

Cellular lipid loading may initiate inflammation through lipid mediators, which are
precursors to inflammatory signaling molecules (23). High fat diets could result in
nonalcoholic fatty liver disease (NAFLD) (24). According to the “two-hit” hypothesis by
Day et al. (25), saturated fatty acids could be a first hit and LPS could be a second hit
(26). The second hit leads to hepatic inflammation and non-alcoholic steatohepatitis
(NASH) (27). LPS stress in combination with high fat diets may result in NAFLD/NASH
(26). NAFLD is associated with low-grade systemic inflammation (28). NAFLD, gut
leakiness and systemic inflammation could form a self-perpetuating cycle (Figure 1.1).
The milk polar lipids reduce hepatic steatosis in mice fed a high fat diet (29). It would be
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interesting to explore how milk polar lipids may affect liver lipid metabolism in mice fed
a high fat diet and stressed by LPS.

This study was designed to test the hypotheses that dietary polar lipids may prevent
the increase of gut permeability and plasma inflammatory cytokines, reduce liver lipid
levels, and affect the expression of genes associated with fatty acid synthesis and
cholesterol regulation in the liver during the acute and chronic inflammation induced by
the subcutaneously injected lipopolysaccharide (LPS).

Materials and Methods

Diets formulation
Three diets were the same as described in Chapter 3 (Table 3.1): CO diet, GG diet
and PL diet.

Animals and stresses
Five-week-old male C57BL/6J mice (n = 18; Jackson Laboratory) were housed in
single cages at a constant temperature of 22 ± 1 °C with a 12-h light/dark cycle. They
were allowed ad libitum access to diet and water. After one week’s feeding on chow (for
the acclimatization and the baseline data collection), mice were randomly assigned to one
of the following treatments (Table 3.1): 1) CO diet (n = 6); 2) GG diet (n = 6); 3) PL diet
(n = 6). The diet intake was monitored daily and the body weight was measured every
other day. The body composition was assessed every week by using the magnetic
resonance imaging (MRI) with an EchoMRI-900 Body Composition Analyzer (EchoMRI,
Houston, TX).
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The mice were fed the experimental diets for 2 weeks before they were challenged
with the LPS injected subcutaneously (5 mg/kg body weight). The LPS injected
intraperitoneally is absorbed at a faster rate compared with the LPS injected
subcutaneously (10). To prevent lethal inflammatory response, the LPS was injected
subcutaneously. The LPS injected subcutaneously at 2 mg/kg (7) and 10 mg/kg (8) body
weight has induced intestinal stress and endotoxemia. Those mice were sacrificed within
24h and no animal death was reported. So a dose of 5 mg/kg body weight was chosen for
this study to guarantee intestinal stress and prevent lethal effect. After the LPS injection
and the oral gavage of sugar probes, 0.5 ml PBS was injected subcutaneously to facilitate
the urine production. The animals were observed periodically during the following week
to monitor the gross pathological changes, including the eye discharge. After the LPS
challenge, all animals were fed the experimental diets for another 6 weeks. The
experiments were conducted in conformity with the Public Health Service Policy on
Humane Care and Use of Laboratory Animals and were approved by the Utah State
University Institutional Animal Care and Use Committee.

Assessments of intestinal barrier integrity
The intestinal permeability was assessed by using the FITC-dextran absorption test
and the DST as described in Chapter 3. The FITC-dextran absorption test was done at the
baseline, week 5 and 8. The DST was carried out at the baseline, week 3, 4, and 7.

Tissue sample collection
The mice were sacrificed by CO2 asphyxiation after a 4h fast. After the blood
collection, the liver, the quadriceps muscle, the intestinal and colonic mucosa, the feces
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and the adipose tissue samples were collected. The adipose depots included the gonadal,
retroperitoneal, mesenteric, and subcutaneous depots. Each category of tissue was saved
separately and the tissue mass was recorded. The tissue samples were flash frozen and
stored at -80 °C until further analysis.
Biochemical analyses of plasma
The blood samples were collected and the plasma were analyzed as described in
Chapter 3 to measure the levels of glucose, insulin, leptin, resistin, MCP-1, IL-6, TNF-α,
plasminogen activator inhibitor-1 (PAI-1) and endotoxin. The homeostasis model
assessment of insulin resistance (HOMA-IR) index was calculated from the fasting
glucose and insulin levels (fasting glucose*fasting insulin/22.5) (30, 31).

Western Immunoblotting for zonula occludens (ZO)-1 and occludin proteins
The mucosal samples of the small intestine and the colon were collected and the
Western immunoblotting for the ZO-1 and occludin proteins were carried out as
described in Chapter 3.

Liver gene expression analysis
The expression of 13 genes associated with lipid metabolism in the liver was
analyzed as described in Chapter 3.

Tissue lipid profiling
The tissue lipid profiles of the liver, the skeletal muscle and the gonadal adipose were
analyzed as described in Chapter 3. The lipid classes included phosphatidylethanolamine
(PE), PC, phosphatidylserine (PS), and phosphatidylinositol (PI), SM, diglycerides (DG),
free fatty acids (FFA), triglycerides (TG), and cholesteryl ester (CE).
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GG analysis of intestinal mucosa
The GG content in the intestinal mucosa was determined as describe in Chapter 3.

Statistical analyses
One-way or mixed models analysis of variance (ANOVA) was performed by SAS 9.2.
The group means were compared by Ryan-Einot-Gabriel-Welsch Multiple Range Test or
Least Squares Means Contrast in SAS. The data were reported as Mean ± Standard Error
of the Mean (SEM).

Results
There were no significant differences among the groups regarding the daily diet
intake (Figure 4.1) and the total weight gain. The PL group had higher body weight at
day 2 compared with the CO group (Figure 4.2a). The GG and PL groups had higher
body fat percentage 3 days after the dietary treatments compared with the CO group and
the difference was maintained during the rest of the study (diet effect: p = 0.03, Figure
4.2b).

Two mice from the GG group and two mice from the PL group died after the LPS
stress (64-112 h after the LPS injection). For the data analysis after the LPS challenge,
the following number of mice was used: CO, n = 6; GG, n = 4; PL, n = 4.

Tissue and plasma lipid profiles
The PL group had lower liver mass (p = 0.01) and lower liver/body weight percentage
(p = 0.024) compared with the CO group while the GG group was in the middle (Figure
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4.3a). The GG group had less PE and PC in the visceral adipose tissue compared with the
CO group. The GG group had less SM in the visceral adipose tissue than the PL group.
The PL group had less TG and more PI in the skeletal muscle compared with the CO and
GG groups. The GG and PL groups had more FFA and PI in the liver compared with the
CO group (p < 0.05, Figure 4.3b). The GG increased hepatic expression of the betaoxidation gene Acaa2 (vs the CO & the PL). The PL suppressed hepatic expressions of
the fatty acid synthesis gene Acacb and the cholesterol synthesis gene Hmgcr (vs the CO
& the GG) (p < 0.05, Figure 4.3c). The PL group had less PE, PC and PL in the jejunum
mucosa, less PE and PL in the colon mucosa, and less PE, PC and PL in the mucosa of
the small intestine and the whole gut on a per organ basis compared with the other two
groups (p < 0.05, Figure 4.4a). The PL group had lower level of gangliosides in the colon
mucosa compared with the other two groups (p < 0.05, Figure 4.4b).

The plasma CE level was lower in the GG and PL groups at day 34 compared with
the CO group (p < 0.05, Figure 4.5a). The plasma CE level decreased during day 34 and
57 (p < 0.05, Figure 4.5a). The plasma TG level decreased over time and there was no
significant treatment effect (time effect p < 0.0001, Figure 4.5b). The plasma free fatty
acids level decreased over time (p < 0.0001) and the PL group had higher level at day 34
compared with the CO and GG groups (p =0.04, Figure 4.5c). The plasma DG level
increased slightly toward day 34 and decreased significantly from day 34 to 57 (p <
0.0001, Figure 4.5d). There was no diet effect for the plasma DG level.
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Gut permeability
The PL increased the expression of the TJ proteins ZO-1 and occludin in the colon
mucosa compared with the CO and the GG (Figure 4.6a). The GG and the PL decreased
the occludin expression in the jejunum mucsoa compared with the CO (Figure 4.6a). The
plasma FITC level decreased in the PL and GG groups during the study (Figure 4.6b). At
day 34, the PL group had lower plasma FITC level compared with the CO and GG
groups (p < 0.05). Five weeks of feeding plus the LPS challenge two weeks after dietary
treatment did not increase the plasma LPS level significantly in the CO and GG groups
but increased the plasma LPS level in the PL group (Figure 4.6c). The plasma LPS level
is strongly correlated with body fat mass in the PL group (r = - 0.93, p = 0.07) but not in
the CO (r = 0.55, p = 0.26) group and GG (r = - 0.48, p = 0.52) group. The difference
disappeared after the LPS levels were normalized by the body fat mass (Figure 4.6d).
After 3 more weeks of experimental feeding post the LPS stress, the plasma LPS level
increased significantly (Figure 4.6c).

The urinary Lactulose/Mannitol ratio increased significantly after the LPS challenge
at day 18 and returned to the baseline level by day 44. There was no treatment effect
(Figure 4.7a). The urinary Sucrose/Lactulose ratio decreased after the LPS challenge and
increased during the rest of the study. The PL increased the urinary Sucrose/Lactulose
ratio compared with the CO at day 29 and especially at day 44 (Figure 4.7b). The urinary
Lactulose/Sucralose ratio increased after the LPS challenge and then returned to the
baseline level. There was a trend of PL and GG increasing the urinary
Lactulose/Sucralose ratio after the LPS stress and decreasing the ratio during the recovery
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compared with CO (Figure 4.7c). The urinary Sucralose/Mannitol ratio did not change
right after the LPS challenge and the Sucralose/Mannitol ratio increased significantly
during the recovery. There was no treatment effect (Figure 4.7d).

Systemic inflammation and plasma cytokines
All mice developed severe conjunctivitis 16h after the LPS stress as indicated by the
bilateral purulent discharges (32). The plasma insulin level decreased toward day 34 and
then stayed stable (Figure 4.8a). The plasma IL-6 level increased (measured at day 34)
and then decreased (measured at day 57) but did not return to the baseline level. There
was no treatment effect (Figure 4.8b). The plasma PAI-1 level increased slightly during
the first 34 days and then increased at a higher rate toward the end of the study (Figure
4.8c). The plasma resistin level stayed stable during the first 34 days and then increased
(Figure 4.8d).

Neither high fat feeding nor LPS challenge increased the plasma TNF-α level (Table
4.1). There was neither statistically significant time effect nor diet effect for the plasma
levels of leptin and MCP-1 (Table 4.1).

Body fat changes
The plots of body fat against fat-free mass indicated dynamic changes in the body fat
mass during the course of the study (Figure 4.9a-j). When all measurements at 9 time
points (at day -7, -1, 3, 5, 11, 23, 32, 39, 54) were included, there was no obvious
segregation of the mice and the slope was 0.1 (Figure 4.9a). The slope was around 0
during the first MRI scan at day -7 (7 days before dietary intervention, Figure 4.9b). The
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slope decreased to -0.5 at day -1 (Figure 4.9c) and then increased to 0.3 at day 3 and 0.4
at day 5 (Figure 4.9d & e). The slope dropped to 0 at day 11 and stayed around 0 at day
23 (Figure 4.9f & g). From day 23 to day 32, the slope increased to 0.08 (Figure 4.9h).
The slope kept increasing to 0.62 at day 39 (Figure 4.9i) and 0.65 at day 54 (Figure 4.9j).

Discussion
This study was designed to test the hypotheses that 1) the milk polar lipids prevent
the increase of gut permeability, 2) reduce the plasma inflammatory cytokines, and 3)
reduce the liver lipid level and affect the gene expression associated with the liver lipid
metabolism in the C57BL/6J mice stressed with the subcutaneous LPS. The first and the
second hypotheses were not supported by the data. The milk phospholipids decreased the
occludin protein expression in the jejunum mucosa and increased the ZO-1 & occludin
protein levels in the colon mucosa. The milk phospholipids increased the permeability of
small intestine and the plasma LPS, and did not affect the plasma inflammatory cytokines.
The milk gangliosides did not affect gut permeability and systemic inflammation. The
data supported the third hypothesis. The milk phospholipids decreased the liver mass but
did not affect liver TG. The milk phospholipids decreased hepatic expression of Acacb &
Hmgcr and the plasma CE. Surprisingly the milk phospholipids decreased the PC & PE
in the ileum mucosa and the PE & GG in the colon mucosa. The milk gangliosides
decreased the adipose PE, PC & SM and the liver FFA & PI. The milk gangliosides
increased hepatic expression of Acaa2.

The mouse model of LPS-induced inflammation and increased gut permeability was
established in the context of moderately high fat diets. The LPS stress in combination
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with the high fat diets increased gut permeability and plasma proinflammatory cytokine
levels. The LPS stress reduced the plasma insulin level, blocked the accumulation of
body fat, and increased the plasma IL-6 level. The experimental feeding increased the
plasma LPS but did not raise the plasma cytokine levels.

The mice in the PL group gained more weight compared with the other groups by day
2 (Figure 4.2a). During the first 32 days, the PL and GG groups tended to have higher
body weight (Figure 4.2a). The body fat percentage increase was blocked by the LPS
challenge except in the PL group where the body fat percentage increased at day 23
(Figure 4.2b). Eventually the body fat percentage dropped in all groups and then started
to increase back after day 39. The mean retention of the LPS injected subcutaneously is
73.4% after 6h, 49.1% after 3 days, 23.1% after 14 days, and less than 6% after 32 days
in the injection site (10).The retained LPS can continuously stimulate B cells and
macrophage lineage cells at the draining lymph node (10). The decrease of body fat
percentage might be due to the persistent existence of the LPS and the resultant chronic
inflammation.

The LPS stress decreased the plasma insulin level. While the C57BL/6J mice are
prone to high fat diet-induced obesity (33) and the mice were fed a high fat diet in the
present study, the mice did not gain body fat during the 6 weeks after the LPS stress. The
mice gained considerable amount of the body weight during that period of time. Insulin
plays an important role in increasing body fat storage (34). It is possible that the plasma
insulin level after the LPS stress was sufficient in promoting animal growth but was not
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high enough to stimulate body fat accumulation. It might be hypothesized that the
decreased plasma insulin level may be responsible for the lack of the body fat
accumulation.

The plasma insulin level decreased during the first 34 days and then increased toward
the end of the study. The decrease of the plasma insulin may be caused by the injected
LPS. The intraperitoneal injection of LPS at 10 µg per mouse induces pancreatic cell
damage in 10-week-old BALB/c male mice (35). The LPS injection caused low or a lack
of insulin expression in the pancreatic islets as revealed by immunohistochemistry and
RT-PCR. The expression of the insulin mRNA in the pancreatic tissues decreased to less
than half of the original level during 3h and 6h after the LPS injection (35). The amount
of the injected LPS was about 9% of the dose used in this study. Although the LPS was
injected subcutaneously in this study, it may induce similar pancreatic damages due to the
higher dose used. The intravenous injection of LPS decreased plasma insulin from 0.5
ng/ml at baseline to 0.2 ng/ml at day 11 in C57BL/6 mice fed the chow diet at 4 months
of age (36). The proinflammatory cytokine, TNF-α, decreases serum insulin in mice. In
C57BL/6 mice at 10–11 weeks of age, serum insulin level decreased from 1.3 ng/ml at 6
hrs to 0.6 ng/ml at 24 hrs after the intraperitoneal injection of TNF-α at a dose of 0.166
mg/kg (37). High fat feeding decreases plasma insulin level in rats. Plasma insulin level
peaks at 6 nmol/L (34.8 ng/ml) on day 8 and decreases to 3.5 nmol/L (20.3 ng/ml) in
female obese ZDF rats fed a high fat (48% energy) diet while the plasma insulin level
stays at around 6 nmol/L (34.8 ng/ml) in the control group fed the rodent chow diet (38).
The main cause for the decreased plasma insulin level in this study should have been the
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LPS injection. Further studies are needed to clarify if the high-fat feeding itself may
decrease the plasma insulin level in mice.

The plasma resistin level increased steadily throughout the course of the study in the
GG group. The plasma resistin level decreased during the first 34 days and then increased
toward the end of the study in the CO and PL groups. That could mean the resistin level
was more influenced by the high fat diet than by the LPS stress and the GG tended to
increase the plasma resistin level regardless of the background condition. As an
adipocytokine secreted in proportion to obesity level, resistin counteracts the effects of
insulin in mice (39). The GG may have negative effect on insulin action by increasing
resistin.

Although the GG increased the expression of the beta-oxidation gene Acaa2 in the
liver (vs the CO & the PL, Figure 4.3c), the GG group had similar FFA level in the liver
as the PL group and higher FFA level than the CO group. The PL suppressed hepatic
expression of the fatty acid synthesis gene Acacb and the suppression did not decrease the
FFA level in the liver.

The fact that the GG and PL groups had lower level of PE, PC and SM in the visceral
adipose tissue than the CO group is surprising since the polar lipids groups had higher
dietary content of PE, PC and SM. It was quite surprising that the PL group had lower PE,
PC and PL in intestinal mucosa given the fact that the PL diet had much higher level of
these polar lipid classes. This may indicate that dietary phospholipids suppress the
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incorporation of luminal phospholipids into the mucosa. It is not clear through which
mechanism did the dietary polar lipids affect the tissue polar lipids levels.

The plasma lipids stayed stable or increased slightly during the first 34 days and
decreased significantly from day 34 to 57. The decrease of plasma lipids level may be
associated with the increasing storage of body fat into adipose tissue after the
inflammation was relieved.

The PL increased the expression of the TJ proteins ZO-1 and occludin in the colon
mucosa compared with the CO and the GG and decreased the occludin expression in the
jejunum mucosa compared with the CO. The increased amount of the TJ proteins in the
PL group could decrease the permeability of colon but the PL group did not have lower
plasma LPS level (Figure 4.6c) or different permeability to the sugar probes (Figure 4.7
a-d). The decrease of the jejunal occludin in the PL group was not associated with the
increased gut permeability as indicated by the plasma LPS and FITC levels and the
urinary sugar levels. Not only the amount of the TJ proteins but more importantly the
distribution of the TJ proteins affects the intestinal permeability (40). The plasma LPS
level was negatively correlated with the occludin level in the jejunum mucosa (r = -0.84,
p = 0.038) in the CO group but not in the polar lipid groups. The decreased jejunal
occludin level in the PL group may be compensated by other mechanisms provided by
the PL that may increase the gut integrity.
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The general trend of the decreased gut permeability to FITC in all groups may be
explained by the maturing of the gut barrier during development since the mice barely
entered adulthood (3 months old) by the end of study (41). The gut permeability to larger
molecules was lower in the PL group compared with the other groups as indicated by the
lower plasma FITC level. Although the difference was not statistically different, it is
consistent with the result from a previous mouse study by Snow et al. where milk polar
lipids concentrate prevented the increase in gut permeability to FITC during LPS stress
(12). The plasma FITC level at day 35 was lower than the level at baseline. In the study
by Snow et al., the gut permeability of FITC was assessed at 24 h and 48 h after the LPS
stress. The plasma FITC level in the current study may have increased within 48 h after
the LPS stress. To reduce stress level, the plasma FITC was not measured during that
time when the mice were kept in the metabolic cages for 24h immediately after the LPS
injection. Additional factors may contribute to the difference between the Snow’s result
and the current result. Firstly, the LPS was administered intraperitoneally and
subcutaneously, respectively. Secondly, the milk polar lipids-rich material used in the
Snow’s study contained milk proteins and nonpolar lipids. That material was more
complex than the milk polar lipids concentrate used in the current study. It is not clear
how the PL may have decreased gut permeability to FITC. Given the fact that
phospholipids are important building blocks of the gut epithelium, it may be
hypothesized that the PL facilitate the maturing of the intestinal barrier.

The presence of bilateral purulent discharges in all mice was a good indicator of
successful systemic inflammation induced by the bacterial LPS (42). The PL group had
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higher level of the plasma LPS at day 34 and the difference disappeared after
normalization by the body fat content. This indicates that the plasma LPS may be directly
associated with the body fat mass. The plasma LPS level did not increase to a high level 3
weeks after the LPS challenge by day 34. There could be 6% of the injected LPS still
retained at the injection site at day 34 (10). The low level of plasma LPS may indicate
that the injected LPS did not contribute to the plasma LPS level at this time point. By the
end of the study, the plasma LPS level reached a very high level and the injected LPS
should have been gone by this time. The increased plasma LPS level at day 57 may not
be contributed significantly by the injected LPS. The increase of the gut permeability to
LPS was accompanied by the accumulation of body fat from day 40 to day 57.

The increase of the urinary Lactulose/Mannitol ratio is associated with increased
small intestinal permeability (43). The LPS challenge increased the urinary
Lactulose/Mannitol ratio significantly and the Lactulose/Mannitol ratio returned to the
baseline level during the recovery. The urinary Sucrose/Lactulose ratio decreased right
after the LPS stress and then increased gradually during the recovery. The decrease of the
Sucrose/Lactulose ratio indicated distal damage of the small intestine. The damage
became proximal when the Sucrose/Lactulose ratio increased to a high level (43). The
LPS stress caused the permeability increase of distal small intestine and the experimental
feeding increased the permeability of the proximal small intestine. The increased
permeability of the proximal small intestine was coupled with the decreased expression
of the TJ protein occludin in the jejunum mucosa. The urinary Lactulose/Sucralose ratio
selectively increases upon intestinal damage and decreases upon colonic damage (43).
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The Lactulose/Sucralose ratio increased significantly after the LPS stress, indicating the
permeability increase for the small intestine. The Lactulose/Sucralose ratio dropped back
below the baseline during the recovery for the GG and PL groups, which means the
experimental feeding did not affect the small intestine permeability but caused the
colonic damage. Combined with the indication of the Sucrose/Lactulose ratio, the
permeability of the proximal small intestine may not affect the Lactulose/Sucralose ratio
significantly. The colonic damage is coupled with the increase of the urinary
Lactulose/Mannitol ratio (43). The LPS stress barely affected the Lactulose/Mannitol
ratio and the feeding during the recovery increased the Lactulose/Mannitol ratio
significantly. Taken together, the high-fat feeding in the context of systemic
inflammation mainly resulted in the colonic damage while the LPS-induced systemic
inflammation caused the permeability increase in the small intestine.

The rise of the urinary Sucralose/Mannitol ratio without the Lactulose/Mannitol ratio
being affected indicated that the permeability of the colon increased (43). The increased
colon permeability may result in an increase of the plasma LPS through the enhanced
LPS absorption from the colon. The Sucralose/Mannitol ratio returned to the baseline
level while the plasma LPS level increased significantly toward the end of the study. The
high level of plasma LPS should have been contributed mainly by the LPS absorbed
through the gut.

The PAI-1 level in plasma increased slightly during the first five weeks and increased
at a faster rate during the last three weeks of the study. The plasma PAI-1 level became
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much higher in the PL group by the end of the study compared with the CO and GG
groups. Lysophosphatidylcholine (LPC) in oxidized low-density lipoprotein (OxLDL)
enhances the PAI-1 expression in mouse 3T3-L1 adipocytes (44). The extra increase of
the plasma PAI-1 level in the PL group may be caused by the metabolites of the dietary
PC.

The plasma IL-6 level increased significantly after the LPS stress and receded to the
baseline level by the end of the experiment. The increased plasma IL-6 level could be due
to the activation of the TLR4 (45) by the increased plasma saturated fatty acids level. But
the plasma fatty acids level decreased in all groups during the experimental feeding.
Although the change of the fatty acid profile is yet to be determined, the increased IL-6
level at week 3 (day 34) after the LPS stress may be due to the LPS challenge. The
plasma IL-6 level was not in parallel with the high plasma LPS level at the end. This
could mean that the LPS absorbed from the gut is not as proinflammatory as the injected
LPS. The intestinal LPS may have been deactivated. The intestinal alkaline phosphatase
(IAP) secreted by the enterocytes detoxifies the intestinal LPS by dephosphorylation of
the lipid A moiety (46, 47). The IAPs reduce the serum LPS content in Wistar male rats
(48). The IAPs affect both the toxicity and the concentration of the LPS in the plasma. It
is not clear whether the IAPs reduced plasma LPS in this study. The LPS is absorbed
gradually from the gut into the circulation. The tolerance to the LPS could also help
explain the lack of proinflammatory response by the LPS absorbed from the gut. The
tolerance to LPS-induced increase of serum colony-stimulating factor develops in
C57BL/6J mice after either intravenous or intraperitoneal injection of LPS and the
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tolerance occurs after one to two preinjections (49). The inhaled low-dose LPS can
induce adaptation to subsequent higher doses for cellular and inflammatory parameters in
bronchoalveolar lavage from young and old C57BL/6J mice (50). A third explanation is
that the plasma LPS may be deactivated by anti-LPS antibodies (51). It is not clear if the
anti-LPS antibodies involved in the process of deactivating the plasma LPS that were
absorbed from the gut.

The plots of body fat against fat-free mass suggested that stresses may have
considerable effect on body fat content in the C57BL/6J mice. The second MRI scan (at
day -1) was carried out right after the first DST (at day -2). The housing in the metabolic
cage reduced the adipocity as indicated by the decreased slope (Figure 4.9b & c). Once
the stress was removed, the body fat increased back within a week (Figure 4.9d & e). The
LPS stress decreased the body fat content as indicated by the decreased slope (Figure
4.9g). The third DST also decreased the body fat content (Figure 4.9h). During the
following recovery the body fat content kept increasing (Figure 4.9i & j). Based on these
observations, it is important to prevent unnecessary stresses and make sure the animals
are handled in the same manner to reduce variances caused by the potential variability in
the stresses.

The LPS induced inflammation model in this study had two phases, the acute and
chronic stages. Dietary milk polar lipids did not protect the gut integrity during the acute
phase, 24 h after LPS injection. The LPS was injected subcutaneously and the LPS can be
retained in the body until a month later (10). In the context of chronic inflammatory stress
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induced by the LPS in young C57BL/6J mice, gut permeability to large molecules
decreased and to small molecules increased. High fat feeding increased the plasma level
of resistin and plasma resistin level could also increase over time in C57BL/6J mice (52).
The milk GG decreased gut permeability and increased the hepatic gene expression of
Acaa2. The milk PL had complex effect on gut permeability, decreased the liver mass,
and suppressed the hepatic gene expression of Acacb and Hmgcr. The milk polar lipids
were provided as semi-purified concentrates containing multiple compounds. Further
studies are needed to explore which components of the polar lipids are responsible for the
observed effects. The LPS dosage may be slightly decreased (e.g., at 2.5-3 mg/kg body
weight) to prevent animal death for chronic studies.

Summary
The major effects of the dietary polar lipids during the LPS-induced inflammation are
summarized in Figure 4.10. The dietary PL increased the plasma LPS level and the
permeability of the small intestine. The PL decreased the liver mass and affected hepatic
expression of genes associated with fatty acid and cholesterol synthesis. The PL did not
affect the plasma inflammatory cytokines. The GG slightly affected lipid metabolism and
did not affect the gut permeability and the systemic inflammation.

Although the results support the hypotheses that the polar lipids may have positive
effects on lipid metabolism and negative or no effects on gut permeability and systemic
inflammation in the ob/ob mice, the effects of the polar lipids on other biological
functions are still unclear. Before systematic investigations of all major biological
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endpoints are done on the main organ systems in the ob/ob mice, comprehensive and
conclusive statements cannot be generated regarding the effects of dietary polar lipids.

The experimental feeding and the LPS stress together resulted in increased gut
permeability to small molecules, increased body weight and decreased body fat content,
and increased the plasma LPS and inflammatory cytokines (Figure 4.10). The data from
the current study indicated that the acute and chronic inflammation induced by the
subcutaneously injected LPS is a great animal model for studying systemic inflammation
and gut permeability. The increased LPS absorption from the gut into the plasma was not
accompanied by the increase of the plasma proinflammatory cytokines but the injected
LPS increased the systemic inflammation. The LPS stress decreased the plasma insulin
level. The decrease of the plasma insulin level may have increased the body weight
without increasing the body fat content. It may be hypothesized that the insulin level may
be intervened for controlling the body fat content.
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Table 4.1 Effects of milk polar lipids on plasma levels of leptin, MCP-1 and TNF-α in
mice challenged with LPS (Mean ± SEM; unit: Log10(pg/ml)).

Lipids
Baseline
Leptin
MCP-1
TNF-α
Day 34
Leptin
MCP-1
TNF-α
Day 57
Leptin
MCP-1
TNF-α

CO

GG

PL

3.13±0.05
1.61±0.03
1.49±0.02

3.11±0.11
1.50±0.08
1.45±0.03

3.03±0.14
1.52±0.05
1.46±0.03

3.44±0.14
1.55±0.08
1.39±0.02

3.34±0.06
1.54±0.13
1.42±0.02

3.09±0.10
1.53±0.13
1.45±0.05

3.76±0.19
1.60±0.03
1.46±0.03

3.50±0.14
1.55±0.06
1.38±0.05

3.46±0.11
1.54±0.05
1.49±0.03

Figure 4.1 Dietary milk polar lipids did not significantly affect food intake during the
first two days, daily food intake during the study, and weight gain. The data represent
mean ± SEM.
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Figure 4.2 Effects of the polar lipids on body weight and body fat content. Initial body
weight for CO, GG and PL groups: 22.0 ± 0.2, 21.9 ± 1.0, 21.1 ± 0.2 (g). Initial body fat
for CO, GG and PL groups: 2.14 ± 0.31, 2.28 ± 0.14, 2.14 ± 0.18 (g). (a) Body weight
changes as percentage of baseline. (b) Body fat changes as percentages of baseline. The
data represent mean ± SEM.
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Figure 4.3
Effects of milk
polar lipids on
liver mass,
tissue lipid
profile, and
gene
expression
associated with
lipid
metabolism in
the liver. The
data represent
mean ± SEM.
(a) GG and esp.
PL decreased
liver mass. (b)
GG decreased
PE, PC & SM
in adipose, PL
decreased TG
and increased
PI in muscle,
GG and PL
increased FFA
and PI in the
liver. (c) GG
up regulated
Acaa2, Acacb
and Hmgcr
compared with
PL. Means in a
row with
different
superscripts are
significantly
different (p <
0.05).
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Figure 4.4 Effects of milk polar lipids on PL and GG content in intestinal mucosa. The
data represent mean ± SEM. (a) PL decreased PE, PC & PL in ileum mucosa and PE &
PL in colon mucosa compared with CO and GG. (b) PL decreased GG level in colon
mucosa compared with CO and GG. Means in a row with different superscripts are
significantly different (p < 0.05).
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Figure 4.5 Effects of milk polar lipids on plasma lipid profile. The data represent mean ±
SEM. (a) GG and PL groups had lower plasma CE level at day 34 compared with CO. (b)
Plasma TG level decreased over time. (c) Plasma FFA level decreased over time and PL
group had higher plasma FFA at day 34. (d) Plasma DG level increased at day 34 and
decreased significantly at day 57.
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Figure 4.6 Effects of milk polar lipids on gut permeability. The data represent mean ±
SEM. (a) PL increased ZO-1 and occludin expression in colon mucosa, PL and GG
decreased occludin expression in jejunum mucosa. (b) Plasma FITC decreased over time.
(c) PL increased plasma LPS level at day 34 and LPS level increased significantly by the
end of the study. (d) The effect of PL on LPS at day 34 disappeared after normalization
by body fat mass. Means in a row with different superscripts are significantly different (p
< 0.05).
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Figure 4.7 Effects of milk polar lipids on gut permeability as revealed by differential
sugar probes test. The data represent mean ± SEM. (a) Urinary Lactulose/Mannitol ratio
increased after LPS stress and returned to baseline level during recovery. (b) Urinary
Sucrose/Lactulose ratio decreased after LPS stress and increased gradually during
recovery. (c) Urinary Lactulose/Sucralose ratio increased after LPS stress and returned to
baseline level during recovery. (d) Urinary Sucralose/Mannitol ratio did not increase after
LPS stress, increased during recovery and returned to baseline level by the end of the
study.
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Figure 4.8 Effects of milk polar lipids on plasma cytokines. The data represent mean ±
SEM. (a) Plasma insulin level decreased. (b) Plasma IL-6 level increased after LPS stress
and returned to baseline level by the end of the study. (c) Plasma PAI-1 level increased.
(d) Plasma resistin level increased.

155

Figure 4.9a Body fat plotted against fat-free mass for individual animals during day -7
through day 54.
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Figure 4.9b-d Body fat plotted against fat-free mass for individual animals at (e) day -7,
(f) day -1 and (g) day 3.
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Figure 4.9e-g Body fat plotted against fat-free mass for individual animals at (e) day 5, (f)
day 11 and (g) day 23.
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Figure 4.9h-j Body fat plotted against fat-free mass for individual animals at (e) day 32,
(f) day 39 and (g) day 54.
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Figure 4.10 Summary of major findings in Chapter 4. Horizontal white arrows indicate
the effects of the control diet. Horizontal T-shaped purple arrows indicate undesirable
effects. Horizontal solid purple and blue arrows indicate desirable or neutral effects. SQ:
subcutaneous, L/M: Lactulose/Mannitol, S/L: Sucrose/Lactulose, L/S:
Lactulose/Sucralose, S/M: Sucralose/Mannitol.
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CHAPTER 5
DIETARY MILK POLAR LIPIDS PROMOTE FAT ACCUMULATION AND
AFFECT GUT PERMEABILITY, SYSTEMIC INFLAMMATION, AND LIPID
METABOLISM IN C57BL/6J MICE FED A MODERATELY HIGH-FAT DIET

Abstract
Metabolic inflammation is associated with increased gut permeability, endotoxemia
and obesity. High fat diets increase endotoxin absorption from the gut and result in
endotoxemia. It is not clear which one occurs first, a compromised gut barrier,
endotoxemia, metabolic inflammation or obesity. Studying the effects of different lipid
classes on the aforementioned endpoints may facilitate the clarification of their complex
interrelationships. This study was designed to test the hypotheses that dietary milk polar
lipids will (1) prevent the gut permeability increase, (2) reduce systemic inflammation
during the development of DIO and (3) reduce the lipid level in the liver and affect the
expression of genes associated with fatty acid synthesis and cholesterol regulation in the
liver. An additional objective was to explore the dynamic changes in gut permeability,
systemic inflammation, and lipid metabolism during the development of DIO. Three
groups of C57BL/6J mice (n = 6) were fed diets with 34% fat as energy for 15 weeks: (1)
modified AIN-93G diet (CO); (2) control diet supplemented with a milk gangliosides
concentrate (GG); (3) control diet supplemented with a milk phospholipids concentrate
(PL). The milk PL increased food consumption, weight gain and body fat accumulation
compared with the CO and the GG. Neither the GG nor the PL had a significant effect on
the fasting plasma glucose, cholesteryl ester or triglyceride. The PL significantly down
regulated hepatic expression of the fatty acid synthesis gene acetyl-Coenzyme A
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carboxylase beta compared with the GG and up regulated hepatic expression of the
scavenger receptor class B member 1 gene compared with the CO and the GG. As
revealed by the differential sugar test, gut permeability showed a significant time effect
and diet x time interaction over the course of the study. The small intestinal permeability
increased slightly at the beginning and then decreased significantly over the feeding
period. There was a gradual increase in colonic damage as indicated by the declining of
the urinary Lactulose/Sucralose ratio and the colonic recovery as indicated by the urinary
Sucralose/Mannitol ratio. During the early phase, the PL and especially the GG had some
protective effect against the increase of small intestinal permeability. As indicated by
Western blot, the PL decreased the tight junction protein occludin level in the jejunum
but did not affect the occludin level in the ileum and the colon compared with the CO.
The tight junction protein zonula occludens-1 level was not affected in the small intestine
and the colon. The GG and PL did not affect the plasma endotoxin level, which increased
significantly after 14 weeks. The GG and PL did not significantly affect the plasma levels
of interleukin-6, insulin, monocyte chemotactic protein-1, leptin, tumor necrosis factor-α,
plasminogen activator inhibitor-1, and resistin. The plasma levels of leptin and resistin
increased significantly after 14 weeks. In conclusion, the milk polar lipids had little effect
on the gut permeability and systemic inflammatory cytokines during the development of
DIO. The milk PL increased the polar lipids level in the liver and facilitated the body fat
accumulation in the context of DIO.

Introduction
Excess energy can result in body fat accumulation (1, 2) and eventually lead to
obesity (3). Excessive fat accumulation in the adipocytes may initiate inflammation since
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lipid mediators are precursors to inflammatory signaling molecules (4). The inflamed
adipose tissue can produce proinflammatory cytokines, such as tumor necrosis factor-α
(TNF-α), and interleukin-6 (IL-6) (4). These cytokines can initiate local intestinal
inflammation, which increase mucosal permeability and bacterial translocation. In obese
subjects, the high level of inﬂammatory cytokines disrupt intestinal barrier (5, 6).
Therefore, obesity, adipose inflammation and compromised gut integrity can selfperpetuate (see Figure 1.1) (7).

One of the mechanisms for leaky gut (8, 9) in obese animals is the adaptation for
nutrient absorption by intestinal hyperplasia (10), which causes the TJ proteins to
malfunction (11). Mice with diet-induced obesity (DIO) develop endotoxemia compared
with the lean mice (12). Increased gut barrier permeability can result in endotoxemia and
metabolic inflammation (13). High fat diets can independently increase gut permeability
and result in metabolic endotoxemia that leads to metabolic inflammation (14). Metabolic
inflammation can also promote obesity. Patients with periodontitis develop endotoxemia
and tend to become obese (15).

According to current evidence, gut barrier permeability, endotoxemia, systemic
inflammation and obesity may be a series of continuous events during the development of
DIO. These events could also occur in the order of DIO, adipose/systemic inflammation,
leaky gut, and aggravation of obesity. In general, compromised gut barrier integrity,
endotoxemia, systemic inflammation and DIO are complexly interrelated (see Figure 1.1).
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The interrelatedness of the aforementioned events may be elucidated by investigating
them along with lipid metabolism, which is involved in all events.

Various studies have explored the physiological effects of milk polar lipids. Milk
sphingolipids reduce the uptake of cholesterol (16, 17), protect against bacterial
infections in the gut (18-20), and reduce inflammatory response (21-24). Sphingomyelin
(SM) affects neonatal gut maturation in rats (25) and regulates intestinal cholesterol
absorption (26). Dairy gangliosides (GG) inhibit degradation of gut occludin tight
junction (TJ) protein during lipopolysaccharide (LPS) - induced acute inflammation (27).
PL reduce hepatic TG and cholesterol (28) in rats. A PL-rich MFGM extract reduces
hepatomegaly, hepatic steatosis and hyperlipidemia in mice (29). A buttermilk MFGM
isolate promotes intestinal barrier integrity against LPS stress in mice (30). Based on
these findings, it is possible that the milk polar lipids may influence endotoxemia and
systemic inflammation through affecting the intestinal barrier integrity. The milk polar
lipids could also influence lipid metabolism and the development of DIO. The dietary
supplementation of milk polar lipids during the development of DIO may facilitate the
understanding of the interrelationships among intestinal barrier integrity, endotoxemia,
systemic inflammation and obesity.

This study was designed to test the hypotheses that dietary milk polar lipids will
prevent the gut permeability increase and reduce systemic inflammation during the
development of DIO in C57BL/6J mice fed a diet with 34% fat by energy. A tertiary
hypothesis was that dietary milk polar lipids will reduce liver lipid levels and affect the
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expression of genes associated with fatty acid synthesis and cholesterol regulation in the
liver.

Materials and Methods

Diets formulation
The three diets were the same as described in Chapter 3 (Table 3.1): CO diet, GG diet
and PL diet.

Animals
Five-week-old male C57BL/6J mice (n = 18; Jackson Laboratory) were housed in
single cages at a constant temperature of 22 ± 1 °C with a 12-h light/dark cycle. They
were allowed ad libitum access to diet and water. After being put on normal chow diet for
2 weeks (for acclimatization and baseline data collection), the mice were randomly
assigned to one of the following treatments: 1) CO diet (n = 6); 2) GG diet (n = 6); 3) PL
diet (n = 6). The mice were fed the experimental diets for 14 weeks. The diet intake was
monitored daily and the body weight was measured every other day. The body
compositions were assessed every week by magnetic resonance imaging (MRI) using an
EchoMRI-900 Body Composition Analyzer (EchoMRI, Houston, TX). The experiments
were conducted in conformity with the Public Health Service Policy on Humane Care
and Use of Laboratory Animals and were approved by the Utah State University
Institutional Animal Care and Use Committee.
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Assessments of intestinal barrier integrity
The intestinal permeability was assessed by the FITC-dextran absorption test and the
DST as described in Chapter 3. The FITC-dextran absorption test was done at the
baseline, day 35 and 101. The DST was carried out at the baseline, day 15, 30, 45, 73 and
87.
Tissue sample collection
The mice were sacrificed by CO2 asphyxiation after a 4h fast. After the blood
collection, the liver, the quadriceps muscle, the intestinal and colonic mucosa, the feces
and the adipose tissue samples were collected. The adipose depots included the gonadal,
retroperitoneal, mesenteric, and subcutaneous depots. Each category of tissue was saved
separately and the tissue mass was recorded. The tissue samples were flash frozen and
stored at -80 °C until further analysis.

Biochemical analyses of plasma
The blood samples were collected and the plasma was analyzed as described in
Chapter 3 to measure glucose, insulin, leptin, resistin, monocyte chemotactic protein-1
(MCP-1), IL-6, TNF-α , plasminogen activator inhibitor-1 (PAI-1) and endotoxin. The
homeostasis model assessment of insulin resistance (HOMA-IR) index was calculated
from fasting glucose and insulin levels (fasting glucose*fasting insulin/22.5) (31, 32).

Western Immunoblotting for zonula occludens (ZO)-1 and occludin proteins
Mucosal samples of the small intestine and the colon were collected and Western
immunoblotting for the zonula occludens (ZO-1) and occludin proteins were carried out
as described in Chapter 3.
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Liver gene expression analysis
The expression of 13 genes associated with lipid metabolism in the liver was
analyzed as described in Chapter 3.

Tissue lipid profiling
Tissue lipid profiles of the liver, the skeletal muscle and the gonadal adipose were
analyzed as described in Chapter 3. The lipid classes included phosphatidylethanolamine
(PE), phosphatidylcholine (PC), phosphatidylserine (PS), and phosphatidylinositol (PI),
SM, diglycerides (DG), free fatty acids (FFA), triglycerides (TG), and cholesteryl ester
(CE).

GG analysis of intestinal mucosa
The GG content in the intestinal mucosa was determined as described in Chapter 3.

Statistical analyses
One-way or mixed models analysis of variance (ANOVA) was performed by SAS 9.2.
The group means were compared by Ryan-Einot-Gabriel-Welsch Multiple Range Test or
Least Squares Means Contrast in SAS. The data were reported as Mean ± Standard Error
of the Mean (SEM).

Results
The PL group consumed more diet than the other two groups during the first 3 days
and the difference persisted until day 10 (Table 5.1). The PL group consumed 1.3 g more
experimental diet during the first day than the CO group and 0.97 g more diet than the
GG group. The daily diet intakes for the first 3 days were larger than daily food
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consumption during the whole study. That difference in food intake disappeared by day
10. There were no differences among groups regarding diet intake during the rest of the
study. There was a significant diet effect for body weight gain (p = 0.02) during the first
3-10 days of dietary treatment (Figure 5.1a). The PL group consumed more energy,
gained more body fat and converted a higher percentage of consumed energy into body
fat from day -3 to day 4 (3 days before to 4 days after dietary intervention, Table 5.2).

The body fat composition data (by MRI) indicated that the body fat percentage
plateaued at around 70 days of the experimental feeding (Figure 5.1b). The PL facilitated
fat accumulation after day 70 compared with the CO and GG (Figure 5.1b). The body fat
percentage of the PL group increased at a faster rate compared with that of the other
groups (Figure 5.1c). The accumulating body weight gain of the PL group also increased
at a higher rate compared with the other groups but the slope was much smaller (Figure
5.1d) than that of the body fat increase.

Tissue and plasma lipid profiles
Dietary treatment did not affect the final liver mass and the liver weight percentage
(Table 5.3). There were no differences in tissue masses for skeletal muscle and adipose
depots (Table 5.3). The PL decreased the adipose PC and SM compared with the CO. The
PL increased the liver PE, PC and SM (Figure 5.2a) compared with the CO. Dietary
treatment did not affect lipid profile in the skeletal muscle.

As shown in Figure 5.2b, the PL suppressed hepatic expression of the fatty acid
synthesis gene Acacb (vs the GG) and up regulated cholesterol reverse transport gene
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Scarb1 (vs the CO & the GG). Dietary GG did not affect the mucosal gangliosides
content. Dietary PL increased the mucosal PC in the small intestine and decreased the
mucosal PC, PE and SM in the colon compared with the CO and the GG (Figure 5.2c).

The plasma TG level increased over time and the PL group had higher plasma TG
level (Figure 5.3a) compared with the CO and GG groups at the end of the study. The
plasma CE level increased over time during the study and there was no treatment effect
(Figure 5.3b). The plasma FFA (Figure 5.3c) and PC (Figure 5.3d) levels were lower in
the PL and GG groups compared with that in the CO group at day 35. Those differences
disappeared toward the end of the study.

Gut permeability
Dietary PL decreased the gut permeability to the FITC-dextran before the DIO and
increased it after the DIO was achieved (Figure 5.4a). The differential sugar tests
revealed significant time effect and diet x time interactions on the gut permeability. The
urinary Lactulose/Mannitol ratio increased slightly and then decreased in the CO group
(Figure 5.4b). The PL increased the urinary Lactulose/Mannitol ratio significantly at day
73 and then decreased it toward the end of the study (Figure 5.4b). The urinary
Sucrose/Lactulose ratio increased in the CO group and decreased in the GG and PL
groups during the first 15 days (Figure 5.4c). Then the urinary Sucrose/Lactulose ratio
increased gradually in all groups toward day 30 and dropped down by day 45 before
rising again (Figure 5.4c). The PL group had high level of the urinary Sucrose/Lactulose
ratio at day 73 compared with the CO and GG groups and the ratio decreased toward the
end of the study (Figure 5.4c). The urinary Lactulose/Sucralose ratio decreased

169

significantly during the first 45 days (Figure 5.4d). The urinary Lactulose/Sucralose ratio
stayed stable from day 45 to the end except in the PL group where the ratio increased
significantly at day 73 (Figure 5.4d). The urinary Sucralose/Mannitol ratio in the CO
group increased slightly during the first 15 days, decreased toward day 30, increased
significantly toward day 45, dropped significantly toward day 73 and then increased
toward day 87 (Figure 5.4e). The PL group had higher urinary Sucralose/Mannitol ratio
at day 45 compared with the other groups (Figure 5.4e). The GG group had lower urinary
Sucralose/Mannitol ratio at day 87 compared with the CO group (Figure 5.4e).

As indicated by Western blot (Figure 5.4f), the PL decreased the tight junction
protein occludin level in jejunum mucosa but did not affect occludin level in the mucosa
of ileum and colon compared with the CO. The GG increased the tight junction protein
ZO-1 level in the colon mucosa compared with the CO and the ZO-1 level was not
affected in the mucosa of jejunum and ileum.

Plasma endotoxin and cytokines
The plasma LPS level increased slightly in the GG and PL groups compared with the
CO group during the first 35 days (Figure 5.5a). The plasma LPS level increased
significantly after 101 days (Figure 5.5a). The PL group had higher plasma LPS level
compared with the CO group at day 101 (Figure 5.5a).

The GG and PL did not significantly affect the plasma levels of MCP-1, TNF-α, IL-6,
leptin, resistin, PAI-1 and insulin (Table 5.4 and Figure 5.5 b-f). The plasma IL-6 level
increased during the first 35 days and then returned toward baseline level (Figure 5.5b).
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The plasma levels of leptin and resistin increased significantly after 101 days (Figure
5.5c&d).

The PL increased the plasma PAI-1 level during the study compared with the other
two groups (Figure 5.5e). The plasma insulin level increased over time (Figure 5.5f).

Plasma glucose and HOMA-IR
Hyperglycemia was observed at day 101 (Figure 5.6a). The HOMA-IR index
increased over time (Figure 5.6b). By the end of the study, insulin resistance was
developed as indicated by HOMA-IR (33).

Body fat changes
The plots of body fat against fat-free mass revealed the gradual increase and the
dynamic changes in the body fat mass during the study (Figure 5.7a-g). When all
measurements at 12 time points (at day -15, -11, -7, -3, 4, 20, 27, 34, 55, 68, 83, 96) were
included, the data points fell into two groups with different slopes (0.98 and 0.39) (Figure
5.7a). The slope was around 0 during the first MRI scan at day -15 (Figure 5.7b). The
slope increased to 0.14 at day -7, 0.2 at day -3 (Figure 5.7c), and 0.33 at day 4 (Figure
5.7d). The slope decreased from 0.35 at day 20 to 0.30 at day 34. The slope then
increased back to 0.36 at day 55 (Figure 5.7e). At day 68, the data points started to
segregate into two groups with different slopes (1.02 and 0.27) (Figure 5.7f). From day
68 to day 96, the slopes for the two groups increased further to 1.18 and 0.34 at day 96
(Figure 5.7g).
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Comparison between lean and obese mice
The lean and obese mice (Figure 5.7g) had differences in many parameters at the end
of the study (Figure 5.8) regardless of dietary interventions. The obese mice had higher
plasma insulin and leptin compared with the lean mice (Figure 5.8a). The obese mice had
higher HOMA-IR compared with the lean mice (Figure 5.8b). The obese mice had higher
plasma CE, DG, TG, PC and higher liver TG compared with the lean mice (Figure 5.8C).
The obese mice had lower occludin protein expression in jejunum mucosa compared with
the lean mice (Figure 5.8d). The obese mice had higher amount of brown adipose tissue,
inguinal, gonadal, mesenteric and retroperitoneal fat depots compared with the lean mice
(Figure 5.8e). Obese mice had lower amount of cecum content, jejunum, ileum, colon,
jejunum mucosa and ileum mucosa compared with lean mice (Figure 5.8e).

Discussion
This study was designed to test the hypotheses that the milk polar lipids (1) reduce
liver lipid level and affect the expression of genes associated with fatty acid synthesis and
cholesterol regulation in the liver, (2) prevent the increase of gut permeability, and (3)
reduce plasma inflammatory cytokines in the C57BL/6J mice during the development of
DIO. The first hypothesis was not supported by the data. The milk phospholipids
promoted body fat accumulation and increased obesity. The milk phospholipids increased
the liver PE, PC, SM & the plasma TG and decreased the plasma FFA & PC. The milk
phospholipids decreased the PC & SM in the colon mucosa. The milk gangliosides
decreased the adipose SM, the plasma FFA & PC and increased the liver PE & SM.
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The data did not support the second and the third hypotheses. The milk phospholipids
increased the gut permeability and decreased the occludin in the jejunum mucosa. The
milk phospholipids increased the plasma LPS and did not affect the plasma inflammatory
cytokines level. The milk gangliosides decreased the ZO-1 in the colon mucosa and did
not affect the gut permeability. The milk gangliosides did not affect the plasma level of
the inflammatory cytokines.

The mouse model of DIO, increased gut permeability and increased systemic
inflammation was established. The high fat feeding increased body fat and the plasma
level of CE, leptin, resistin, insulin, and glucose. The high fat feeding decreased the
insulin sensitivity as indicated by the increased HOMA-IR index. The high fat feeding
decreased the permeability of the small intestine, increased the colon permeability and
the plasma levels of LPS, and increased the plasma IL-6 level before the establishment of
DIO.

The PL group consumed more diet and gained more weight and body fat compared
with the CO group while the GG group was in the middle. The difference was already
significant by the first 3 days and should have been contributed mainly by the first 10
days (Table 5.1). The average chow diet intake was 3.69 g/mouse/day. The mice in the
PL group consumed 4.15 g high fat diet on average on the first day. The
overconsumption of the high fat diet in the PL group during first 3 days may play an
important role in the resulting higher body weight and body fat percentage. It was not
clear which factor caused the overconsumption. The PL diet was slightly softer and the
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GG diet was slightly harder than the CO diet. No measurement of the hardness was done
for the diets. If the texture of the diet caused the difference in the diet intake during the
first 3 days, the PL group should have consumed similar amount of diet later on. The diet
intake decreased in all groups from the beginning and reached the average level by 10
days.

It might be argued that a run-in diet similar to the experimental diets may help
optimize the experimental conditions. Although a run-in diet may reduce the variabilities
in food intake during the transition from baseline diet to experimental diet, it was obvious
that the PL group consumed more food during the first 3-10 days. By the end of the study,
the PL group had consumed 20.54 g (8.0%) more diet than the CO group and 27.26 g
(10.9%) more diet than the GG group. The PL group gained more weight and body fat
than the other two groups. The GG group did not gain more weight and body fat than the
CO group although the GG group consumed more diet. The body weight gain was mainly
contributed by the body fat accumulation.

The plasma LPS did not increase much during the first 35 days. The main increase
occurred from day 35 to 101. For the LPS challenged mice (reported in chapter 4), the
plasma LPS did not increase during the first 34 days. It happened during day 35 to 57. It
is apparent that gut permeability may change significantly from day 35 to 57. An
additional 6 weeks of feeding did not significantly increase the plasma LPS. One week of
feeding increased the plasma LPS to similar level observed in the ob mice (reported in
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chapter 3). The plasma LPS level increased significantly in all groups once the DIO was
established.

There were no significant dietary treatment effects on major plasma inflammatory
cytokines and adipokines, including IL-6, TNF-α, PAI-1, MCP-1, resistin and leptin. The
plasma resistin and leptin increased over time. Dietary phospholipids increased the
plasma insulin level after the DIO (Figure 5.5f).The mechanism for this increase of
insulin is not clear. Dietary phospholipids rich in n-3 polyunsaturated fatty acids reduced
plasma insulin level under obesogenic conditions and the mechanism may be through
modulating the endocannabinoid system activity in the white adipose tissue (34). It could
be possible that the opposite effect of dietary phospholipids on the plasma insulin level in
this study was due to the saturated fatty acids in the milk phospholipids.

Dietary phospholipids decreased phospholipids in the visceral adipose tissue and the
colon mucosa but increased phospholipids in the liver (Figure 5.2a & c). The higher
dietary phospholipids level was not always accompanied by higher phospholipids level in
the tissue. The dietary phospholipids decreased the SM level in the colon mucosa. Little
or no radioactively labeled SM was absorbed intact into the chyle (35). Luminal SM is
hydrolyzed to ceramide, and then to sphingosine and free fatty acids (36). The free
sphingosine is well absorbed and most of the absorbed sphingosine is rapidly converted
to palmitic acid and incorporated into chylomicrons (37, 38). A smaller portion of the
sphingosine is incorporated into the mucosa as ceramide and SM (35, 39). It may be
hypothesized that the dietary SM may have suppressed the tissue SM level in the
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intestinal mucosa through down regulation of the receptors for sphingosine. Similar
mechanisms of receptor regulation may account for the effects of dietary phospholipids
on tissue phospholipids level in the visceral adipose tissue and the liver.

During the maturation of the gut, gut permeability to FITC decreased (Figure 5.4a).
Compared with the CO and the GG, the PL facilitated the decrease of permeability to
FITC when the mice were lean and increased the permeability to FITC when the animals
were obese. Although the difference between the PL and the other two was not
statistically significant at any of the time points, the opposite effect of the PL before DIO
and after DIO was quite interesting. It is not clear what the mechanism was for the
opposite effect in the PL group. Further studies are needed to explore how the PL may
have different effect on gut permeability when the mouse is lean and after DIO.

The permeability of the small intestine decreased during the first 45 days (Figure 5.4b)
in all groups as revealed by the urinary Lactulose/Mannitol ratio (40). Taken together, the
intestinal integrity was enhanced during the first 45 days. The mice were still developing
during that period of time and the gut may be maturing. After the DIO was established,
the small intestinal permeability increased significantly in the PL group compared with
that in the CO and GG groups. There was a peaking of the body fat percentage around
that time point (Figure 5.1b). The decrease of the urinary Sucrose/Lactulose ratio
indicated the distal damage of small intestine. The damage became proximal when the
urinary Sucrose/Lactulose ratio increased to a high level (40).

176

The high-fat feeding increased the permeability of the proximal small intestine and
the GG and PL supplementations caused a permeability increase of the distal small
intestine during the first 15 days (Figure 5.4c). Then the damage became proximal also in
the GG and PL groups by day 30. The damage then moved to the distal small intestine
and back to the proximal by the end of the study. This is consistent with the Western blot
result that the dietary polar lipids (especially phospholipids) suppressed the TJ protein
occludin expression in the jejunum mucosa. The urinary Lactulose/Sucralose ratio
selectively increases upon the intestinal damage and decreases upon the colonic damage
(40). The high fat feeding increased the permeability of the colon (Figure 5.4e). The
colon permeability stayed stable from day 45 to the end except in the PL group where
small intestine permeability increased during the early phase of the DIO. There was an
increase of the colon permeability during the first 15 days and the permeability receded
by day 30. Then the colon permeability increased significantly at day 45. The significant
increase of the colon permeability at day 45 (Figure 5.4e) may be due to the increased
inflammation as indicated by the increase of the plasma IL-6 level (Figure 5.5b) around
this time. Taken together, the high-fat feeding increased the permeability of proximal
small intestine and the colon at the beginning and there was a recovery after the initial
permeability increase. Then the permeability of the distal small intestine and the colon
increased when the systemic inflammation increased during the early phase of the DIO.

The dietary fat level was 34% fat as energy, which was lower than most of the fat
levels used for the DIO model. The colon permeability increased significantly at the onset
of the DIO (Figure 5.4c) and then decreased significantly. The initial increase of the
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colon permeability may be caused by the high fat diet, which increases intestinal
permeability through the dietary fat and increased luminal bile juice levels (41). The high
fat feeding before the DIO increased the colon permeability but did not increase the
plasma LPS level significantly. The colon permeability decreased (Figure 5.4e) and the
plasma LPS increased (Figure 5.5a) after the establishment of DIO. The increase of the
plasma LPS level after the DIO may not be contributed significantly by the decreased
colon permeability but may be mediated through the chylomicrons as the postprandial
carriers for the LPS (42). The chylomicron secretion process is different in DIO from
when the mice are lean (43). The mechanisms remain unclear for the altered intestinal TG
metabolism in mouse models of obesity (43). Compared with lean controls, men with
visceral obesity may have normal fasting plasma lipids but an abnormal postprandial
accumulation of TG-rich remnant lipoproteins due to the greatly decreased clearance of
chylomicron remnants (44). Taken together, it may be hypothesized that the absorption of
gut LPS in DIO is mainly mediated through the transcellular pathway instead of the
paracellular route. If the absorbed gut LPS in the plasma during DIO is mainly carried by
chylomicron remnants, this may help explain the lack of a considerable inflammatory
response corresponding to the increased plasma LPS since the lipoproteins may inactivate
LPS (45).

The plasma LPS level did not increase (Figure 5.5a) at day 35 but the IL-6 level
increased manyfold (Figure 5.5b). The plasma IL-6 then decreased toward the end of the
study while the LPS level increased dramatically. These results indicate that a diet with
34% fat as energy may not pose a strong inflammatory stress for the C57BL/6J mice. The
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PL and GG supplementations enhanced the inflammatory response. On the other hand the
DIO was complicated with the high level of plasma LPS but not a strong inflammatory
response.

The plasma resistin level increased steadily throughout the course of the study in the
CO and GG groups. That could mean the resistin level is influenced more by the high fat
diet than by the DIO. As an adipocytokine secreted in proportion to the obesity level,
resistin counteracts the effects of insulin in mice (46). The PL did not increase the resistin
level during the first 35 days and the resistin level was lower in the PL group compared
with the CO and GG groups after the DIO. The PL prevented the increase of the resistin
during the high fat feeding and the DIO. It is not clear which component of the milk
phospholipids had this effect.

The PL increased the plasma PAI-1 level during the first 35 days and the plasma PAI1 level flattened in the PL group when the mice became obese (Figure 5.5e). The CO and
the GG decreased the plasma PAI-1 level before the DIO and the level regressed after the
DIO. PAI-1 is an adipocytokine and the increased PAI-1 level in obesity has been
associated with the mediation of obesity, insulin resistance and metabolic syndrome (47,
48). Lysophosphatidylcholine (LPC) in oxidized low-density lipoprotein (OxLDL)
enhances the PAI-1 expression in mouse 3T3-L1 adipocytes (49). The increase of the
plasma PAI-1 level in the PL group may be caused by the metabolites of dietary PC and
may have contributed to the development of the DIO. Suppression of de novo ceramide
synthesis significantly reduces the PAI-1 expression in the adipose tissue of obese mouse
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(50). It is not clear why the CO and the GG decreased the plasma PAI-1 level before the
DIO. Taken together, dietary supplementations of PL may pose risk factors for obesity
and metabolic syndrome by increasing the plasma PAI-1.

The plasma leptin level did not increase by the high fat feeding itself and the leptin
level was proportional to the body fat content for the PL group (Figure 5.5c). For the
plasma leptin level, variances exist in the literature. Levi et al. reported that the plasma
leptin of 11-week old C57BL/6J was at 1.5 ng/ml (51) measured by an enzyme-linked
immunosorbent assay (Crystal Chem, Downers Grove, IL, USA). Burgueño reported that
the plasma leptin of 12-week-old C57BL/6J was at 0.2 ng/ml measured by an enzymelinked immunoassay kit (Assay Designs, Ann Arbor, MI) (52). In this study, the plasma
leptin level (measured by fluorescent immunoassay) increased over time, from 2.3 - 3.4
ng/ml for the 12-week-old to 17 - 28 ng/ml for the 21-week-old. The range is similar to
Murphy et al.’s report that the plasma leptin level (measured by radioimmunoassay) was
3.8 ng/ml for the 12-week old, peaked at 4.2 ng/ml for the 14-week-old, and declined to
2.3 ng/ml at week 16 (53). The increase of leptin level may be explained by the increase
of body fat accumulation.

The plots of body fat against fat-free mass showed that the slope increased gradually
until the data points segregated at day 68 (Figure 5.7f), which indicated the establishment
of the DIO. This coincided with the plateauing of the body fat percentage at day 68
(Figure 5.1b). These data support that the plot of body fat against fat-free mass is an
effective way for defining obesity (54). By the end of the study, 10 out of the 17 mice

180

were obese according to the aforementioned definition. The obese and lean mice had
significant differences in many parameters (Figure 5.8) regardless of the dietary
treatments. Significant body weight increase is usually used to define obesity (55). The
use of body weight gain to define obesity is more arbitrary than using the plot of body fat
against fat-free mass. The data in the current study and the data from the ob/ob mouse
model (Chapter 3) and the LPS-stressed mouse model (Chapter 4) all support that the
Fenton’s method is an effective and relatively objective way for defining obesity.

The data from the present study also showed that stresses may have considerable
effect on body fat content in the C57BL/6J mice. The MRI scan at day 34 was carried out
soon after the third DST (at day 30). Residing in the metabolic cage may be responsible
for the reduced body fat content as indicated by the decreased slope (0.35 at day 20 to
0.30 at day 34). Once the stress was removed, the body fat increased back (Figure 5.7e).
The other 5 DST did not affect the MRI data when those DST were at least 5 days apart
from the MRI scans. It may be emphasized that unnecessary stresses should be avoided
and the animals should be handled in the same manner to reduce variances from the
potential variability in the stresses.

Summary
The major effects of the dietary polar lipids on gut permeability, systemic
inflammation, and lipid metabolism during the development of the DIO are summarized
in Figure 5.9. During the development of the DIO in the C57BL/6J mice fed high fat diets,
gut permeability to sugar probes increased before the DIO and decreased after the DIO.
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The plasma LPS level increased after the DIO. Hyperglycemia and insulin resistance
developed by the end of the study. Compared with the CO, the PL decreased the TJ
protein occludin in the jejunum mucosa and increased the permeability of the small
intestine and the colon after the DIO. The PL increased the body fat content and the
plasma LPS level compared with the CO. Compared with the CO, the PL increased the
polar lipids content in the liver and decreased the polar lipids content in the colon mucosa.
Compared with the CO, the PL increased the plasma TG, decreased the plasma FFA and
PC, and decreased the adipose PC. The dietary milk GG increased the TJ protein ZO-1 in
the colon mucosa and did not affect the gut permeability compared with the CO and the
PL. Compared with the CO, the GG decreased the adipose SM, increased the liver PE and
SM, and decreased the plasma FFA and PC. The GG did not affect the plasma
inflammatory cytokines.

In conclusion, the plasma inflammatory cytokines were not significantly affected by
the high fat feeding or the dietary treatments. The dietary phospholipids increased obesity,
gut permeability and the plasma LPS. This study revealed important dynamic changes in
gut permeability and the body fat content during the development of DIO. The milk
phospholipids may have unfavorable effects on obesity and gut permeability in the
context of high fat diet induced obesity. Further studies are needed to identify which
components of the milk polar lipids concentrates are responsible for the observed effects.

The data from the current study did not support the hypotheses that during the
development of DIO dietary milk polar lipids will 1) prevent the gut permeability
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increase and subsequent systemic inflammation and 2) reduce liver lipid levels and affect
the expression of genes associated with fatty acid synthesis and cholesterol regulation in
the liver. The polar lipids are important building blocks for all the organ systems. The
dietary polar lipids may affect all of the organ systems in the body. It is still not clear
how the polar lipids may affect those organ systems that were not assessed in the present
study. The overall effects of the dietary polar lipids cannot be concluded until the effects
of the polar lipids are systematically evaluated in all of the major organ systems.
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Table 5.1 Food intake (Mean ± SEM; unit: g).

1
2
3
4
5
6
7
8
9
10
days 1-3 sum
days 1-3 mean
days 1-10 sum
days 1-10 mean
General sum
General mean
a,b

CO
3.18±0.27
3.03±0.23
2.30±0.14
2.25±0.11
2.85±0.27
2.45±0.12
2.32±0.18
2.28±0.12ab
2.85±0.18
2.25±0.11b
8.52±0.18b
2.84±0.06b
25.77±0.52b
2.58±0.05ab
257.72±8.34
2.58±0.08

GG
2.85±0.65
2.83±0.25
2.80±0.30
2.35±0.21
2.38±0.24
2.22±0.26
2.73±0.20
1.92±0.26b
2.33±0.17
2.47±0.18b
8.48±0.69b
2.83±0.23b
24.88±1.08b
2.49±0.11b
251.00±8.57
2.51±0.09

PL
4.15±0.17
3.40±0.25
2.97±0.17
2.68±0.30
2.60±0.27
2.72±0.16
2.47±0.16
2.80±0.14a
2.38±0.19
3.05±0.22a
10.52±0.52a
3.51±0.17a
29.22±1.16a
2.92±0.12a
278.26±11.53
2.78±0.12

Means in a row with different superscripts are significantly different (p < 0.05).

Table 5.2 Food intake and energy stored as body fat from day -3 to day 4 (Mean ± SEM).

Food intake as energy (Kcal)
Body fat gain as energy (Kcal)
%Energy of fat gain/food intake (%)
a,b

CO
84.74±2.05b
0.64±1.58b
0.62±1.87b

GG
86.60±4.21b
7.82±3.50ab
8.26±3.49ab

PL
98.35±3.61a
12.79±2.16a
12.89±2.08a

Means in a row with different superscripts are significantly different (p < 0.05).
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Table 5.3 Effects of milk polar lipids on liver and adipose tissue mass (Mean ± SEM).
Tissue mass/body weight (%)
Liver%
Brown adipose tissue depot%
Inguinal fat depot%
Gonadal fat depot%
Mesenteric fat depot%
Retroperitoneal fat depot%
Visceral fat depots%
Subcutaneous fat depot%
Total fat depots%
a,b

CO
3.32±0.25
0.42±0.04
2.82±0.49
3.34±0.58
1.39±0.26
1.19±0.28
5.92±1.10
5.30±1.08
11.64±2.20

GG
3.50±0.13
0.52±0.08
3.34±0.52
4.37±0.63
1.75±0.22
1.47±0.26
7.59±1.09
5.90±0.98
14.01±2.11

PL
3.26±0.05
0.52±0.06
3.69±0.38
4.81±0.36
2.19±0.25
1.72±0.18
8.72±0.71
6.56±0.52
15.80±1.27

Means in a row with different superscripts are significantly different (p < 0.05).

Table 5.4 Effects of milk polar lipids on plasma levels of MCP-1 and TNF-α in
C57BL/6J mice during the development of diet-induced obesity (Mean ± SEM; unit:
Log10(pg/ml)).

Lipids
Baseline
MCP-1
TNF-α
Day 35
MCP-1
TNF-α
Day 101
MCP-1
TNF-α
a,b

CO

GG

PL

1.42±0.07
1.38±0.06

1.51±0.10
1.36±0.06

1.14±0.15
1.16±0.14

1.50±0.04a
1.37±0.05

1.46±0.03a
1.25±0.11

1.32±0.06b
1.33±0.15

1.48±0.04
1.35±0.08

1.54±0.05
1.39±0.08

1.38±0.07
1.28±0.11

Means in a row with different superscripts are significantly different (p < 0.05).
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Figure 5.1 Effects of the polar lipids on body weight and body fat content. Initial body
weight for CO, GG and PL groups: 20.9 ± 0.5, 21.2 ± 0.3, 21.7 ± 0.7 (g). Initial body fat
for CO, GG and PL groups: 2.17 ± 0.09, 2.06 ± 0.08, 2.18 ± 0.14 (g). (a) PL group gained
more body weight during the first 10 days. (b) PL group accumulated more body fat
compared with CO and GG groups. (c) PL group gained more body weight compared
with CO and GG groups. (d) PL increased body fat at a faster rate compared with CO and
GG. The data represent mean ± SEM (n = 6).
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Figure 5.2 Effects of milk polar lipids on tissue lipid profile. The data represent mean ±
SEM (n = 6, 5, 6 for CO, GG, PL). (a) GG and PL decreased PC and SM in visceral
adipose and increased PE, PC and SM in the liver compared with CO. (b) GG up
regulated the expression of Acacb in liver compared with PL; PL up regulated expression
of Scarb1 compared with CO and GG. (c) PL decreased PE, PC and SM in colon mucosa
compared with CO and GG. Means in a row with different superscripts are significantly
different (p < 0.05).
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Figure 5.3 Effects of milk polar lipids on plasma lipid profile. The data represent mean ±
SEM (n = 6, 5, 6 for CO, GG, PL). (a) Plasma TG increased over time in GG and PL
groups; PL group had higher TG at the end compared with CO. (b) Plasma CE increased
over time. (c) Plasma FFA increased in CO group and the level returned to baseline level
by the end of the study. (d) Plasma PC level increased in CO group compared with that in
GG and PL groups and the level decreased by the end of the study.
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Figure 5.4 Effects of milk polar lipids on gut permeability. The data represent mean ±
SEM (n = 6, 5, 6 for CO, GG, PL). (a) The polar lipids did not affect the plasma FITC. (b)
The urinary Lactulose/Mannitol ratio decreased over time. (c) The urinary
Sucrose/Lactulose ratio decreased over time. (d) The urinary Lactulose/Sucralose ratio
decreased over time. (e) The urinary Sucralose/Mannitol ratio increased gradually until
day 45 and then decreased. (f) GG and PL increased ZO-1 expression in colon mucosa;
PL and GG decreased occludin expression in jejunum mucosa. Means in a row with
different superscripts are significantly different (p < 0.05).
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Figure 5.5 Effects of the polar lipids on plasma LPS and cytokines. The data represent
mean ± SEM (n = 6, 5, 6 for CO, GG, PL). (a) Plasma LPS level increased over time and
the PL increase the plasma LPS at day 101. (b) Plasma IL-6 level increased by day 35
and then decreased. (c) Plasma leptin level increased over time. (d) Plasma resistin level
increased over time. (e) Plasma PAI-1 level increased in PL group, decreased in CO and
GG groups during the first 35 days and then increased back toward the end of the study.
(f) Plasma insulin level increased over time.
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Figure 5.6 Effects of milk polar lipids on fasting glucose and HOMA-IR. The data
represent mean ± SEM (n = 6, 5, 6 for CO, GG, PL). (a) The urinary Lactulose/Mannitol
ratio increased after LPS stress and returned to baseline level during recovery. (b) The
urinary Sucrose/Lactulose ratio decreased after the LPS stress and increased gradually
during the recovery.
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Figure 5.7a Body fat plotted against fat-free mass for individual animals during day 1
through day 96.
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Figure 5.7b-d Body fat plotted against fat-free mass for individual animals at (b) day -15,
(c) day -3 and (d) day 4.
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Figure 5.7e-g Body fat plotted against fat-free mass for individual animals at (e) day 55,
(f) day 68 and (g) day 96.
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Figure 5.8 Comparison between lean and obese mice. The data represent mean ± SEM (n
= 7 and 10 for Lean and Obese). (a) Obese mice had higher plasma insulin and leptin
compared with lean mice. (b) Obese mice had higher homeostasis model assessment of
insulin resistance (HOMA-IR). (c) Obese mice had higher plasma cholesteryl ester (CE),
triglycerides (TG), diglycerides (DG), phosphatidylcholine (PC) and higher liver TG
compared with lean mice. (d) Obese mice had lower occludin protein expression in
jejunum mucosa compared with lean mice. (e) Obese mice had higher amount of brown
adipose tissue (BAT), inguinal, gonadal, mesenteric and retroperitoneal fat depots
compared with lean mice. Obese mice had lower amount of cecum content, jejunum,
ileum, colon, jejunum mucosa and ileum mucosa compared with lean mice. Means in a
row with different superscripts are significantly different (p < 0.05).
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Figure 5.9 Summary of major findings in Chapter 5. Horizontal white arrows indicate the
effects of the control diet. Horizontal T-shaped purple arrows indicate undesirable effects.
Horizontal solid purple and blue arrows indicate desirable or neutral effects. L/M:
Lactulose/Mannitol, S/M: Sucralose/Mannitol.
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CHAPTER 6
SUMMARY AND FUTURE DIRECTIONS

In this dissertation, I explored the effects of the dietary milk polar lipids on gut
permeability, systemic inflammation, and lipid metabolism in several rodent models. The
major hypotheses were that the dietary polar lipids would increase the gut barrier
integrity, reduce systemic inflammation, and reduce liver lipid levels and affect the
expression of genes associated with fatty acid synthesis and cholesterol regulation in the
liver. The hypotheses were tested in the context of stressful diets, systemic inflammation,
and obesity. The results did not support the majority of the hypothesized effects (Figure
6.1). The milk phospholipids as dietary supplements may increase gut permeability and
systemic inflammation and promote body fat accumulation during obesity and
inflammatory responses. The milk gangliosides as dietary supplements may have little
effect on gut permeability, systemic inflammation, and lipid metabolism during obesity
and inflammatory responses. Based on the data from this dissertation, the dietary
supplementation of milk polar lipids should not be recommended in the context of
obesity and systemic inflammation. Although the milk-derived concentrates used in this
dissertation were semi-purified, there were several active compounds in each of the
concentrates. The PL concentrate contained sphingomyelin (SM), phosphatidylcholine
(PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS). The GG concentrate
contained gangliosides, PC and PS. The bioactivities of the individual compounds in the
milk polar lipids concentrates need to be explored by systematic investigations. Here I
will summarize the major findings in four models separately first and then look
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comprehensively at the major endpoints, namely gut permeability, systemic inflammation,
and lipid metabolism.

Rat Model with High Sucrose Diet
The AIN-76A diet is still commonly used in the aberrant crypt foci (ACF) studies
with rodents (1) and the high sucrose content of the AIN-76A diet causes fatty liver in
animals fed the diet for long periods of time (2). Since the diets were quite stressful
metabolically, the findings in this study may not be extrapolated to other circumstances.
Compared with the milk fat diets, the corn oil diet caused a significant increase in hepatic
free fatty acids, a potential trigger for the development of nonalcoholic steatohepatitis
(NASH) from non-alcoholic fatty liver disease (NAFLD). The anhydrous milk fat diet
resulted in more hepatic TG storage compared with corn oil and MFGM supplemented
diets. Saturated fat may facilitate TG accumulated in the liver. Unsaturated fatty acids
and polar lipids may alleviate the accumulation of TG in the liver. The mechanism of
polar lipids on reducing the accumulation of hepatic TG may be through promoting lipid
export into plasma. In conclusion, the fat source of the AIN-76A diet affects the lipid
profile of key tissues involved in lipid trafficking and storage as well as gene expression
networks within these tissues.

Since the AIN-76A diet has an unreasonably high amount of sucrose and is
metabolically stressful, it may confound the findings in gut permeability, lipid
metabolism and systemic inflammation. Future studies may use diets with lower sucrose
(such as AIN-93G diet) to explore which components of the MFGM have the observed
effect.
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Rats and mice have different metabolic responses to dietary intervention. For example,
after a 48h fast, the hepatic TG increased significantly in 6-8 weeks old Swiss albino
mice but declined in Sprague-Dawley derived rats at similar age (3). When 5 weeks old
male Wistar CpbIWU rats and NMRI mice were fed a cholesterol-free diet containing
corn oil for 20 days, serum TG were reduced and fecal excretion of neutral steroids were
increased in the rats but not affected in the mice. The rats and mice had similar responses
to corn oil when the diet was supplemented with 1 % (w/w) of cholesterol (4). There are
significant differences in postprandial TG patterns between Wistar rats and C57BL/6J
mice at the age of 8 weeks fed regular rodent chow diet. C57BL/6J mice have similar
postprandial lipid profile in the serum as healthy men (5). So it is reasonable to expect the
effects of MFGM to be different in mouse models from rat models. Given the fact that rat
models still serve as important platforms for exploring metabolism and nutrition, it may
still be worthwhile to test the effects of the individual components of MFGM in rat
models.

Genetic Obesity Model with High Fat Diet
In the ob/ob mouse model, the gut barrier integrity was compromised, the plasma
lipids level was decreased, and most of the systemic inflammatory cytokine levels did not
change from baseline. The food restriction aggravated the hepatic lipidosis and may have
caused death in some of the animals. The dietary GG increased the tight junction (TJ)
protein occludin expression in the colon mucosa and had little effect on lipid metabolism
and systemic inflammation. The dietary PL supplementation increased the total body fat
percentage and redistributed lipids from liver and visceral fat depots into the plasma. The
dietary PL increased the plasma SM, which was strongly associated with the increase of
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the plasma inflammatory cytokine IL-6. Taken together, the supplementation of high fat
diets with phospholipids and sphingomyelin could result in unfavorable effects on lipid
metabolism and systemic inflammation in the ob/ob mice. The dietary milk gangliosides
at the current dietary level may not have significant effect on the intestinal barrier
integrity, lipid metabolism and systemic inflammation in the ob/ob mice fed moderately
high fat diets. Future studies may further explore which components of the milk
phospholipids concentrate are responsible for the observed effects.

The PL supplementation reduced lipid levels in the liver but did not have any effect
on the gut permeability to FITC-dextran and sugar probes. The dietary PL also increased
systemic inflammation. Often times, a few organ systems are assessed during dietary
interventions. The limitation of this kind of study is that the dietary treatment may benefit
one or a few organ systems but could be detrimental to the other systems. During this
study, only four out of the eleven major organ systems were assessed in some detail.
There are still many systems that were not assessed, such as the nervous system,
cardiovascular system, skeletal system, respiratory system, excretory system,
reproductive system and immune system. The general effects cannot be concluded until
all systems are taken into consideration. Therefore, the effects of dietary milk polar lipids
on the whole body in the ob/ob mice needs to be further assessed in a systematic manner.

The obese mouse model with a moderately high fat diet is an excellent representation
of the dietary practice in America, where over one third of the people are obese and
consuming a diet with 34% of fat by energy on average. The evidence from human
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studies suggests that leptin mainly affects the human energy balance through regulating
appetite instead of energy expenditure (6). The ob/ob mouse model may not provide
much information regarding the development of obesity but could offer important
insights for the development of the comorbidities associated with obesity. The ob/ob
mouse is a great model for studying preexisting obesity if the diabetic mice are excluded.
Stresses should be kept at a very low level for this model. Caution should be taken since
the ob/ob mouse is leptin deficient and the possibility cannot be excluded that the
negative results may be leptin dependent.

The differential sugar test (DST) is an effective method to evaluate the site-specific
gut permeability. But the currently available metabolic cages are not suitable for carrying
out the DST in the ob/ob mice. A specific metabolic cage system designed for the ob/ob
mice is needed to prevent the food restriction. The regular metabolic cage for the lean
mice is too small and the ones for the rats are too big for the ob/ob mice.

Since the ob/ob mice have a higher feed efficiency and significantly different energy
metabolism at the early age compared with the lean mice (7), adult ob/ob mice may be
used in the high fat diet model to prevent extreme fat accumulation and to achieve a
healthier development when the mice are young. By using the adult ob/ob mice, diets
with 34% fat by energy may pose less stress on the animals comparing with using the
younger ob/ob mice. Caution should always be kept in mind since the ob/ob mouse
model is leptin deficient and findings from animal models may not be directly applicable
in the humans.
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There is an association between the self-reported lifetime stress and an increased risk
of obesity in adult Canadians (8). Psychological stress is negatively correlated with
healthy dietary behaviors and positively correlated with body weight (9). Human and
animal studies have shown that the chronic psychological stress tends to affect the dietary
pattern and increase craving for the nutrient-dense “comfort foods.” The stress associated
visceral obesity may be linked to the hyperactivity of the sympathetic branch of the
autonomic nervous system (ANS) and the hypothalamic-pituitary-adrenal (HPA) axis
(10). The depression and anxiety commonly observed in obese people (11-14) can
activate the HPA axis (15). The increase of depression and/or anxiety is associated with
an increase of waist-to-hip circumference ratio (16, 17). Repeated stresses increase
visceral adiposity independent of changes in body weight and the stress-induced visceral
obesity may be mediated by the stress-induced IL-1β in non-visceral white adipose tissue
(Figure 6.2) (18). In healthy and non-obese rats, the acute stress increases IL-1β more in
the subcutaneous white adipose tissue than in the visceral white adipose tissue (18). IL-1β
may function through autocrine and/or paracrine signaling in the white adipose tissue
(19). The acute rise of IL-1β can have beneficial functions such as increasing
lipolysis, increasing leptin secretion and potentiating glucocorticoid signaling. But
sustained IL-1β signaling through repeated stress can increase visceral adiposity, which
may be achieved by adipose hypertrophy and/or adipocytes hyperplasia in
the subcutaneous adipose tissue during energy overflow (18).

The data from this ob/ob mouse study indicate that acute stress during obesity may
affect the comorbidities of obesity. The postmortem pathology revealed severe hepatic
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lipidosis and renal lipidosis in the ob/ob mouse. One of the possible reasons for the
animal death was the stress induced during the second 24-hour stay in the metabolic cage
and the last MRI scan one day after the metabolic cage stay. Two days’ staying in the
metabolic cage results in transient hypertension and sustained tachycardia in the
C57BL/6J lean mice (20). It takes 3–4 days for the plasma and urinary biochemistry to
reach stable values when the C57BL/6J mice are housed in metabolic cages (21). The
serotonin (5-HT)(2C) receptor knockout mice (C57BL/6J background) develop
hyperphagia and midlife obesity and they are hyperresponsive to repeated stress (22).

It is possible that the stresses from the second 24-hour stay in the metabolic cage and
the MRI scan caused acute hepatic failure on top of the chronic renal and hepatic
lipidosis. With the fatty liver in place, the hepatocytes are more vulnerable to damages.
There are more apoptotic events in the livers from patients with NAFLD (23). The
injection of anti-Fas antibody results in animal death within 12 hrs in 90% of the obese
ob/ob mice while all lean control animals survive (24). The animal death is due to the
hemorrhagic liver failure mediated by the apoptotic cell death. The ob/ob mice represent
a model of NAFLD complicated with type 2 diabetes mellitus and hypertriglyceridemia
(24). The hepatic failure in this study could have resulted from the food restriction and
the sustained activation and subsequent exhaustion of the ANS and the HPA axis. The
ob/ob mice develop spontaneous liver steatosis and the high fat diet can induce a more
severe liver injury (25). The activation of the HPA axis could release a large amount of
corticoids, which worsens the condition of the acute hepatic failure (26). Further studies
are needed to clarify the mechanisms behind the mortality occurred in those ob/ob mice.
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The ob/ob mouse is widely used as an animal model of type 2 diabetes. Diabetes
mellitus is sometimes defined by fasting hyperglycemia (27). Diabetes mellitus may be
more appropriately defined as a group of metabolic disorders featuring hyperglycemia
due to defects in insulin secretion and/or insulin action (28). Although most of the ob/ob
mice had hyperglycemia toward the end of the study, only two mice developed obvious
symptoms of diabetes. The ob/ob mice on a diet with 6% fat (by mass) or on a rodent
chow only develops transient hyperglycemia, which partially remits between 10 and 14
weeks of age (29). Therefore, the fasting hyperglycemia may not be an ideal criterion for
defining diabetes in the ob/ob mice. Clinical symptoms in combination with
hyperglycemia may be used for defining diabetes in these mice. When the ob/ob mouse is
used as an animal model of obesity or type 2 diabetes, the mice should be screened to
differentiate diabetic and nondiabetic animals. The nondiabetic mouse may be used as a
model of obesity and the diabetic mouse may be used as a model of type 2 diabetes to
reduce confounding factors.

LPS-induced Systemic Inflammation Model
The LPS induced inflammation model used in this dissertation had two phases, the
acute and chronic stages. Dietary milk polar lipids did not protect the gut barrier integrity
during the acute phase, within 24 h after the LPS injection. The LPS was injected
subcutaneously and the LPS can be retained in the body until a month later (30). In the
context of the chronic inflammatory stress induced by the LPS in young C57BL/6J mice,
the gut permeability to extra large molecules increased (Figure 4.6c, LPS: 100-1000 kD),
to large molecules decreased (Figure 4.6b, FITC-dextran: 4000 Da) and to small
molecules increased (Figure 4.7a-d, lactulose and sucrose: 342.3 Da, sucralose: 397.64
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Da). The decreased permeability to the large molecules could be due to the maturation of
the gut barrier during development in the weaning mice (31). The increased permeability
to the smaller molecules could be due to the compromise of the gut barrier integrity by
the high fat diet and the LPS-induced inflammation. The absorption of the intestinal LPS
can be mediated both through the paracellular diffusion and during the chylomicron
secretion (32). So the increase of the plasma LPS may not be explained by the increase of
gut permeability to large molecules but should be mediated mainly through chylomicron
secretion.

The plasma level of resistin increased overtime in the C57BL/6J mice challenged
with the LPS. The increase of plasma levels of resistin may be explained by the high fat
feeding and the time of the feeding period (32). The diet with 45% fat by energy
increases plasma resistin level compared with the diet with 13% fat by energy (32). The
plasma resistin level is higher in the 29-week-old C57BL/6J mice than in the
15-week-old mice regardless of the dietary fat level (32).

The plasma insulin level decreased in the C57BL/6J mice stressed by the
subcutaneous LPS injection. The decrease of plasma insulin may be caused by the
injected LPS. The intraperitoneal injection of LPS (at 10 µg per mouse) results in a more
than half decrease of the insulin mRNA expression in the pancreatic islets in the
10-week-old BALB/c male mice by 6h after the LPS injection (33). About 85% of the
LPS injected intraperitoneally and 26% of the LPS injected subcutaneously should have
been absorbed by 6h after the injection (34). The amount of the absorbed LPS by 6h post
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injection in this study would be higher than the absorbed LPS in the BALB/c mice study
(32.5 µg vs 8.5 µg). Although there could be species difference, the damage to the
pancreas should have been much more severe in this study compared with that in the
BALB/c mice study. The intravenous injection of LPS and the intraperitoneal injection of
TNF-α can also decrease the plasma level of insulin in the C57BL/6 mice (34, 35). The
high fat feeding decreases the plasma insulin level in the rats (36). It is not clear if high
fat feeding contributed to the decrease of plasma insulin or not in this study. The decrease
of the plasma insulin level was accompanied by the lack of body fat increase and the lack
of the plasma leptin increase. There were significant increases of the body fat and the
plasma leptin in the C57BL/6J mice fed the identical diets but were not stressed by the
LPS injection (Figure 5.1b and 5.5c, Chapter 5). The LPS challenge may have prevented
the accumulation of body fat by suppressing the secretion of insulin during the high fat
diet feeding. It may be hypothesized that the suppression of insulin expression in the
pancreas may prevent the body fat accumulation.

Two mice died in each of the GG and PL groups. The cause of the animal death was
the LPS challenge. The LPS dosage may be slightly decreased (e.g., at 2.5-3 mg/kg body
weight) to prevent animal death for chronic studies. The interesting effect of the
decreased insulin level on the body fat content can be further explored by using an ideal
dose of the LPS. The amount of LPS may be optimized to induce enough pancreas
damage but not result in considerable damages to the other organs.
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In this study, the injected LPS resulted in a strong inflammatory response while the
high level of plasma LPS (absorbed through the gut) was not accompanied by increased
proinflammatory cytokine levels in the plasma. There is strong evidence from animal and
human studies indicating that high fat diets result in absorption of the intestinal LPS into
the blood (endotoxemia). The majority of the aforementioned studies did not evaluate
how the amount, the quality and the structure of the dietary fat may affect the
endotoxemia (32). The factors other than the plasma LPS may be changed by the high fat
diets, which could affect the systemic inflammation. The dietary fat may serve as
detergent and affect the absorption of antigens other than the LPS. The dietary
triglycerides increase the intestinal absorption of a protein antigen, ovalbumin, into
adipose tissue in a chylomicron-dependent manner (37). The dietary fat absorption
increases the ovalbumin absorption into the adipose tissues and the absorbed ovalbumin
promotes the T-lymphocyte responses and inflammation (38). Given the fact that the
intestinal lumen contains such a mosaic of foreign materials, there could potentially be
other antigenic substances that may be absorbed and therefore facilitate systemic
inflammation. The possibility of other potential gut-derived antigens is important to keep
in mind. Data from the DIO mouse model (chapter 5) shed some light on the potential
mechanism for the lack of a considerable inflammatory response corresponding to the
increased plasma LPS absorbed from the gut. Chylomicron secretion may play an
important role in the mechanism. The exact mechanisms for how the gut-derived LPS
may affect systemic inflammation need further study.
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The finding that the foreign LPS may play a bigger role in promoting inflammation
compared with the LPS absorbed from the gut could have important implications in this
metagenomic era. Currently big expectations are given to the study of microbiota. The
composition of the gut microbiota is closely associated with adiposity in mice and
humans (39). The body should also have flexibility in adapting to the changes in the
microbiota composition. The organism may be able to adapt to the antigens released from
the gut bacteria. Further studies are warranted to explore how the gut-derived LPS may
not induce a strong systemic inflammation.

Diet-induced Obesity Model
In the DIO model, the differences in diet intake during the first few days may have
made a difference in the fat accumulation process. This may have important implications
in the dietary practice for human beings. People would not be concerned about the
overconsumption of food for a short period of time. The data from this study suggest that
the short-term overfeeding may have long-term consequences. Compared with mice in
the CO and GG groups, the mice in the PL group consumed more diet during the first 3
days and the difference was still significant by 10 days (Table 5.1). The body fat
percentage was higher in the PL group compared with that in the CO and GG groups
(Figure 5.1b). The differences in the body fat percentage between three groups were
maintained until about day 55 when the body fat percentage started to increase at a faster
rate in the PL group compared with the other two groups (Figure 5.1b). Obesity was
established in half of the mice by day 68 (Figure 5.7f). There was no corresponding
increase of food intake in the PL group starting from day 55.

214

Two hypotheses may be proposed to explain the faster increase of the body fat
percentage in the PL group from day 55. One hypothesis is that phospholipids promote
the preadipocyte differentiation and result in the adipocytes hyperplasia in the PL group.
Another hypothesis is that the phospholipids increase lipid incorporation into the
adipocytes and result in the adipocytes hypertrophy in the PL group. Lecithin promotes
the preadipocyte differentiation, upregulates differentiation-specific gene expression, and
increases lipid levels in the adipocytes (40). The L-α-lysophosphatidylinositol is
positively associated with obesity in humans (41). During the early phase of obesity in
humans, the adipose expansion is mainly due to adipocyte hypertrophy. In the later stage
of obesity after the body weight exceeds 170 per cent of the ideal, the adipocytes
hyperplasia starts to play a role and the degree of the hyperplasia is well correlated with
the obesity severity (42). At the time when the fat accumulation started to occur at a
faster rate in the PL group (day 55, Figure 5.7e), the mice were not obese yet. So the first
hypothesis may be better supported. The body fat percentage of the CO group reached a
plateau at day 65. At around day 85, the body fat percentage plateaued in the GG and PL
groups. The further increase of the body fat after day 65 in the GG and PL groups could
have been caused by the phospholipids in the diets. It is possible that the phospholipids
induced the preadipocytes differentiation from the beginning of the dietary treatment. It
may be further hypothesized that the phospholipids-induced adipocytes hyperplasia did
not contribute significantly to the body fat content and the later hypertrophy of the newly
differentiated adipocytes were responsible for the higher body fat content observed in the
PL group.
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This study revealed important dynamic changes in gut permeability and interesting
interactions between dietary lipids and gut permeability during the development of the
DIO. During the development of the DIO in the C57BL/6J mice fed high fat diets, gut
permeability to FITC-dextran decreased (Figure 5.4a) in the CO and GG groups and in
the PL group during the first 5 weeks. The decreased permeability to large molecules
(FITC-dextran: 4000 Da) could be due to the maturation of the gut barrier during
development in weaning mice. The same pattern has been observed in the mice
challenged by the LPS (Figure 4.6b). Gut permeability to lactulose decreased over time in
all groups except at week 11 in the PL group where the permeability to lactulose
increased (Figure 5.4b). Gut permeability to sucralose fluctuated over time, increased to
the highest level at week 6 and then decreased toward the end (Figure 5.4e). In general,
the gut permeability to sugar probes decreased over time. That means the gut
permeability to small molecules decreased and the mechanism could be the maturing
process during development in young mice. So gut permeability to both small and large
molecules decreased. That could mean the gut permeability through the paracellular
diffusion decreased since the aforementioned molecules are absorbed primarily through
the paracellular route (43).

The gut permeability to the intestinal LPS increased (Figure 5.5a) in all groups. The
absorption of the intestinal LPS can be mediated through paracellular diffusion and
chylomicron secretion (32). Given the fact that gut permeability was decreased to both
the small molecules (sugar probes) and the large molecules (FITC-dextran), it is unlikely
that the LPS was mainly absorbed through the paracellular diffusion since the LPS’s
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molecular weight is much bigger (100-1000 kD). The increased permeability to the LPS
may be mediated mainly through the chylomicron secretion (44). The chylomicron
secretion is altered in both obese mice compared with lean animals and obese humans
compared with lean controls (45, 46). Data from the LPS-stressed mouse model (chapter
4) indicated that the plasma LPS increased considerably once the mice started to gain
body fat but there was no corresponding increase in systemic inflammation. Taken
together, it may be hypothesized that the absorption of gut LPS is mainly mediated
through the transcellular pathway instead of the paracellular route. More attention should
be paid to the nonparacellular pathways for exploring the absorption of the intestinal LPS.
If the absorption of bacterial LPS into the plasma is mainly carried by chylomicron
remnants, the lack of a considerable inflammatory response corresponding to the
increased plasma LPS may be explained by the LPS-neutralizing activity of the
lipoproteins (47).

The milk PL increased the permeability of small intestine and colon and decreased
the expression of TJ protein occludin in the jejunum mucosa compared with the CO after
the DIO. The milk GG increased the expression of the intestinal TJ protein ZO-1
compared with the CO after the DIO but did not affect the gut permeability as measured
by the FITC-absorption test and the DST. The change of the TJ proteins level in the
intestinal mucosa was not always accompanied by the corresponding change in the gut
permeability. The functional endpoints such as the DST and the FITC-absorption test
may provide better estimation of the gut permeability than the measurement of TJ
proteins. The change of the TJ proteins may help reveal the relevant mechanisms.
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The plasma inflammatory cytokines were not significantly affected by the high fat
feeding or the dietary treatments. There was significant increase of the plasma LPS by the
end of the study. The PL increased the plasma LPS compared with the CO but the PL did
not increase the plasma inflammatory cytokines. These data support the finding from the
LPS-stressed mouse model that the intestinal LPS may not pose a strong inflammatory
response. Further studies are needed to explore the mechanisms for how the intestinal
LPS may not induce a potent inflammatory response.

The dietary phospholipids increased obesity. A few days of higher food intake
resulted in a significant higher body weight gain in the mice fed the PL-supplemented
diet during the first 10 days of the feeding period. A similar trend was observed in the
LPS-stressed model. In this study, the mice in the PL group eventually accumulated
significantly more body fat after the establishment of the DIO even when they did not
consume significantly more food. These observations indicate that the acute nutrient
overconsumption or energy overflow may result in an important long-term impact on
metabolism. The mechanisms for how dietary milk polar lipids may promote the body fat
accumulation may shed light on the etiology of the diet-induced obesity.

Although the C57BL/6J mice are known to be an obesity-prone strain (48), not all of
the C57BL/6J mice developed the DIO in this study. For a model of the DIO, the ideal
situation may be achieved by using only the obese mice. Once the majority of the mice
develop the DIO, the Fenton’s method may be used to identify the obese mice. By using
only the obese mice, the confounding factors can be reduced to the minimum.
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The high-fat diets are usually used to induce the DIO in the C57BL/6J mice while
they are weaned on the rodent chow. A run-in diet will help optimize the model by
smoothing the diet transition from the rodent chow to the high fat diet. The mice
consumed more food in the PL group in this study compared with the other two groups.
There are a couple of possible reasons for the higher amount of the diet intake in the PL
group. The PL diet was slightly softer than the other diets. Efforts may be taken to
equalize the texture of the diets. The addition of the milk polar lipids into the PL and GG
diets may have contributed the milk flavors, which could confound the results. At the
beginning of the study, the mice had been weaned for 3 weeks and they may still have a
strong preference for the milk flavors. If possible, the flavor of the diets should also be
controlled. For example, a strong flavor may be added to all diets to mask other flavors.

The dynamic and static phases of obesity in the rats were reported in 1987 by
Fukushima (49). More recently, Smith described the two phases during the development
of obesity, the dynamic phase and the static phase (50). The dynamic phase is the phase
of rapid weight gain. The static phase is when weight gain slowed significantly or
stopped and the meal size returned to normal. The dynamic phase is associated with the
hyperphagia while the static phase is associated with the endocrine and metabolic
abnormalities. Both the DIO obesity model and the hypothalamic obesity model show
these two phases of body weight gain (51). Most of the information about human obesity
was obtained by studying people in the static phase. The studies on childhood obesity
also usually did not monitor the dynamic processes leading to the obesity. While there is
a lot of information about the static state of obesity, the data on the dynamic state of
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obesity is just beginning to emerge. Little attention has been paid to the initial dynamic
phase during the obesity development and the resurgence of the dynamic phase during
the weight gain rebound after the weight loss. The dynamic phase is a better situation
than the static phase for studying the relevant mechanisms when they are more active and
available (50). A recent study revealed that the short-term overeating compromises the
insulin sensitivity in the adipocytes (52). Four weeks of high energy diet results in a 10%
body weight gain and a 19% body fat increase in the lean young adults. Those volunteers
did not become overweight (BMI = 24.3 kg/m2) and developed moderate systemic
insulin resistance. Insulin signaling in adipocytes was impaired in those volunteers (52).
The data from the current mouse study also indicated that the overeating during the
dynamic phase may significantly affect the static phase.

Effects of Dietary Polar Lipids across Different Rodent Models

Effects of dietary polar lipids on gut permeability
The dietary gangliosides did not affect gut permeability and the dietary phospholipids
increased the permeability of the colon when the ob/ob mice were fed a moderately high
fat diet (Figure 6.1a). The ob/ob mouse model is a leptin-deficient model. The lack of the
hypothesized effect of the dietary polar lipids on the gut permeability could be due to the
absence of the active leptin. In the DIO model, the dietary gangliosides did not affect the
gut permeability and the dietary phospholipids increased the permeability of the small
intestine and the colon after the DIO. The lack of the expected effect of the polar lipids
on the gut permeability in the lean C57BL/6J mice during the DIO indicated that the lack
of the effect may not be leptin dependent. Taken together, the polar lipids did not reduce
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gut permeability when the mice were obese no matter if they were leptin-deficient or not.
The effects of dietary polar lipids on gut permeability may not be leptin-dependent in the
context of obesity. In the LPS-stressed mouse model, the gangliosides did not affect the
gut permeability and the phospholipids increased the permeability of the small intestine
(Figure 4.7). The data from the three mouse models consistently revealed that the
gangliosides may not have significant effect on the gut permeability while the
phospholipids tend to increase the gut permeability.

Effects of dietary polar lipids on systemic inflammation
When the ob/ob mice were severely obese and fed a stressful diet, the dietary
phospholipids increased systemic inflammation as indicated by the increase of the plasma
IL-6 level. The dietary gangliosides did not significantly affect systemic inflammation. In
the DIO model, the dietary phospholipids increased the plasma LPS level by the end of
the study (Figure 6.1a) and had little effect on the plasma inflammatory cytokines. The
dietary phospholipids tended to increase the plasma IL-6 level after 5 weeks of dietary
treatment. Since no cytokine data were available between 5 and 15 weeks, it is highly
possible that the dietary phospholipids may significantly increase the plasma IL-6 level
during that period of time. The dietary polar lipids did not affect systemic inflammation
when the C57BL/6J lean mice were having acute inflammation after the subcutaneous
injection of the LPS. Neither did the dietary polar lipids affect systemic inflammation in
the chronic inflammatory process during recovery nor when the LPS-induced
inflammation dissipated. The phospholipids increased the plasma LPS level (Figure 6.1b)
without affecting the systemic inflammation. It is not clear if the increased endotoxemia
was a direct effect of the phospholipids or was due to the increased gut permeability
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(Figure 6.1). In conclusion, the dietary phospholipids may increase the plasma IL-6 level
in the context of obesity in the C57BL/6J mice and the dietary gangliosides may not have
significant effect on systemic inflammation in the C57BL/6J lean and obese mice.

Effects of dietary polar lipids on lipid metabolism
The dietary phospholipids lowered the liver mass in the ob/ob mice and the
LPS-stressed C57BL/6J mice (Figure 3.3a & 4.3a). The dietary polar lipids did not have
any effect on the liver mass in the C57BL/6J mice with the DIO. The effect of the dietary
polar lipids on liver mass may not be leptin-dependent. The dietary polar lipids may have
a stronger effect on the liver mass in the context of inflammation as in the ob/ob mice and
the LPS-stressed C57BL/6J mice.

The dietary phospholipids decreased the cholesteryl ester and the PI in the liver and
decreased the PI in the skeletal muscle of the ob/ob mice. The dietary phospholipids
decreased the PI in the skeletal muscle and the dietary phospholipids and gangliosides
increased the PI in the liver of the C57BL/6J lean mice stressed with LPS. The PI in the
skeletal muscle and the liver was not significantly affected by the dietary polar lipids in
the C57BL/6J mice with the DIO. Taken together, the phospholipids decreased the PI in
the skeletal muscle in both the ob/ob mice and the LPS-stress mice. It is possible that the
effect of the phospholipids on the PI in the skeletal muscle may be affected by the
systemic inflammation. The PI can be phosphorylated into phosphoinositides, which play
important roles in lipid signaling, cell signaling and membrane trafficking.
Phosphoinositides are essential components of the insulin secretory system (53). The

222

dietary polar lipids had a bigger effect on the tissue PI level when the organism was in
less homeostatic conditions such as severe obesity and systemic inflammation.

The dietary PL down regulated the fatty acid synthesis gene Acacb in the liver of all
three mouse models. For the fatty acid oxidation gene Acaa2, it was down regulated by
the dietary PL and GG compared with the CO in the ob/ob mice. The Acaa2 was down
regulated by the dietary PL compared with the GG in the C57BL/6J mice stressed with
LPS and was not significantly affected in the C57BL/6J mice with the DIO. The dietary
PL suppressed the cholesterol synthesis gene Hmgcr in the liver of the C57BL/6J mice
stressed with LPS and up regulated the cholesterol reverse transport gene Scarb1 in the
C57BL/6J mice with the DIO. The dietary polar lipids did not significantly affect the
gene expression associated with the cholesterol regulation in the liver of the ob/ob mice.
Taken together, the dietary polar lipids had different effects on lipid metabolism in the
liver in three mouse models. The decrease of the liver lipids level by the phospholipids
may be mediated through the down regulation of the fatty acid synthesis gene Acacb. The
phospholipids tend to decrease the cholesterol level in the liver by either suppressing
synthesis or increasing excretion in the C57BL/6J lean mice models.

The dietary polar lipids also had slightly different effects on the plasma lipid levels in
the three models. The plasma lipid profile was not significantly affected by the dietary
polar lipids in ob/ob mice. The dietary GG and PL reduced the plasma CE level after the
LPS stress in the C57BL/6J mice and did not significantly affect the plasma CE level in
the C57BL/6J mice with the DIO. The dietary GG and PL reduced the plasma FFA level
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before DIO in the C57BL/6J mice and the dietary GG reduce the plasma FFA level in the
C57BL/6J mice stressed with the LPS. The gangliosides tend to reduce the plasma FFA
level in the C57BL/6J mice regardless of the inflammatory status.

The dietary polar lipids did not significantly affect the polar lipids levels in the
intestinal mucosa of the ob/ob mice. Compared with the CO and the GG, the dietary PL
decreased PE in the colon mucosa of the C57BL/6J mice stressed by the LPS and the
C57BL/6J mice with the DIO. The dietary PL decreased PC in the small intestinal
mucosa of the LPS stressed C57BL/6J mice but increased the PC in small intestinal
mucosa of the C57BL/6J mice with the DIO. The effects of the dietary polar lipids on PC
level in the intestinal mucosa were different during the LPS-induced systemic
inflammation and the DIO. The phospholipids tend to decrease the polar lipids in the
intestinal mucosa and the skeletal muscle. It is not clear how the dietary phospholipids
may reduce the polar lipids level in the tissues. It may be hypothesized that the high
dietary phospholipids level may have down regulated the receptors for the absorption of
the polar lipids.

Future Directions
Although the milk polar lipids exist in almost all dairy products, the absolute amount
of the polar lipids in the dairy products is quite low, ranging from 9 mg per 100 g skim
milk to 1250 mg per 100 g butter serum (54). It is quite expensive to purify and collect
the individual class of the milk polar lipids. The milk polar lipids may be enriched as a
complex compound or a semi purified isolate. So in this dissertation the milk polar lipids
were supplemented in the diets either as a complex isolate or a semi-purified isolate to
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increase the applicability of the results. In order to pinpoint which specific component of
the polar lipids resulted in the increase of gut permeability and plasma LPS, the dietary
supplementation of the purified polar lipid classes one at a time is needed to explore the
relevant mechanisms. Both the in vitro cell model and the animal models may be used to
study the mechanisms. For gut permeability, the Caco-2 cell monolayer could be a great
model. The well-established animal models of colitis could also be used. For systemic
inflammation, the LPS induced acute and chronic animal models could be a good place to
start. For lipid metabolism, the animal models of NAFLD and/or NASH can be used. The
metabolomic and lipidomic approaches can also be adopted for studying the effects of the
dietary polar lipids.

The undesirable effects of the dietary phospholipids on gut permeability and systemic
inflammation in this dissertation may be due to the high dietary level of the phospholipids.
The phospholipids were supplemented at the level of 1% (w/w) of the diet. Future studies
may target a level less than 1% (w/w) of the diet. There may be a dose effect. Different
dietary levels may be compared to find a level that may generate more desirable effects.

Large amounts of the milk polar lipids rich material may be produced as a byproduct
from buttermilk or cheese whey during the butter or cheese making processes. While it is
worthwhile to try a lower dietary level of purified milk polar lipids in the dietary
supplementation studies, it is also interesting to look at the effects of the direct dietary
incorporation of the polar lipids rich dairy byproducts such as the whey powder and
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buttermilk powder. A systematic approach would be ideal to assess the effects of the milk
polar lipids rich dairy products on the major organ systems in animal models.
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Figure 6.1 Most of the hypothesized effects of the polar lipids were not supported by the
data. The phospholipids did not reduce gut permeability but increased obesity and the
plasma LPS in the ob/ob mouse model and the DIO model (a). The phospholipids did not
reduce gut permeability but increase the plasma LPS in the LPS-stressed mouse model
(b). Red X indicates that the data did not support the hypothesis. Red arrow indicates the
undesirable effect.
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Figure 6.2 Stress-induced dysfunction of the subcutaneous white adipose tissue
contributes to the development of visceral adiposity (18).
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APPENDIX
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CORRELATION COEFFICIENT NETWORK ANALYSIS

Dietary supplementation of bioactive compounds should affect the eleven organ
systems in the body. Claims about the effects of bioactive compounds cannot be
appropriately and responsibly made until the main organ systems are assessed. When
multiple organ systems are assessed, it is common to observe contradictory effects on
different endpoints. A method is needed to assess the overall effect of dietary
supplements on multiple endpoints. The network analysis could be a potential method for
evaluating the overall effect of dietary supplements. Limited literature indicates that
correlation network analysis may help reveal the overall pattern of biological endpoints
(1). A lot of parameters were evaluated in the mouse studies of this dissertation. Dietary
polar lipids had mixed effects on different endpoints. It is helpful to explore the overall
effect of dietary milk polar lipids on the parameters related to the major hypotheses
through correlation network analysis. The correlation network analysis was carried out
for the LPS-stressed mouse model and the diet-induced obesity model. The network
analysis was not done for the ob/ob mouse model since the number of animals per group
was low (smallest n = 3).

The Pearson correlation coefficients of all final parameters were generated by SAS
9.2. Data from the same number of animals were used among groups. The correlation
coefficient matrices were subjected to network analysis. The matrices were imported as
Excel workbooks into network analysis software Cytoscape desktop application 2.8.3.
Correlation coefficients and associated p values were used as edge attributes. Parameter
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names were used as node names and they were categorized into types. Networks were
generated and edges were filtered by setting cutoffs for p values, which was 0.05. Nodes
connected by the filtered edges were included in the filtered child networks. The GirvanNewman fast greedy algorithm (by GLay Cytoscape plugin), operating exclusively on
connectivity, was carried out to generate community clusters for correlation networks.
Nodes for parameters related to the major hypotheses and their first neighbors were
selected to generate child networks. The following parameters were selected to reflect the
major hypotheses: colon permeability, small intestine permeability, plasma interleukin-6
(IL-6) and tumor necrosis factor-α (TNF-α), and liver triglycerides (TG). Only edges
connecting those selected parameters were retained and the other edges were discarded.
Then force-directed network layouts were generated from the retained nodes and edges.

Correlation Network Analysis for Chapter 4
The correlation network analysis assessed all of the parameters measured at the end
of the study (day 57, n=4). The legends for the network analysis are shown in Figures
A1a-c. The community cluster analyses indicated less connectivity in the PL group
compared with the CO and GG groups (9 vs 7 communities). The PL group had less
significant negative and positive correlations compared with the CO and GG groups
(Table A1). Less correlations in the PL group is accompanied by less desirable biological
functions (Figure 4.10). The deduction in positive correlations is associated with a
metabolic disorder in the disease model animals (1). The undesirable effect of PL may be
mainly associated with the decrease of positive correlations. Decrease of positive
correlations may indicate the compromise of biological functions by dietary polar lipids
in the context of systemic inflammation induced by lipopolysaccharide (LPS).
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For correlations involve parameters related to the major hypotheses, the forcedirected network layout is shown in Figure A2. In the CO group, small intestine
permeability is negatively correlated with liver mass and cecum content mass. Small
intestine permeability is positively correlated with plasma insulin, retroperitoneal fat
mass and body weight. Colon permeability is positively correlated with
phosphatidylcholine (PC) content in jejunum mucosa, liver sphingomyelin (SM), muscle
free fatty acids (FFA), and jejunum mass. Colon permeability is negatively correlated
with liver phosphatidylinositol (PI), plasma diglycerides (DG), TG and cholesteryl ester
(CE). Plasma TNF-α is positively correlated with liver DG and muscle CE. Plasma IL-6
is positively correlated with jejunum mucosa mass, colon mucosa mass, adipose PE, and
gangliosides content in colon mucosa. Plasma IL-6 is negatively correlated with body fat
mass and ileum mucosa mass.

In the GG group (Figure A2), small intestine permeability is positively correlated
with plasma PC and is negatively correlated with muscle phosphatidylethanolamine (PE)
and phosphatidylserine (PS), and GG content in colon mucosa. Plasma IL-6 is negatively
correlated with plasma monocyte chemoattractant protein-1 (MCP-1) and is positively
correlated with mesenteric fat mass and occludin protein expression in jejunum mucosa.
Liver TG is positively correlated with PC in ileum mucosa and is negatively correlated
with colon mucosa mass.

In the PL group (Figure A2), small intestine permeability is positively correlated with
adipose TG. Colon permeability is positively correlated with liver PI and is negatively
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correlated with subcutaneous fat in upper body. Plasma TNF-α is positively correlated
with cecum mass and muscle FFA. Plasma IL-6 is negatively correlated with liver PS and
is positively correlated with plasma leptin and LPS, PE in colon mucosa, and
gangliosides in ileum mucosa. Liver TG is positively correlated with retroperitoneal fat
mass.

It is unexpected that plasma IL-6 is negatively correlated with subcutaneous fat mass,
visceral fat mass, brown adipose tissue mass and total fat depots in the CO group. This
unexpected observation is not observed in the GG and PL groups. Plasma IL-6 is
positively correlated with mesenteric fat mass in the GG group and is not correlated with
fat mass in the PL group. There is no good explanation for those unexpected correlations
in the CO group.

It is interesting to notice that the small intestine permeability is positively correlated
with plasma insulin and body weight in the CO group. These correlations were not
observed in the GG and PL groups. It might be speculated that the increase of small
intestine permeability may increase plasma insulin. The increase of small intestine
permeability may result in endotoxemia and systemic inflammation, which may decrease
insulin sensitivity. The body may compensate the decreased insulin sensitivity by
increasing plasma insulin. It is unexpected that there were no correlations between tight
junction proteins in gut mucosa and gut permeability. This lack of correlation may
indicate that the amount of tight junction proteins is not critical in determining gut
permeability during inflammatory stress.
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The CO group had more correlations involving plasma IL-6 and colon permeability
compared with GG and PL groups (Figure A2). The more correlations in the CO group
may indicate more desirable biological functions. It might be hypothesized that GG and
PL have undesirable effect on biological functions associated with plasma IL-6 and colon
permeability.

Correlation Network Analysis for Chapter 5
The correlation network analysis assessed all of the parameters measured at the end
of the study (day 101, n=5). The CO group had more total correlations compared with the
GG and PL groups (Table A2). The GG group had less negative correlations compared
with the CO group (Table A2). The community cluster analyses indicated little difference
in connectivity among three groups (Table A2).

The GG and PL groups had less positive correlations compared with the CO group
(Table A2). The decrease of positive correlations is associated with a metabolic disorder
in the disease model animals (1). If the reduction in positive correlations is an indicator of
compromised biological functions, the overall effect of GG and PL may have been
undesirable. The GG and PL decreased the negative correlations compared with the CO
group (Table A2). Although there is little difference in connectivity of the network
layouts among three groups, the GG and PL groups had less total correlations. The
overall effect of CO on all endpoints was less desirable compared with that of GG
(Figure 5.9). The overall effect of PL on all endpoints is mixed compared with that of CO
(Figure 5.9). The decrease of positive correlations in the PL group may indicate the
overall effect of PL is undesirable compared with CO. The decrease of negative
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correlations in the GG group is accompanied by the lack of undesirable effect compared
with the PL group. It may be hypothesized that the decrease of negative correlations is
associated with reduction in negative effect.

For correlations involve parameters related to major hypotheses, the force-directed
network layout is shown in Figure A3. In the CO group, small intestine permeability is
positively correlated with muscle CE and is negatively correlated with plasma insulin.
Colon permeability is negatively correlated with occludin protein expression in jejunum
mucosa. Plasma IL-6 is positively correlated with plasma PC and is negatively correlated
with liver SM and adipose TG. Plasma TNF-α is positively correlated with liver
expression of beta-actin and body lean mass. Plasma TNF-α is negatively correlated with
subcutaneously fat mass, visceral fat mass, body fat mass, liver TG, and colon mucosa
mass. Liver TG is negatively correlated with plasma TNF-α and is positively correlated
with plasma FITC and FFA.

In the GG group (Figure A3), small intestine permeability is positively correlated
with homeostasis model assessment of insulin resistance (HOMA-IR) and is negatively
correlated with muscle PS and liver mass. Colon permeability is positively correlated
with PE in jejunum mucosa and PC in colon mucosa. Colon permeability is negatively
correlated with colon mass and colon mucosa mass, liver PI and CE, and muscle PC and
TG. Plasma IL-6 is negatively correlated with occludin protein expression in colon
mucosa, homeostasis model assessment of insulin resistance (HOMA-IR), and liver PE.
Plasma TNF-α is positively correlated with liver PE and muscle TG. Liver TG is
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positively correlated with body fat mass, subcutaneous fat mass, and mesenteric fat mass.
Liver TG is negatively correlated with plasma LPS, PC content in ileum mucosa and
body lean mass.

In the PL group (Figure A3), colon permeability is negatively correlated with
occludin protein expression in jejunum mucosa, plasma TNF-α, and liver expression of
acetyl-Coenzyme A acyltransferase 2. Small intestine permeability is positively
correlated with cecum mass, cecum content mass, PE in ileum mucosa, and beta actin
expression in liver. Small intestine permeability is negatively correlated with adipose DG,
liver expression of acetyl-Coenzyme A acyltransferase 2, retroperitoneal fat mass and
inguinal fat mass. Plasma IL-6 is positively correlated with liver FFA and cecum mass.
Plasma IL-6 is negatively correlated with body fat mass, plasma TG, muscle TG and liver
TG. Plasma TNF-α is positively correlated with PI content in colon mucosa and occludin
protein expression in jejunum mucosa. Plasma TNF-α is negatively correlated with colon
permeability and ileum mucosa mass. Liver TG is positively correlated with plasma FFA,
body fat mass, plasma TG, body weight, and liver expression of scavenger receptor class
B, member 1. Liver TG is negatively correlated with body lean mass, liver FFA, plasma
IL-6, and muscle mass.

It is unexpected that plasma TNF-α is negatively correlated with subcutaneous fat
mass, visceral fat mass, brown adipose tissue mass and total fat depots in the CO group.
These unexpected correlations were not observed in the GG and PL groups. Plasma TNFα is not correlated with fat mass in the GG and PL groups. This observation is consistent
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with the unexpected negative correlation between plasma IL-6 and fat mass in the CO
group of the LPS model (Figure A2 – CO, Chapter 4). Most of the mice in the CO group
were not obese according to Fenton’s definition for obesity. It may be hypothesized that
the increase of adipose tissue in lean mice decreases plasma proinflammatory cytokines
such as IL-6 and TNF-α; GG and PL may compromise this negative correlation.

It is surprising that no correlations were observed between tight junction proteins in
gut mucosa and gut permeability. This lack of correlation may indicate that the amount of
tight junction proteins does not play an essential role in determining gut permeability
during diet-induced obesity. The CO group had more correlations involving plasma TNFα compared with GG and PL groups. The small intestine permeability is negatively
correlated with plasma insulin in the CO group and positively correlated with insulin
sensitivity (HOMA-IR). Positive correlation was observed between small intestine
permeability and plasma insulin in the CO group of the LPS model (Figure A2 – CO,
Chapter 4). Taken together, the increase of small intestine permeability may decrease
insulin sensitivity through increasing systemic inflammation and the body may
compensate the decreased insulin sensitivity by increasing plasma insulin.

Liver TG is positively correlated with body fat and negatively correlated with body
lean mass in GG and PL groups. Liver TG is not correlated with body fat in the CO group.
It may be hypothesized that GG and PL potentiate the effect that body fat accumulation
increases liver TG. The GG and PL groups had more correlations involving liver TG
compared with the CO group. The GG group had more correlations involving colon
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permeability compared with CO and PL groups. The PL group had more correlations
involving plasma IL-6 and small intestine permeability. It may be hypothesized that GG
and PL have a bigger influence on liver TG and a smaller influence on plasma TNF-α
compared with CO; GG has a bigger influence on colon permeability compared with CO
and PL; PL has a bigger influence on plasma IL-6 and small intestine permeability
compared with CO and GG.

Summary
The results of correlation network analyses in three mouse studies consistently
support the hypotheses that decreased network connectivity is associated with less
integrative and cohesive connections of biological functions; decrease in positive
correlations is associated with compromised biological functions while decrease in
negative correlations is associated with less undesirable effects; increased correlations of
a parameter is associated with a bigger influence of the treatment on that parameter.
Since very little literature is available regarding correlation network analysis of
functional biological endpoints, correlation network analysis should be advocated to
further test the hypotheses.
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Table A1 Number of Pearson correlation coefficients (p < 0.05) among parameters
measured at day 57 in the LPS-stress mouse model.

Diet
Negative correlations
Positive correlations
Total correlations
Community clusters

CO
105
109
214
7

GG
97
106
203
7

PL
72
82
154
9

Table A2 Number of Pearson correlation coefficients (p < 0.05) among parameters
measured at day 101 in the DIO mouse model.

Diet
Negative correlations
Positive correlations
Total correlations
Community clusters

CO
162
168
330
7

GG
136
160
296
8

PL
152
154
306
7
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Figure A1a Visual legend – node color mapping. ALIG: adipose lipid per gram tissue;
BC: body composition; CK: cytokine; DST: differential sugar-absorption test; FITC:
fluorescein isothiocyanate; GE: gene expression; GGs: gangliosides; GIM:
gastrointestinal mass; GLU: glucose; LLIG: liver lipid per gram tissue; MLIG: muscle
lipid per gram tissue; MuLIG: mucosa lipid per gram tissue; PLI: plasma lipid; TJP: tight
junction protein; TM: tissue mass.
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Figure A1b Visual legend – node shape mapping. ALIG: adipose lipid per gram tissue;
BC: body composition; CK: cytokine; DST: differential sugar-absorption test; FITC:
fluorescein isothiocyanate; GE: gene expression; GGs: gangliosides; GIM:
gastrointestinal mass; GLU: glucose; LLIG: liver lipid per gram tissue; MLIG: muscle
lipid per gram tissue; MuLIG: mucosa lipid per gram tissue; PLI: plasma lipid; TJP: tight
junction protein; TM: tissue mass.
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Figure A1c Visual legend – color, line width and line style of edge mapping. Edge is
colored by p value. Edge line width and style are coded by correlation coefficient (CR).
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Figure A2 Correlations (p <
0.05) involve the following
parameters measured at the end
of the LPS study: liver
triglycerides level, small
intestine permeability, colon
permeability, and plasma IL-6
and TNF-α. %: percentage of
body weight. Adipose: gonadal
adipose tissue. BAT: brown
adipose tissue. LPS:
lipopolysaccharide. SI: small
intestine.
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Figure A3 Correlations
(p < 0.05) involve the
following parameters
measured at the end of
the DIO study: liver
triglycerides level, small
intestine permeability,
colon permeability, and
plasma IL-6 and TNFα. %: percentage of body
weight. Acaa2: acetylCoenzyme A
acyltransferase 2. Actb:
beta-actin. Scarb1:
scavenger receptor class
B, member 1. Adipose:
gonadal adipose tissue.
FITC: fluorescein
isothiocyanate. HOMAIR: homeostasis model
assessment of insulin
resistance. LPS:
lipopolysaccharide. SI:
small intestine.
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Professional Experience
 Research Assistant, Utah State University, August 2006 – present


Collected and analyzed electrophysiological data in animal model using
interactive graphic user interface



Established Caco-2 cell monolayer model for studying the effect of polar
lipids on intestinal barrier integrity



Analyzed large bioinformatic and lipidomic data sets and carried out
comprehensive statistical analyses



Carried out experimental design and statistical analyses planning for animal
studies



Received Institutional Review Board training



Established mouse models of obesity and inflammation for studying the
development of diet-induced obesity (DIO) and explored the effects of
dietary polar lipids in influencing intestinal barrier integrity, systemic
inflammation, and lipid metabolism during DIO and in the context of
inflammation



Attended Getting Started as a Successful Proposal Writer and Academician
workshop



Supervised four undergraduate student researchers

 Teaching Assistant, Utah State University, August 2006 – May 2009


Prepared and taught General Biology (BIOL 1610) lab, Fall 2006



Prepared and taught Human Anatomy (BIOL 2320) lab, Spring 2007,
Spring 2008, Summer 2008 and Spring 2009



Prepared and taught Elementary Microbiology (BIOL 2060) lab, Fall 2007
and Fall 2008
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 Research Assistant, Beijing Institute of Geriatrics, August 2003 – July 2006


Established cell models of different insulin sensitivity using 3T3-L1
adipocytes



Assessed insulin sensitivity by stable isotope labeled glucose uptake test



Studied the effect of caloric restriction on insulin sensitivity in cell model

 Resident/Neurologist, Hubei University of Medicine affiliated Dongfeng General
Hospital, July 2001 – July 2003


Worked in inpatient wards and outpatient clinics



Carried out patient assessment, diagnosis and therapeutic planning



Provided psychological counseling and psychotherapy for patients

 Instructor, Hubei University of Medicine, July 2001 – July 2003


Supervised senior medical students in doing internship

Publications
 Albert Lihong Zhou, Korry J. Hintze, Rafael Jimenez-Flores and Robert E. Ward.
Dietary Fat Composition Influences Tissue Lipid Profile and Gene Expression in
Fischer-344 Rats. Lipids 2012 (In press)
 Review: Lihong Zhou and Tiemei Zhang. Recent research advancements in
biological functions of adipose tissue. Foreign Medical Sciences Geriatrics 2006;
27(2): 83-86

Manuscripts in Preparation
 Albert Lihong Zhou and Robert E. Ward. Dietary Milk Polar Lipids Affect Lipid
Metabolism, Gut Permeability and Systemic Inflammation in ob/ob Mice (In
manuscript for Nutrition Research)
 Albert Lihong Zhou and Robert E. Ward. Dietary Milk Polar Lipids Benefit Gut
Barrier and Lipid Metabolism in C57BL/6J Mice during Systemic Inflammation
Induced by Escherichia Coli Lipopolysaccharide (In manuscript for Journal of
Nutrition)
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 Albert Lihong Zhou and Robert E. Ward. Dietary Milk Polar Lipids
Supplementation Promotes Body Fat Accumulation and Affects Gut Permeability,
Systemic inflammation, and lipid Metabolism in C57BL/6J Mice Fed a Moderately
High-fat Diet (In manuscript for Obesity)

Invited Presentations/Seminars
1. Oral Presentation: Effects of Dietary Milk Polar Lipids on Lipid Metabolism in
Genetically Obese Mice Fed a Moderately High-Fat Diet. Albert Lihong Zhou and
Robert E. Ward. Food, Health & Nutrition Student Professional Development Oral
Session, Institute of Food Technologists Annual Meeting & Food Expo. Las Vegas,
June 25-28, 2012
2. Poster Presentation: Effects of Dietary Milk Polar Lipids on Lipid Metabolism in
Genetically Obese Mice Fed a Moderately High-Fat Diet. Albert Lihong Zhou and
Robert E. Ward. Dairy Division Food, Health & Nutrition Posters, Institute of Food
Technologists Annual Meeting & Food Expo. Las Vegas, June 25 – 28, 2012
3. Oral Presentation: Dietary Milk Polar Lipids Benefit Lipid Metabolism and Gut
Barrier in Obese Mice Fed Moderately High-fat Diet. Albert Lihong Zhou, R.
Ward. American Oil Chemists' Society, 103rd Annual Meeting & Expo. Long Beach,
April 29 – May 3, 2012
4. Oral Presentation: Dietary Milk Polar Lipids Benefit Gut Barrier Integrity and Lipid
Metabolism in C57BL/6J Mice during Systemic Inflammation Induced By
Escherichia Coli Lipopolysaccharide. Albert Lihong Zhou, Robert E. Ward and
Korry J. Hintze. American Society for Nutrition Annual Meeting, Experimental
Biology. San Diego, April 21 – 25, 2012
5. Poster Presentation: Dietary Milk Polar Lipids Benefit Gut Barrier Integrity and
Systemic Inflammation in Mice during Inflammatory Stress Induced by
Lipopolysaccharide. Albert Lihong Zhou, Robert E. Ward and Korry J. Hintze.
American Society for Nutrition Dietary Bioactive Components Research Interest
Section poster competition, Experimental Biology. San Diego, April 21 – 25, 2012
6. Poster Presentation: Dietary Milk Polar Lipids Benefit Gut Barrier Integrity and
Lipid Metabolism in Mice during Inflammatory Stress Induced by
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Lipopolysaccharide. Albert Lihong Zhou, Robert E. Ward and Korry J. Hintze.
American Society for Nutrition Energy and Macronutrient Metabolism Research
Interest Section poster competition, Experimental Biology. San Diego, April 21 –
25, 2012
7. Oral Presentation: Effects of Dietary Milk Polar Lipids on Gut Permeability and
Systemic Inflammation in Genetically Obese Mice Fed a Moderately High-fat Diet.
Albert Lihong Zhou and Robert E. Ward. Intermountain Graduate Research
Symposium, Utah State University. Logan, April 5 – 6, 2012
8. Poster Presentation: Effects of Dietary Milk Polar Lipids on Gut Integrity and
Systemic Inflammation in Mice during Development of Diet-Induced Obesity.
Albert Lihong Zhou and Robert E. Ward. Intermountain Graduate Research
Symposium, Utah State University. Logan, April 5 – 6, 2012
9. Poster presentation: Effects of Dietary Milk Polar Lipids on Gut Permeability,
Systemic inflammation, and lipid Metabolism in C57BL/6J Mice during
Inflammatory Stress Induced by Escherichia Coli Lipopolysaccharide. Albert
Lihong Zhou and Robert E. Ward. IFT/AACT Utah Food & Candy Expo, Institute
for Food Technologists Bonneville Section and American Association of Candy
Technologists Rocky Mountain Section. Sandy, April 10, 2012
10. Oral Presentation: Effects of Dietary Milk Fat Globule Membrane on Tissue Lipid
Metabolism and Related Gene Expression in Fischer-344 Rats. Albert Lihong
Zhou, R. Ward, K. Hintze. American Oil Chemists' Society, 102nd Annual Meeting
& Expo. Cincinnati, May 1 – 4, 2011
11. Oral Presentation: Effects of Dietary Milk Fat Globule Membrane on Brain Lipid
Metabolism and Gene Expression. Albert Lihong Zhou, R. Ward. American Oil
Chemists' Society, 102nd Annual Meeting & Expo. Cincinnati, May 1 – 4, 2011
12. Poster Presentation: The Effects of Whey Milk Fat Globule Membrane Lipids on
Barrier Function of Caco-2 Cell Monolayer against LPS Stress. Albert Lihong
Zhou, R. Ward, K. Hintze. American Oil Chemists' Society, 102nd Annual Meeting
& Expo. Cincinnati, May 1 – 4, 2011
13. Oral Presentation: Effects of Dietary Milk Fat Globule Membrane on Lipid
Metabolism and Gene Expression in Fischer-344 rats. Albert Lihong Zhou, Robert
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E. Ward, Rafael Jimenez-Flores and Korry J. Hintze. Intermountain Graduate
Research Symposium, Utah State University. Logan, April 15, 2011
14. Poster presentation: Effects of Dietary Milk Fat Globule Membrane on Tissue Lipid
Metabolism and Gene Expression in Fischer-344 rats. Albert Lihong Zhou, Robert
E. Ward, Rafael Jimenez-Flores and Korry J. Hintze. IFT/AACT Utah Food &
Candy Expo, Institute for Food Technologists Bonneville Section and American
Association of Candy Technologists Rocky Mountain Section. Sandy, April 5, 2011
15. Poster presentation: Effect of dietary fat source on tissue lipids distribution and gene
expression associated with lipid metabolism in Fishcer-344 rats. Albert Lihong
Zhou, Robert E. Ward and Korry J. Hintze. 7th International Symposium on Milk
Genomics & Human Health, International Milk Genomics Consortium. Davis,
October 20 – 22, 2010
16. Poster presentation: Effect of dietary fat source on tissue lipid profiles in Fishcer-344
rats. Albert Lihong Zhou, Robert E. Ward and Korry J. Hintze. IFT/AACT Utah
Food & Candy Expo, Institute for Food Technologists Bonneville Section and
American Association of Candy Technologists Rocky Mountain Section. Sandy,
April 6, 2010
17. Oral Presentation: Effect of adding Milk Fat Globule Membrane (MFGM) to
anhydrous milk fat on lipid metabolomics in Fischer 344 rats compared to corn oil
control. Robert E. Ward*, Korry Hintze, Albert Lihong Zhou and Dallin Snow.
American Oil Chemists' Society, 101st Annual Meeting & Expo. Phoenix, May 16 –
19, 2010
18. Poster and Oral Presentation: Effect of dietary fat source on tissue lipid profiles in
Fishcer-344 rats. Albert Lihong Zhou, Robert Ward and Korry Hintze.
Intermountain Graduate Research Symposium, Utah State University. Logan, March
31, 2010
19. Poster Presentation: Responses of cochlear nucleus neurons to harmonic and
mistuned complex tones. Donal Sinex and Albert Lihong Zhou. Association for
Research in Otolaryngology, Midwinter Research Meeting. Phoenix, February 16 –
21, 2008
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20. Seminar: Adipose tissue as an endocrine organ. Albert Lihong Zhou. Seminar at
Beijing Institute of Geriatrics. Beijing, May 2005
21. Presentation: Introduction to systems biology. Albert Lihong Zhou. Graduate Salon
at Beijing Institute of Geriatrics. Beijing, September 2004

Institutional Review Board Training
 Human Research Curriculum: Board Members; Group 1.Social & Behavioral
Research Investigators and Key Personnel
 CITI Health Information Privacy and Security (HIPS) Curriculum: CITI Health
Information Privacy and Security (HIPS)

Grants
 Graduate Student Senate Research and Projects Grant, $1000, Utah State
University, 2010
 College of Agriculture Travel Grant, $600, Utah State University, 2010
 Graduate Student Senate Travel Grant, $900, Utah State University, 2011-2012

Professional Society Memberships
 The Obesity Society, 2012 – present
 American Oil Chemists' Society, 2010 – present
 American Society for Nutrition, 2011 – present
 Institute of Food Technologists, 2011 – present
 National Lipid Association, 2010-present
 Association for Research in Otolaryngology, 2007 – 2009
 American Association for the Advancement of Science, 2007 – 2009
 Society for Neuroscience, 2008 – 2009

Students Mentored
 Philip Bassett, Under Undergraduate Research & Creative Opportunities Project:
The effects of dietary ganglioside supplementation on ganglioside content of
intestinal mucosa in C57BL/6J wild type mice. Utah State University, 2010 – 2011

262

 Thiel Lehman, Under Undergraduate Research & Creative Opportunities Project:
The Effects of Dietary Phospholipids and Gangliosides on Gene Expression in the
Liver of Obese mice. Utah State University, 2010 – 2011
 Brent Pickett, Under Undergraduate Research & Creative Opportunities Project:
Effects of Dietary Gangliosides and Phospholipids on Occludin Expression in
Intestinal Mucosa of C57BL/6J ob/ob Mice. Utah State University, 2010 – 2011
 Allen Chen, high school student, Biomedical Program in Alhambra High School,
Alhambra, CA. 2012 – present

Awards and Special Recognition
 American Oil Chemists' Society Peter & Clare Kalustian award, 2012
 American Oil Chemists' Society Honored Student Award, 2012
 American Oil Chemists' Society Health & Nutrition Division Student Award, 2012
 American Society of Nutrition Energy & Macronutrient Research Interest Section
Student-Postdoc Abstract Competition Award, 2012
 2nd place poster session, IFT/AACT Utah Food & Candy Expo, Sandy, Utah, 2012
 Graduate Student Senate Enhancement Award, Utah State University, 2011
 3rd place poster session in Health and Nutrition Division, American Oil Chemists'
Society 102nd Annual Meeting & Expo, 2011
 2nd place poster session, IFT/AACT Utah Food & Candy Expo, Sandy, Utah, 2011
 2nd place lecture session, IGRS, Utah State University, 2011
 1st place poster session, IFT/AACT Utah Food & Candy Expo, Sandy, Utah, 2010
 1st place poster session and 3rd place lecture session, IGRS, Utah State
University, 2010
 1st Award, Campus Public Speaking Contests, Hubei University of Medicine, 2000


Second Award, National College Students English Speaking Contests, Hubei
University of Medicine, 1999



Heng’an Group Stipend for College Students, Hubei University of Medicine, 1998



First Class Scholarship, Hubei University of Medicine, 1996 – 1999



Excellent Student Award, Hubei University of Medicine, 1996 – 1999
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Leadership Experience
 American Society for Nutrition Student Interest Group Awards Chair, 2012 –
present
 AOCS Health and Nutrition Division Newsletter Coeditor, 2012 – present
 AOCS Student Common Interest Group Leadership Committee, 2011 – present
 Founder and the first appointed chairman of Psychological Health
Promotion Association, Hubei University of Medicine, 1998 – 2000
 Executive VP of student government, Hubei University of Medicine, 1996 – 1998

Services
 Food, Health & Nutrition Subpanel member for IFT’s 2013 Annual Meeting
Scientific Program Development, 2012 – present
 IFT Career Center eCareer Mentor, 2012 – present
 Conrad Foundation’s Spirit of Innovation Challenge Mentor, 2012 – present
 Official judge, Health and Nutrition category of Conrad Foundation’s Spirit of
Innovation Challenge partnered by American Society for Nutrition, 2011 – present
 Chair for General Nutrition Session at 102nd AOCS Annual Meeting & Expo, 2011
 Volunteer tutor for Chinese classes at USU, 2009
 Volunteer head chef for the International Banquet at USU, 2007
 Volunteer barber for Chinese Students & Scholars Association, 2006
 Volunteer service in the welfare house and orphanage of Shiyan City, 2001 – 2003


Volunteer psychological consultant for college students and patients in
neurological department, 2000 – 2003

 Volunteer English course instructor for children, Shiyan City, 2001 – 2002
 Volunteer guide of Great Three Gorges Travel Service, May 2000

Language Abilities
 Native in Mandarin, professionally fluent in English, good at public speaking
 Written and spontaneous translation between English and Chinese
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Computer Skills
 Fluent in SAS, R, STATA, Cytoscape, Windows, Mac, Microsoft Office,
Photoshop, ImageJ, Fluidigm and FlexArray
 Experienced in computer hardware

Main Coursework
U

Utah State University (2006 – present)

Nutrition GPA 4.0
Endocrine Aspect of Nutrition (A)
Nutrient Gene Interactions (A)
Statistical Bioinformatics (A)

International Nutrition (A)
Molecular Nutrition Lab (A)
Scientific Paper Critics Seminar (A)

Biology GPA 3.94
Advanced Topics in Psychophysics (A)
Cell Biology (A)
Neurobiology(A)
Graduate College Teaching Seminar (P)

Animal Physiology Lab (A)
Medical Physiology (A-)
Graduate Topic in Biology (A)
Linear regression/time series (CI)(QI) (A)

COMD GPA 4.0
Psychoacoustics and Instrumentation (A)
Speech Science (A)
Pediatric Aural Rehabilitation (A)
Independent Study: Observation/ Graduate
Preparation (A)

U

Peking Union Medical College (2003 – 2006)

Philosophy of Science (A)
Experimental Physiology (A)
Lecture on Cell Biology (B)
Histochemistry (B+)

U

Language/Speech/Hearing Development (A)
Language Assessment and Intervention (A)
Basic Audiology (A)

Molecular Biology of the Gene (D)
Basic and Clinical of Endocrinology (A)
Computer Sciences (B+)
Tissue Culture (B+)

Hubei University of Medicine (1996 – 2001)

Higher Mathematics (A)
Physics (B)
Inorganic Chemistry (A)
Organic Chemistry (A)
Human Anatomy (A)
Histology & Embryology (A)

Biochemistry (B)
Physiology (A)
Human Parasitology (A)
Pathoanatomy (A)
Regional Anatomy (A)
Microbiology & Immunology (B)

